RNAI conjugates and their uses

By using nucleic acid-ligand conjugates and oligonucleotide-ligand conjugates, especially RNAi oligonucleotides targeting STAT3, in cancer treatment, the resistance of immune cells in the tumor microenvironment is addressed, anti-tumor immune responses are enhanced, and tumor growth and metastasis are reduced.

CN117015384BActive Publication Date: 2026-11-17NOVO NORDISK AS
View PDF 33 Cites 0 Cited by

Patent Information

Application Number
CN202280019137.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-06-23
Filing Date
2022-03-04
Publication Date
2026-11-17
Estimated Expiration
2042-03-04

AI Technical Summary

Technical Problem

In current cancer treatments, the tumor microenvironment (TME) has a significant impact on the efficacy of anticancer therapies and drug resistance. Furthermore, multidrug resistance leads to tumor recurrence and low quality of life for patients. Existing treatment regimens have failed to effectively target immune cells within the TME.

Method used

Develop nucleic acid-ligand conjugates and oligonucleotide-ligand conjugates to enhance delivery of immune cells to the tumor microenvironment using hydrophobic ligands such as lipid moieties, regulate target gene expression through RNA interference (RNAi), particularly by inhibiting the expression of signal transducer and activator of transcription 3 (STAT3), thereby modulating immune cell function.

Benefits of technology

By regulating immune cells in the tumor microenvironment, it enhances the anti-tumor immune response, reduces the immunosuppressive environment, improves sensitivity to anti-cancer treatment, and reduces tumor growth and metastasis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117015384B_ABST
    Figure CN117015384B_ABST
Patent Text Reader

Abstract

The subject matter disclosed herein relates to the use of siRNA compositions and methods to regulate gene expression, wherein the siRNA compositions and methods involve influencing key cell populations that support cancer growth and metastasis in order to influence beneficial treatment, remission or removal of potential tumors in patients.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-related applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 157,465, filed March 5, 2021, and U.S. Provisional Patent Application No. 63 / 214,153, filed June 23, 2021. The entire contents of these two U.S. Provisional Patent Applications are incorporated herein by reference. Technical Field

[0003] This disclosure relates to oligonucleotides or oligonucleotides linked to a target moiety that can be used to inhibit, alleviate, and / or control cancer in patients. In some embodiments, this disclosure relates to a method of administering a therapeutically effective amount of one or more RNAi oligonucleotides or one or more RNAi molecules to a subject in need, said RNAi oligonucleotides or RNAi molecules inhibiting the expression of signal transduction and transcription activator 3 (“STAT3”) in the subject. Background Technology

[0004] Cancer growth and progression are influenced by many factors, including the tumor microenvironment (“TME”), which contains components that can control, influence, or enhance tumor development, including blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, signaling molecules, and the extracellular matrix (Yin et al., INT J. CANCER (2019) 144(5): 933-46). Despite the heterogeneity of various tumors, tumor development is highly dependent on the physiological state of the TME. Although tumors may originate from multiple anatomical locations and / or cell populations, they will share many common characteristics that can be used to derive therapeutic strategies targeting that tumor. This is especially true for the maturation of the TME in epithelial-derived tumors. Genetic alterations in tumor cells lead to proliferation, uncontrolled growth, resistance to apoptosis, and a shift in metabolism towards anaerobic glycolysis (the so-called “Warburg effect”). These events generate hypoxia, oxidative stress, and acidosis within the TME, thereby triggering adjustments to the extracellular matrix (ECM) surrounding altered cells or cancer cells, responses from neighboring stromal cells (e.g., fibroblasts) and immune cells (lymphocytes and macrophages), inducing angiogenesis, and ultimately leading to metastasis. The TME profile itself also directly affects the efficacy of anticancer therapies (Giraldo et al., BR.J.CANCER (2019) 120:45-53).

[0005] Currently, chemotherapy is the most prevalent cancer treatment worldwide, often combined with surgery or a combination of surgery and radiation therapy, depending on the tumor type and stage (Abbas et al., AN OVERVIEW OF CANCER TREATMENT MODALITIES / INTECHOPEN, 2018). Since the discovery of several important mutations leading to carcinogenesis (e.g., epidermal cell alterations (Yamaoka et al., INT. J. MOL. SCI. (2017) 18(11): 2420)), these mutations and the proteins they represent have been widely used as targets for developing more selective drugs and drug combinations to treat cancer patients. Despite the effectiveness of these drugs, multidrug resistance (MDR) is frequently observed in patients, often leading to tumor recurrence, limited treatment options, and poor quality of life. Furthermore, cancer research often focuses on tumor cells, although the role of the tumor microenvironment (TME) and its “normal” or non-cancerous cells has been demonstrated to play a crucial role in tumor progression, development, and MDR (Klemm et al., TRENDSCELL BIOL (2015) 25(4): 198-213).

[0006] In the late stages of solid tumor development, the tumor microenvironment becomes highly complex and heterogeneous (Runa et al., CURR MOL BIOL REP (2017) 3(4):218-29). Interactions between cancer cells and neighboring cells (including stromal cells and immune system cells, often arising from inflammation at the tumor site) lead to additional alterations in the TME, as well as the formation of cellular components, extracellular matrix, and vascularization systems, all of which contribute to tumor metastasis (Runa et al., CURR MOL BIOL REP (2017) 3(4):218-29). During tumor growth, cancer cells and TME components continuously adapt to environmental conditions, influencing overall tumor growth. Therefore, novel therapies targeting different aspects of the TME that promote tumor growth are needed. Summary of the Invention

[0007] The tumor microenvironment (TME) is a complex system composed of blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular matrix that interacts with tumor tissue. Tumor progression is influenced by the interaction between cancer cells and their environment, ultimately determining whether the primary tumor is eradicated, metastasizes, or establishes dormant micrometastases. The TME can also affect treatment response and drug or treatment resistance. Cancer cells weaken anti-tumor immune responses and create an immunosuppressive environment. Therefore, there is an ongoing need to develop therapeutics that can overcome this immunosuppressive environment and / or sensitize cancer cells to anticancer agents to improve patient outcomes.

[0008] This disclosure provides novel nucleic acids, oligonucleotides, or analogues thereof comprising targeting ligands, such as hydrophobic ligands, including but not limited to adamantyl and lipid conjugates, which can be used to target immune cells in the tumor microenvironment (TME) for therapeutic intervention. This disclosure relates to nucleic acid-ligand conjugates and oligonucleotide-ligand conjugates, methods of their preparation, and uses thereof, which function to regulate the expression of target genes in cells (e.g., immune cells in the tumor microenvironment). Without being bound by theory, the attachment of lipophilic / hydrophobic moieties such as fatty acids and adamantyl to these highly hydrophilic nucleic acids / oligonucleotides significantly enhances plasma protein binding and thus prolongs circulating half-life. As demonstrated herein, the incorporation of hydrophobic moieties such as lipids facilitates the systemic delivery of novel nucleic acids, oligonucleotides, or analogues thereof to immune cell populations in the tumor microenvironment.

[0009] Suitable nucleic acid-ligand conjugates and oligonucleotide-ligand conjugates include nucleic acid inhibitor molecules, such as dsRNA inhibitor molecules, dsRNAi inhibitor molecules, antisense oligonucleotides, miRNAs, ribozymes, antagomir, aptamers, and single-stranded RNAi inhibitor molecules. In some aspects, this disclosure provides nucleic acid-lipid conjugates, oligonucleotide-lipid conjugates, and analogues that can be used as regulators of intracellular RNA levels. The nucleic acid inhibitor molecules of this disclosure regulate RNA expression through a diverse set of mechanisms, such as RNA interference (RNAi). The advantage of the nucleic acid-ligand conjugates, oligonucleotide-ligand conjugates, and analogues provided herein is that they may possess broad pharmacological activities consistent with the regulation of intracellular RNA levels. Furthermore, this disclosure provides methods for treating or improving disease conditions by modulating intracellular RNA levels using effective amounts of the conjugates described herein.

[0010] In some aspects, this disclosure relates to oligonucleotide-ligand conjugates comprising one or more nucleic acid-ligand conjugate units that regulate the expression of target genes in immune cells within a tumor microenvironment via RNA interference (RNAi). In some aspects, this disclosure relates to oligonucleotide-ligand conjugates comprising one or more hydrophobic partial ligands (including, but not limited to, lipid portions), compositions of said oligonucleotide-ligand conjugates, methods of preparation of said oligonucleotide-ligand conjugates, and uses thereof, wherein said oligonucleotide-ligand conjugates regulate (e.g., reduce or inhibit) the expression of target genes in immune cells within a tumor microenvironment. In some aspects, said oligonucleotide-ligand conjugates target genes encoding immunosuppressive regulators, such that reducing or inhibiting the expression of the regulator overcomes an immunosuppressive tumor microenvironment. In some embodiments, reducing or inhibiting the expression of the regulator induces or enhances an antitumor immune response.

[0011] This disclosure is based, at least in part, on the discovery of oligonucleotide-ligand conjugates that effectively reduce the expression of target genes in immune cells present within the tumor microenvironment. Unbound by theory, as described herein, the hydrophobic portion (e.g., lipid) facilitates the delivery and distribution of RNAi oligonucleotide-lipid conjugates to immune cells in the tumor microenvironment, such as cells expressing lipid transport receptors, thereby enhancing the efficacy and persistence of gene knockout. Therefore, this disclosure provides a method for treating cancer and / or reducing tumor growth by administering oligonucleotide-ligand conjugates of this disclosure and pharmaceutically acceptable compositions thereof, as described herein, to modulate the expression of target genes (e.g., genes encoding immunosuppressive regulators) in immune cells within the tumor microenvironment. This disclosure further provides a method for preparing medicaments using oligonucleotide-ligand conjugates for treating cancer and / or reducing tumor growth by modulating the expression of target genes in immune cells within the tumor microenvironment.

[0012] In some aspects, this disclosure provides methods for treating, improving, or preventing cancer and / or preventing cancer metastasis in subjects in need. This disclosure further provides RNAi oligonucleotide molecules that can limit, control, or eliminate the expression of key genes associated with cancer and / or an immunosuppressive tumor microenvironment. Such RNAi oligonucleotide molecules are double-stranded RNAi oligonucleotides targeting various signal transduction and transcription activator 3 (STAT3). In some embodiments, the method includes administering to a subject a therapeutically effective amount of a composition that inhibits STAT3 expression or activity in the subject. Such RNAi oligonucleotide molecules are used to treat subjects with cancer and related conditions and may therefore be therapeutically beneficial to subjects with cancer, sarcoma, melanoma, lymphoma and leukemia, prostate cancer, breast cancer, hepatocellular carcinoma (HCC), colorectal cancer, and glioblastoma.

[0013] STAT3 is an important transcription factor essential for maintaining carcinogenesis and chemoresistance to anticancer drugs. STAT3 is located in the cytoplasm and is activated in response to stimuli from cytokines. Activated STAT3 regulates the transcription of genes controlling cell survival and proliferation, and modulates the expression of genes involved in anti-apoptosis and immune responses. Constitutive activation of STAT3 is essential for proliferation and survival in various cancers (Groner, B. et al., SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, Vol. 19(4):341-50 (2008)). STAT-3 activation provides favorable conditions for cancer cell survival. Similar to NF-κB, inhibition of STAT-3 in various cancer types has been shown to induce apoptosis and chemosensitization (daHora, CC et al., CELL DEATH DISCOV, Vol. 5(72) https: / / doi.org / 10.1038 / s41420-019-0155-9 (2019)). The mRNA sequence of human STAT3 (NM_001369512.1) is shown in SEQ ID NO:85 or SEQ ID NO:1217 (NM_139276.3).

[0014] Therefore, in one aspect, this disclosure provides oligonucleotide-ligand conjugates comprising a nucleotide sequence that reduces the expression of target mRNAs in immune cells associated with the tumor microenvironment and one or more targeting ligands, wherein one or more nucleosides of the nucleotide sequence conjugated to the one or more targeting ligands are represented by formula Ia:

[0015]

[0016] Or its pharmaceutically acceptable salt, wherein each variable is as defined and described herein.

[0017] On the other hand, this disclosure provides oligonucleotide-ligand conjugates comprising a nucleotide sequence that reduces the expression of target mRNAs in immune cells associated with the tumor microenvironment and one or more targeting ligands, wherein one or more nucleosides of the nucleotide sequence conjugated to the one or more targeting ligands are represented by formula II-a:

[0018]

[0019] Or its pharmaceutically acceptable salt, wherein each variable is as defined and described herein.

[0020] In some embodiments, the oligonucleotide-ligand conjugate is represented by the formula II-b, II-c, II-Ib, or II-Ic:

[0021]

[0022]

[0023] Or its pharmaceutically acceptable salt.

[0024] In any of the foregoing or related aspects, R 5 It refers to saturated or unsaturated straight-chain or branched C1-C50 hydrocarbon chains. In some respects, R 5 It refers to saturated or unsaturated straight-chain or branched C8-C30 hydrocarbon chains. In some respects, R 5 It is a saturated or unsaturated straight-chain or branched C16 hydrocarbon chain. In some respects, R 5 It is a saturated or unsaturated straight or branched C18 hydrocarbon chain.

[0025] In any of the foregoing or related aspects, the oligonucleotide-ligand conjugate comprises an antisense strand of 15 to 30 nucleotides and a sense strand of 15 to 40 nucleotides, wherein the sense strand and the antisense strand form a double-stranded region, wherein the antisense strand comprises a complementary region complementary to a target sequence expressed in tumor microenvironment-associated immune cells, wherein the sense strand comprises a stem-loop at its 3' end, the stem-loop comprising a tetraloop containing four nucleotides, wherein one or more of the four nucleotides conjugated to the target ligand are represented by formula II-Ib:

[0026]

[0027] Where B is selected from adenine and guanine nucleobases, and where R... 5 It is a hydrocarbon chain. In some aspects, the four nucleosides of the said tetracycle are numbered 1-4 from 5' to 3', and position 1 is represented by formula II-Ib. In other aspects, position 2 is represented by formula II-Ib. In still other aspects, position 3 is represented by formula II-Ib. In a further aspect, position 4 is represented by formula II-Ib.

[0028] In any of the foregoing or related aspects, the target mRNA encodes a regulator of immunosuppression. In some aspects, the regulator of immunosuppression is a checkpoint inhibitor peptide. In some aspects, the regulator of immunosuppression is a transcription factor.

[0029] In any of the foregoing or related aspects, the immune cells associated with the tumor microenvironment are myeloid cells. In some aspects, the immune cells associated with the tumor microenvironment are T cells. In some aspects, the nucleotide sequence reduces the expression of target mRNAs in more than one type of immune cell associated with the tumor microenvironment. In some aspects, the immune cells are myeloid cells or T cells. In some aspects, the myeloid cells are myeloid-derived suppressor cells (MDSCs). In some aspects, the MDSCs are granulocyte MDSCs (G-MDSCs) or monocyte MDSCs (M-MDSCs). In some aspects, the nucleotide sequence reduces the expression of target mRNAs in both G-MDSCs and M-MDSCs. In some aspects, the T cells are CD8+ T cells or Treg cells.

[0030] In some aspects, the oligonucleotide-ligand conjugate comprises a single-stranded oligonucleotide. In some aspects, the oligonucleotide-ligand conjugate comprises a double-stranded oligonucleotide. In some aspects, the double-stranded oligonucleotide comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises a complementary region that is complementary to a target mRNA in immune cells associated with the tumor microenvironment.

[0031] On the other hand, this disclosure provides RNAi oligonucleotide molecules capable of inhibiting STAT3 expression. Such molecules can be used alone or in combination with a second therapeutic agent, and the dosages can vary. In some embodiments, such RNAi oligonucleotide molecules consist of a sense strand and an antisense strand forming a double-stranded region.

[0032] In some aspects, the oligonucleotide for reducing STAT3 expression comprises an antisense strand of 15 to 30 nucleotides in length and a sense strand of 15 to 40 nucleotides in length, wherein the sense strand and the antisense strand form a double-stranded region, wherein the antisense strand has a complementary region that is complementary to the target mRNA sequence of STAT3 shown in SEQ ID NO:85 or SEQ ID NO:1217, and wherein the complementary region is at least 15 consecutive nucleotides in length and differs from the target sequence by no more than 3 nucleotides. In some aspects, the complementary region is completely complementary to the target sequence of STAT3.

[0033] In some aspects, the oligonucleotides used to reduce STAT3 expression include a complementary region of at least 15 consecutive nucleotides in length that is complementary to a target sequence selected from SEQ ID NO:89-280. In some aspects, the complementary region is selected from SEQ ID NO:89-280.

[0034] In some respects, oligonucleotides used to reduce STAT3 expression include:

[0035] (i) an antisense strand of 19-30 nucleotides in length, wherein the antisense strand comprises a nucleotide sequence containing a complementary region to the target sequence of STAT3 mRNA, wherein the complementary region is selected from SEQ ID NO:89-280, and

[0036] (ii) A sense strand of 19-50 nucleotides in length, comprising a complementary region complementary to the antisense strand, wherein the antisense strand and the sense strand are separate strands forming an asymmetric double-stranded region having a 1-4 nucleotide overhang at the 3' end of the antisense strand.

[0037] In some aspects, the sense strand comprises at least 15 consecutive nucleotides that differ from any one of the nucleotide sequences of SEQ ID NO: 9, 37, 65, or 69 by no more than 3 nucleotides, and the antisense strand comprises at least 15 consecutive nucleotides that differ from the nucleotide sequence of SEQ ID NO: 10, 38, 66, or 70 by no more than 3 nucleotides. In some aspects, the oligonucleotide for reducing STAT3 expression comprises a sense strand and an antisense strand, the sense strand and antisense strand comprising nucleotide sequences selected from:

[0038] (a) are SEQ ID NO:9 and 10, respectively;

[0039] (b) are SEQ ID NO:37 and 38, respectively;

[0040] (c) are SEQ ID NO:65 and 66 respectively; and,

[0041] (d) are SEQ ID NO:69 or 70 respectively.

[0042] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand that comprises a nucleotide sequence selected from SEQ ID NO:857-946.

[0043] In some respects, the oligonucleotides used to reduce STAT3 expression contain an antisense strand containing nucleotide sequences selected from SEQ ID NO:947-1036.

[0044] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0045] (a) are SEQ ID NO: 861 and 951, respectively;

[0046] (b) are SEQ ID NO: 857 and 947, respectively;

[0047] (c) are SEQ ID NO: 858 and 948, respectively;

[0048] (d) are SEQ ID NO: 859 and 949, respectively;

[0049] (e) are SEQ ID NO: 860 and 950, respectively;

[0050] (f) are SEQ ID NO: 862 and 952, respectively;

[0051] (g) are SEQ ID NO: 863 and 953, respectively;

[0052] (h) are SEQ ID NO: 864 and 954, respectively;

[0053] (i) are SEQ ID NO: 865 and 955, respectively;

[0054] (j) are SEQ ID NO: 866 and 956, respectively;

[0055] (k) are SEQ ID NO: 867 and 957, respectively;

[0056] (l) are SEQ ID NO: 868 and 958, respectively;

[0057] (m) are SEQ ID NO: 869 and 959, respectively;

[0058] (n) are SEQ ID NO: 870 and 960, respectively;

[0059] (o) are SEQ ID NO: 871 and 961, respectively;

[0060] (p) are SEQ ID NO: 872 and 962, respectively;

[0061] (q) are SEQ ID NO: 873 and 963, respectively;

[0062] (r) are SEQ ID NO: 874 and 964, respectively;

[0063] (s) are SEQ ID NO: 875 and 965, respectively;

[0064] (t) are SEQ ID NO: 876 and 966, respectively;

[0065] (u) are SEQ ID NO: 877 and 967 respectively;

[0066] (v) are SEQ ID NO: 878 and 968, respectively;

[0067] (w) are SEQ ID NO: 879 and 969, respectively;

[0068] (x) are SEQ ID NO: 880 and 970, respectively;

[0069] (y) are SEQ ID NO: 881 and 971, respectively;

[0070] (z) are SEQ ID NO: 882 and 972, respectively;

[0071] (aa) are SEQ ID NO: 883 and 973 respectively;

[0072] (bb) are SEQ ID NO: 884 and 974, respectively;

[0073] (cc) are SEQ ID NO: 885 and 975 respectively;

[0074] (dd) are SEQ ID NO: 886 and 976, respectively;

[0075] (ee) are SEQ ID NO: 887 and 977 respectively;

[0076] (ff) are SEQ ID NO: 888 and 978, respectively;

[0077] (gg) are SEQ ID NO:940 and 1030 respectively;

[0078] (hh) are SEQ ID NO: 896 and 986 respectively; and

[0079] (ii) are SEQ ID NO:920 and 1010, respectively.

[0080] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0081] (a) are SEQ ID NO: 901 and 991, respectively;

[0082] (b) are SEQ ID NO: 910 and 1000, respectively;

[0083] (c) are SEQ ID NO: 899 and 989, respectively;

[0084] (d) are SEQ ID NO: 896 and 986, respectively;

[0085] (e) are SEQ ID NO: 892 and 982, respectively;

[0086] (f) are SEQ ID NO: 890 and 980 respectively; and

[0087] (g) are SEQ ID NO:889 and 979, respectively.

[0088] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0089] (a) are SEQ ID NO: 940 and 1030, respectively;

[0090] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0091] (c) are SEQ ID NO:939 and 1029, respectively.

[0092] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0093] (a) are SEQ ID NO:915 and 1005, respectively;

[0094] (b) are SEQ ID NO:924 and 1014, respectively;

[0095] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0096] (d) are SEQ ID NO:920 and 1010, respectively.

[0097] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:862 and the antisense strand containing the nucleotide sequence of SEQ ID NO:952.

[0098] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:875 and the antisense strand containing the nucleotide sequence of SEQ ID NO:965.

[0099] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:876 and the antisense strand containing the nucleotide sequence of SEQ ID NO:966.

[0100] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:920 and the antisense strand containing the nucleotide sequence of SEQ ID NO:966.

[0101] In any of the foregoing or related aspects, the antisense strand is 19 to 27 nucleotides in length or 21 to 27 nucleotides in length. In some embodiments, the antisense strand is 22 nucleotides in length.

[0102] In any of the foregoing or related aspects, the sense strand is 19 to 40 nucleotides in length. In some embodiments, the sense strand is 36 nucleotides in length.

[0103] In any of the foregoing or related aspects, the oligonucleotide has a double-stranded region of at least 19 nucleotides in length. In any of the foregoing or related aspects, the oligonucleotide has a double-stranded region of at least 21 nucleotides in length. In some embodiments, the double-stranded region is 20 nucleotides in length.

[0104] In some embodiments, the complementary region to STAT3 is at least 19 consecutive nucleotides in length. In some embodiments, the complementary region to STAT3 is at least 21 consecutive nucleotides in length.

[0105] In any of the foregoing or related aspects, the oligonucleotide comprises, at its 3' end, a stem-loop structure as follows: S1-loop-S2, wherein S1 and S2 are complementary, and wherein the loop forms a loop of 3 to 5 nucleotides in length between S1 and S2.

[0106] In some embodiments, the oligonucleotide for reducing STAT3 expression for the treatment or prevention of cancer and / or prevention of cancer metastasis comprises an antisense strand and a sense strand, wherein the antisense strand is 21 to 27 nucleotides in length and has a complementary region complementary to the target mRNA sequence of STAT3 shown in SEQ ID NO:85 or SEQ ID NO:1217, wherein the sense strand comprises a stem-loop at its 3' end as follows: S1-loop-S2, wherein S1 is complementary to S2, and wherein the loop forms a loop of 3 to 5 nucleotides in length between S1 and S2, and wherein the antisense strand and the sense strand form a double-stranded structure of at least 19 nucleotides in length.

[0107] In some embodiments, the ring is a tetracyclic ring. In some embodiments, the ring is 4 nucleotides in length. In some embodiments, the ring contains the sequence GAAA.

[0108] In some embodiments, the oligonucleotide comprises an antisense strand of 27 nucleotides in length and a sense strand of 25 nucleotides in length. In some embodiments, the oligonucleotide comprises an antisense strand of 22 nucleotides in length and a sense strand of 36 nucleotides in length.

[0109] In any of the foregoing or related aspects, the double-stranded region of the oligonucleotide of this disclosure includes a 3'-overhang sequence on the antisense strand. In some embodiments, the 3'-overhang sequence on the antisense strand is 2 nucleotides in length. In some embodiments, the 3'-overhang sequence is GG.

[0110] In some embodiments, the oligonucleotide comprises an antisense strand and a sense strand, each ranging in length from 21 to 23 nucleotides. In some embodiments, the oligonucleotide comprises a duplex structure ranging in length from 19 to 21 nucleotides. In some such embodiments, the oligonucleotide comprises a 3'-overhang sequence of one or more nucleotides in length, wherein the 3'-overhang sequence is present on the antisense strand, on the sense strand, or on both the antisense strand and the sense strand. In some embodiments, the 3'-overhang sequence is 2 nucleotides in length, wherein the 3'-overhang sequence is located on the antisense strand, and wherein the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length, such that the sense strand and the antisense strand form a duplex of 21 nucleotides in length.

[0111] In some embodiments, the oligonucleotide comprises at least one modified nucleotide. In some embodiments, the modified nucleotide comprises a 2'-modification. In some embodiments, all nucleotides of the oligonucleotide are modified, for example, by a 2'-modification. In some embodiments, about 10-15%, 10%, 11%, 12%, 13%, 14%, or 15% of the nucleotides of the sense strand comprises a 2'-fluorinated modification. In some embodiments, about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35% of the nucleotides of the antisense strand comprises a 2'-fluorinated modification. In some embodiments, about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35% of the nucleotides of the oligonucleotide comprises a 2'-fluorinated modification. In some embodiments, the sense strand comprises 36 nucleotides at positions 1-36 from 5' to 3', wherein positions 8-11 contain a 2'-fluorine modification. In some embodiments, the antisense strand comprises 22 nucleotides at positions 1-22 from 5' to 3', wherein positions 2, 3, 4, 5, 7, 10, and 14 contain a 2'-fluorine modification. In some embodiments, the remaining nucleotides contain a 2'-O-methyl modification.

[0112] In some embodiments, the oligonucleotide comprises at least one modified internucleotide bond, preferably a phosphate thioester bond.

[0113] In some embodiments, the 4'-carbon of the sugar in the 5'-nucleotide of the antisense strand comprises a phosphate ester analog, such as oxymethylphosphonate, vinylphosphonate, or malonylphosphonate.

[0114] In some embodiments, at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands, such as carbohydrates, amino sugars, cholesterol, peptides, or lipids.

[0115] In some embodiments, the targeting ligand is a saturated fatty acid moiety. In some embodiments, the length of the saturated fatty acid moiety varies from C10 to C24. In some embodiments, the saturated fatty acid moiety has a length of C16. In some embodiments, the saturated fatty acid moiety has a length of C18. In some embodiments, the saturated fatty acid moiety has a length of C22.

[0116] In some embodiments, the targeting ligand comprises an N-acetylgalactosamine (GalNAc) moiety. In some embodiments, the (GalNAc) moiety comprises a monovalent GalNAc moiety, a divalent GalNAc moiety, a trivalent GalNAc moiety, or a tetravalent GalNAc moiety.

[0117] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0118] (a) are SEQ ID NO: 1041 and 1131, respectively;

[0119] (b) are SEQ ID NO: 1037 and 1127, respectively;

[0120] (c) are SEQ ID NO: 1038 and 1128, respectively;

[0121] (d) are SEQ ID NO: 1039 and 1129, respectively;

[0122] (e) are SEQ ID NO: 1040 and 1130, respectively;

[0123] (f) are SEQ ID NO: 1042 and 1132, respectively;

[0124] (g) are SEQ ID NO: 1043 and 1133, respectively;

[0125] (h) are SEQ ID NO: 1044 and 1134, respectively;

[0126] (i) are SEQ ID NO: 1045 and 1135, respectively;

[0127] (j) are SEQ ID NO: 1046 and 1136, respectively;

[0128] (k) are SEQ ID NO: 1047 and 1137, respectively;

[0129] (l) are SEQ ID NO: 1048 and 1138, respectively;

[0130] (m) are SEQ ID NO: 1049 and 1139, respectively;

[0131] (n) are SEQ ID NO: 1050 and 1140, respectively;

[0132] (o) are SEQ ID NO: 1051 and 1141, respectively;

[0133] (p) are SEQ ID NO: 1052 and 1142, respectively;

[0134] (q) are SEQ ID NO: 1053 and 1143, respectively;

[0135] (r) are SEQ ID NO: 1054 and 1144, respectively;

[0136] (s) are SEQ ID NO: 1055 and 1145, respectively;

[0137] (t) are SEQ ID NO:1056 and 1146, respectively;

[0138] (u) are SEQ ID NO: 1057 and 1147, respectively;

[0139] (v) are SEQ ID NO: 1058 and 1148, respectively;

[0140] (w) are SEQ ID NO: 1059 and 1149, respectively;

[0141] (x) are SEQ ID NO: 1060 and 1150, respectively;

[0142] (y) are SEQ ID NO: 1061 and 1151, respectively;

[0143] (z) are SEQ ID NO: 1062 and 1152, respectively;

[0144] (aa) are SEQ ID NO: 1063 and 1153 respectively;

[0145] (bb) are SEQ ID NO: 1064 and 1154, respectively;

[0146] (cc) are SEQ ID NO: 1065 and 1155 respectively;

[0147] (dd) are SEQ ID NO: 1066 and 1156, respectively;

[0148] (ee) are SEQ ID NO: 1067 and 1157 respectively;

[0149] (ff) are SEQ ID NO: 1068 and 1158, respectively;

[0150] (gg) are SEQ ID NO: 1120 and 1210 respectively;

[0151] (hh) are SEQ ID NO: 1076 and 1166 respectively; and

[0152] (ii) are SEQ ID NO:1100 and 1190, respectively.

[0153] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0154] (a) are SEQ ID NO: 1081 and 1171, respectively;

[0155] (b) are SEQ ID NO: 1090 and 1180, respectively;

[0156] (c) are SEQ ID NO: 1079 and 1169, respectively;

[0157] (d) are SEQ ID NO: 1076 and 1166, respectively;

[0158] (e) are SEQ ID NO: 1072 and 1162, respectively;

[0159] (f) are SEQ ID NO: 1070 and 1160 respectively; and

[0160] (g) are SEQ ID NO:1069 and 1159, respectively.

[0161] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0162] (a) are SEQ ID NO: 1120 and 1210, respectively;

[0163] (b) are SEQ ID NO: 1117 and 1207 respectively; and

[0164] (c) are SEQ ID NO:1119 and 1209, respectively.

[0165] In some respects, oligonucleotides used to reduce STAT3 expression contain sense and antisense strands, which comprise nucleotide sequences selected from the following:

[0166] (a) are SEQ ID NO: 1095 and 1185, respectively;

[0167] (b) are SEQ ID NO: 1104 and 1194, respectively;

[0168] (c) are SEQ ID NO: 1093 and 1183 respectively; and

[0169] (d) are SEQ ID NO:1100 and 1190, respectively.

[0170] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:1042 and the antisense strand containing the nucleotide sequence of SEQ ID NO:1132.

[0171] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:1055 and the antisense strand containing the nucleotide sequence of SEQ ID NO:1145.

[0172] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:1056 and the antisense strand containing the nucleotide sequence of SEQ ID NO:1146.

[0173] In some respects, the oligonucleotides used to reduce STAT3 expression contain a sense strand and an antisense strand, the sense strand containing the nucleotide sequence of SEQ ID NO:1100 and the antisense strand containing the nucleotide sequence of SEQ ID NO:1190.

[0174] In some embodiments, the targeting ligand is conjugated to one or more nucleotides of the stem-loop. In some embodiments, up to four nucleotides of the stem-loop are each conjugated to a monovalent GalNAc portion.

[0175] In some embodiments, the oligonucleotides disclosed herein are RNAi oligonucleotides.

[0176] In some embodiments, the disclosure of this disclosure is a pharmaceutical composition comprising one or more oligonucleotides and a pharmaceutically acceptable carrier, delivery agent, or excipient.

[0177] In some aspects, the oligonucleotides of this disclosure are provided in the form of a kit for treating cancer. In other aspects, the oligonucleotides of this disclosure are provided in the form of a kit for treating diseases, conditions, or illnesses associated with STAT3 expression. In some embodiments, the kit comprises the oligonucleotides described herein and a pharmaceutically acceptable carrier. In some embodiments, the kit further includes a packaging insert containing instructions for administering the oligonucleotides to a subject with cancer. In some embodiments, the kit further includes a packaging insert containing instructions for administering the oligonucleotides to a subject with a disease, condition, or illness associated with STAT3 expression.

[0178] In some embodiments, this disclosure provides a method for delivering oligonucleotides to a subject, the method comprising administering a pharmaceutical composition to the subject. In some embodiments, this disclosure provides a method for delivering oligonucleotides to immune cells associated with the tumor microenvironment, the method comprising administering the oligonucleotide-ligand conjugates described herein.

[0179] In some embodiments, the oligonucleotide-ligand conjugate is delivered to tumor-associated cells. In some embodiments, the oligonucleotide-ligand conjugate is delivered to immune cells. In some embodiments, the immune cells are myeloid-derived suppressor cells (MDSCs). In some embodiments, the immune cells are T cells.

[0180] In some embodiments, the oligonucleotides described herein target STAT3. In some embodiments, the oligonucleotides target STAT3 and the siRNA also regulates PD-LI mRNA expression.

[0181] In some aspects, this disclosure provides methods for reducing the expression of target mRNAs in cells or cell populations associated with the tumor microenvironment in a subject by administering the oligonucleotides of this disclosure. In other aspects, this disclosure provides methods for reducing STAT3 expression in cells, cell populations, or a subject by administering the oligonucleotides of this disclosure. In some embodiments, the method for reducing STAT3 expression in cells, cell populations, or a subject includes the steps of: contacting the cells or cell population with or administering to the subject an effective amount of one or more oligonucleotides described herein, or a pharmaceutical composition thereof. In some embodiments, the method for reducing STAT3 expression includes reducing the amount or level of STAT3 and PD-L1 mRNA, the amount or level of STAT3 and PD-L1 protein, or both.

[0182] In some embodiments, this disclosure provides pharmaceutical products for use as therapeutic agents. In some embodiments, the therapeutic agent is administered as a monotherapy and is an inhibitor of STAT3 expression.

[0183] In some implementations, a method of treating human subjects resistant to anti-PD1 or anti-PD-L1 therapy is provided, comprising administering any of the STAT3-targeting oligonucleotides described herein. Subjects resistant to anti-PD1 or anti-PD-L1 therapy include those whose benefit from anti-PD1 or anti-PD-L1 therapy has been maintained at a reduction of at least one standard deviation for more than 3 months compared to a non-resistant control.

[0184] In some embodiments, the therapeutic agent is administered as a monotherapy and is an inhibitor of STAT3 and PD-L1 expression. In some embodiments, this disclosure provides a pharmaceutical product comprising at least a first therapeutic agent and a second therapeutic agent, wherein the first therapeutic agent is an inhibitor of STAT3. In some embodiments, the therapeutic agent is administered before or intermittently with the second therapeutic agent. In some embodiments, the first therapeutic agent is administered in parallel or simultaneously with the second therapeutic agent. In some embodiments, this disclosure provides a pharmaceutical product comprising more than two therapeutic agents, wherein the first therapeutic agent is an inhibitor of STAT3.

[0185] In some aspects, this disclosure provides a method of treating a subject's cancer, the method comprising administering to the subject an effective amount of the oligonucleotide-ligand conjugate described herein that targets an immunosuppressive regulator, in combination with one or more additional therapeutic agents or procedures. In some embodiments, this disclosure provides a method of treating a subject's cancer, the method comprising administering to the subject an effective amount of the oligonucleotide described herein that targets STAT3, in combination with one or more additional therapeutic agents or procedures. In some aspects, the second therapeutic agent or procedure is selected from: chemotherapy, targeted anticancer therapy, oncolytic drugs, cytotoxic agents, immunotherapy, cytokines, surgery, radiation procedures, activators of co-stimulatory molecules, inhibitors of inhibitory molecules, vaccines or cellular immunotherapy, gene therapy, or combinations thereof.

[0186] In some embodiments, this disclosure provides a method of treating a subject suffering from a disease, condition, or status associated with STAT3 expression, the method comprising administering to the subject a therapeutically effective amount of the oligonucleotide or oligonucleotide-ligand conjugate described herein. In some embodiments, the oligonucleotide or oligonucleotide-ligand conjugate is administered in combination with a second composition or therapeutic agent. In some embodiments, the second composition or therapeutic agent targets TGFB, CXCR2, CCR2, ARG1, PTGS2, SOCS1, or PD-L1.

[0187] In some embodiments, the one or more additional therapeutic agents are PD-1 antagonists, CTLA-4 inhibitors, TGFB inhibitors, CXCR2 inhibitors, CCR2 antagonists, ARG1 inhibitors, PTGS2 inhibitors, SOCS1 modulators, or combinations thereof.

[0188] In some implementations, the one or more additional therapeutic agents are PD-1 antagonists.

[0189] In some embodiments, the PD-1 antagonist is selected from: PDR001, nivolumab, pembrolizumab, pidilizumab, MEDI0680, REGN2810, TSR-042, PF-06801591, and AMP-224. In some embodiments, the PD-1 antagonist is selected from: FAZ053, atezolizumab, avelumab, durvalumab, and BMS-936559.

[0190] In some embodiments, the one or more additional therapeutic agents are CTLA-4 inhibitors. In some embodiments, the CTLA-4 inhibitor is ipilimumab or tremelimumab.

[0191] In some embodiments, the one or more additional therapeutic agents are TGFB inhibitors. In some embodiments, the TGFB inhibitor is Frisolimumab, LY3022859, or PF-03446962.

[0192] In some embodiments, the one or more additional therapeutic agents are ARG1 inhibitors. In some embodiments, the ARG1 inhibitor is CB-1158. Attached Figure Description

[0193] Figure 1A The structures of chemically modified RNAi oligonucleotide molecules are provided, wherein GalNAc (top) or lipid (bottom) is conjugated with base molecules to generate oligonucleotide-ligand conjugates.

[0194] Figure 1B A structure for a lipid tail suitable for conjugation with RNAi oligonucleotide molecules was provided.

[0195] Figure 2A This is a graph representing the level of residual human ALDH2 mRNA in xenograft epithelium of human LS411N tumors from mice three days after treatment with ALDH2 RNAi-GalXC lipid conjugates with different acyl chain lengths and degrees of unsaturation at 10 mg / kg.

[0196] Figure 2B This is a graph representing the residual mouse Aldh2 mRNA levels in the tumor microenvironment (TME) isolated from a human LS411N tumor xenograft. The TME was isolated from mice three days after treatment with ALDH2-GalXC lipid conjugates with different acyl chain lengths and degrees of unsaturation at 10 mg / kg.

[0197] Figure 3A This is a graph showing the residual human ALDH2 mRNA in human LS411N tumor xenograft epithelium after treatment with different doses of the GalXC-ALDH2-C22 conjugate. Samples were collected from mice on days 3, 7, and 14 post-treatment.

[0198] Figure 3B This is a graph showing the residual mouse Aldh2 mRNA in host mouse tissues within the tumor microenvironment collected from human LS411N tumors after treatment with different doses of the GalXC-ALDH2-C22 conjugate. Samples were collected on days 3, 7, and 14 post-treatment.

[0199] Figure 4A and Figure 4B This is shown in the tumor-draining lymph nodes of mice carrying human LS411N tumor xenografts. Figure 4A ) and in the lymph nodes of mice without tumors ( Figure 4B (Figure showing the remaining Aldh2 mRNA in mice after treatment with 25 mg / kg GalXC-ALDH2-C22 conjugate).

[0200] Figure 5A This is a graph showing the change over time in residual mouse Aldh2 mRNA levels after treatment with the GalXC-ALDH2-C22 conjugate or PBS in mouse tumor draining lymph nodes (TdLN) of human LS411N tumor xenografts, compared to non-TdLN. Normalized mRNA is relative to PBS-treated mice.

[0201] Figure 5B The provided figure shows the Pdl1 mRNA level in mouse tumor draining lymph nodes (TdLN) from LS411N tumor xenograft mice treated with GalXC-ALDH2-C22 compared to non-TdLN.

[0202] Figure 6 This indicates the presence of tumor-associated CD11b isolated from a human LS411N tumor xenograft treated with 25 mg / kg GalXC-ALDH2-C22. + A graph showing Arg1 expression in myeloid-derived suppressor cells (MDSCs) and normal splenic myeloid cells. MDSCs and tumor cells were isolated from mice three days after treatment and measured using CDllb mRNA. BLOQ = lower limit of quantitation.

[0203] Figure 7A and Figure 7B This demonstrates the isolation of CDllb+MDSCs from mice with human LS411N tumor xenografts treated with the GalXC-ALDH2-C22 conjugate. Figure 7A ) and tumor cells ( Figure 7B A graph showing the remaining Aldh2 mRNA levels in mice.

[0204] Figure 8A and Figure 8B It shows a mass of tumor derived from the Pan02 xenograft. Figure 8A ) and liver ( Figure 8B Figure of residual mouse Aldh2 mRNA. Mice were treated with a specified GalXC-ALDH2 lipid conjugate at 25 mg / kg and mRNA was measured on day 3.

[0205] Figure 8C and Figure 8D This is shown on days 7 and 14 after treatment with the designated GalXC-ALDH2-lipid conjugate at 25 mg / kg, in the presence of mass tumors from mice with Pan02 xenografts. Figure 8C A diagram of the remaining mouse Aldh2 mRNA in tumor draining lymph nodes (TdLN).

[0206] Figure 9 The provided figure shows the expression of differentiation mRNA markers (Ly6G, Cxcr2, Slc27a2Ptgs2) in TME-isolated G-MDSCs from untreated (control) PAN02 tumors.

[0207] Figure 10 The provided figure shows the expression of differentiation mRNA markers (Ly6G, Cxcr2, Slc27a2, and Ptgs2) in M-MDSCs isolated from the TME.

[0208] Figure 11 and Figure 12 The provided figure shows the differential expression of lipid transport receptors in G-MDSCs and M-MDSCs in untreated (control) tissues.

[0209] Figure 13A and Figure 13B The provided graph shows the graph from Pan02 ( Figure 13A ) and B16F10 ( Figure 13B The residual Aldh2 mRNA levels in mice after treatment with 25 mg / kg GalXC-ALDH2-C18 conjugate in G-MDSCs and M-MDSCs isolated by TME were determined. Once the tumors reached 300-500 mm, the mice were randomly assigned to groups, treated on day 1, and tissues were collected for analysis on day 3.

[0210] Figure 13C and Figure 13D The provided graph shows the situation on day 3 ( Figure 13C) and the 7th day ( Figure 13D The residual mouse Aldh2 mRNA levels after treatment with 50 mg / kg GalXC-ALDH2-C18 conjugate in G-MDSC and M-MDSC of Pan02 TME from mice.

[0211] Figures 14A-14C This is a G-MDSC (Growth Dependency Syndrome Scale) of a Pan02 xenograft implanted in a mouse. Figure 14A M-MDSC Figure 14B ) and TdLN( Figure 14C A diagram showing the relative representation of Stat3 in ).

[0212] Figure 15A and Figure 15B This is a graph showing the residual mouse Stat3 mRNA levels in the livers of mice treated with GalXC-STAT3-conjugates (GalNAc conjugates) targeting different regions of Stat3 mRNA. Mice were administered a single dose (3 mg / kg)... Figure 15A ) and multiple doses to determine dose-responsiveness ( Figure 15B The arrow indicates which construct to select for further study.

[0213] Figure 16A and Figure 16B This is a graph showing the expression of Stat3 mRNA in mice treated with the GalXC-STAT3-C18 conjugate in the G-MDSCs and M-MDSCs of the Pan02 xenograft implanted in mice. Tumors were treated with 25 mg / kg (…). Figure 16A ) and 50mg / kg ( Figure 16B ) Administer the medication.

[0214] Figure 17A and Figure 17B This is shown to reduce tumor mass (TME) in Pan02 xenograft mice after treatment with the GalXC-STAT3-C18 conjugate at doses of 25 and 50 mg / kg. Figure 17A ) and TdLN( Figure 17B A diagram showing the expression of Stat3 mRNA in mice.

[0215] Figure 18A The provided figure shows the effect of GalXC-STAT3-C18-4123 on Stat3 and Pdl1 mRNA levels in G / M-MDSCs in the TME and TdLN of Pan02 xenograft mice on day 3 after conjugate administration at doses of 25 or 50 mg / kg.

[0216] Figure 18B The provided graph shows the results on day 7 after administration of the conjugate at a dose of 25 mg / kg.

[0217] Effects of GalXC-STAT3-C18-4123 on Stat3 and Pdl1 mRNA levels in TdLN of Pan02 xenograft mice.

[0218] Figure 19A and Figure 19B This is a graph showing the in vivo effect of subcutaneous treatment with a total dose of 50 mg / kg of GalXC-STAT3-C18-4123 on tumor volume in immunocompetent mice bearing Pan02 rat pancreatic tumors. Four doses of 12.5 mg / kg ( Figure 19A ) or two doses of 25 mg / kg ( Figure 19B Mice were treated with a dose of the conjugate.

[0219] Figure 20 The provided figure depicts the percentage (%) of human STAT3 mRNA remaining in Huh7 cells endogenously expressing human STAT3 after 24 hours of treatment with DsiRNA targeting different regions of the STAT3 gene at 1 nM. 192 DsiRNAs were designed and screened. Two primer pairs were used. Expression between samples was normalized using the HPRT and SFRS9 housekeeping genes (forward 1 - SEQ ID NO: 1219, reverse 1 - SEQ ID NO: 1220; probe 1 - SEQ ID NO: 1221; forward 2 - SEQ ID NO: 1222, reverse 2 - SEQ ID NO: 1223; probe 2 - SEQ ID NO: 1224).

[0220] Figure 21A and Figure 21B The provided figure depicts the percentage (%) of human STAT3 mRNA remaining in Huh7 cells endogenously expressing human STAT3 after 24 hours of treatment with DsiRNA targeting different regions of the STAT3 gene at 0.05 nM, 0.3 nM, or 1 nM. Figure 21A Forty-eight GalNAc-conjugated STAT3 oligonucleotides were identified, and 34 of these oligonucleotides were selected for further in vivo assays. Figure 21B ).

[0221] Figure 22A and Figure 22BThe provided figure depicts the percentage (%) of residual human STAT3 mRNA in the livers of mice (hydrodynamic injection model) exogenously expressing human STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered 1 mg / kg of the GalNAc-STAT3 oligonucleotides shown, prepared in PBS. Three days post-administration, mice were hydrodynamically injected (HDI) with a DNA plasmid encoding human STAT3. Human STAT3 mRNA levels were measured from liver samples collected 18 hours post-injection. Arrows indicate the oligonucleotides selected for dose-response analysis. Hs / Mf = human / monkey co-sequence; Hs / Mm = human / mouse co-sequence; Hs / Mf / Mm = human / monkey / mouse triple co-sequence.

[0222] Figure 23 A graph depicting the dose-response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of residual human STAT3 mRNA in the livers of exogenously STAT3-expressing mice (HDI model) after treatment with human GalNAc-conjugated STAT3 oligonucleotides at three doses (0.3 mg / kg, 1 mg / kg) was measured. Human STAT3 mRNA levels were determined from liver samples collected 18 hours after injection of the plasmid encoding human STAT3. Arrows indicate the oligonucleotides selected for dose-response analysis. Hs / Mf = human / monkey common sequence; Hs / Mm = human / mouse common sequence.

[0223] Figure 24 The provided figure depicts the normalized relative mouse STAT3 mRNA (relative to Ppib) remaining in the liver of mice endogenously expressing mouse STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered 3 mg / kg of the GalNAc-STAT3 oligonucleotides prepared in PBS as shown. Liver samples were collected five days post-administration, and mouse STAT3 mRNA levels were measured. Arrows indicate the top-ranked oligonucleotides and those selected for dose-response studies.

[0224] Figure 25 The provided figure depicts the normalized relative mouse STAT3 mRNA (relative to Ppib) remaining in the liver of mice endogenously expressing mouse STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered 3 mg / kg of the GalNAc-STAT3 oligonucleotides prepared in PBS as shown. Liver samples were collected five days post-administration, and mouse STAT3 mRNA levels were measured. Arrows indicate the oligonucleotides selected for dose-response studies.

[0225] Figure 26A and Figure 26BA plot depicting the dose-response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of residual mouse STAT3 mRNA in the livers of mice endogenously expressing STAT3 was measured after treatment with human GalNAc-conjugated STAT3 oligonucleotides at three doses (0.3 mg / kg, 1 mg / kg, and 3 mg / kg). Mouse STAT3 mRNA levels were determined from liver samples collected after 5 days. TC = triple common (mouse / human / monkey); Hs_Mm = human / mouse.

[0226] Figure 27 The provided figure depicts the percentage (%) of residual human STAT3 mRNA in the livers of mice (hydrodynamic injection model) exogenously expressing human STAT3 after treatment with GalNAc-conjugated STAT3 oligonucleotides. Mice were subcutaneously administered 1 mg / kg of the GalNAc-STAT3 oligonucleotides shown, prepared in PBS. Three days post-administration, mice were hydrodynamically injected (HDI) with a DNA plasmid encoding human STAT3. Human STAT3 mRNA levels were measured from liver samples collected 18 hours post-injection. Arrows indicate the oligonucleotides selected for dose-response studies.

[0227] Figure 28 A graph depicting the dose-response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of residual human STAT3 mRNA in the livers of exogenously human STAT3-expressing mice (hydrodynamic injection model) after treatment with GalNAc-conjugated STAT3 oligonucleotides is shown. Mice were subcutaneously administered three doses (0.3 mg / kg, 1 mg / kg, and 3 mg / kg) of the GalNAc-STAT3 oligonucleotides prepared in PBS. Three days post-administration, mice were hydrodynamically injected (HDI) with a DNA plasmid encoding human STAT3. Human STAT3 mRNA levels were measured from liver samples collected 18 hours post-injection. TC = triple common (mice / humans / monkeys); Hs_Mm = human / mice; Hs = human.

[0228] Figure 29 A graph depicting the dose-response of GalNAc-conjugated STAT3 oligonucleotides is provided. The percentage (%) of residual human STAT3 mRNA in the livers of exogenously human STAT3-expressing mice (hydrodynamic injection model) after treatment with GalNAc-conjugated STAT3 oligonucleotides is shown. Mice were subcutaneously administered two doses (0.3 mg / kg and 1 mg / kg) of the GalNAc-STAT3 oligonucleotides prepared in PBS as shown. Three days after administration, mice were hydrodynamically injected (HDI) with a DNA plasmid encoding human STAT3. Human STAT3 mRNA levels were measured from liver samples collected 18 hours post-injection.

[0229] Figure 30 The provided figure depicts the percentage (%) of residual human STAT1 mRNA in Huh7 cells endogenously expressing STAT3 and STAT1 treated with GalNAc-conjugated STAT3 oligonucleotides. Cells were treated with three doses (0.05 nM, 0.3 nM, and 1 nM) of oligonucleotides for 24 hours. Detailed Implementation

[0230] This disclosure will now be described more fully below with reference to the accompanying drawings, which illustrate illustrative embodiments of the disclosure. However, this disclosure may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.

[0231] In some aspects, this disclosure provides oligonucleotide-ligand conjugates (e.g., RNAi oligonucleotide-lipid conjugates) that reduce the expression of target genes (e.g., those encoding immunosuppressive regulators) in immune cells within the tumor microenvironment. In other aspects, this disclosure provides methods for treating diseases or conditions (e.g., cancer) using the oligonucleotide-ligand conjugates described herein or pharmaceutically acceptable compositions thereof. In other aspects, this disclosure provides methods for preparing medicaments for treating cancer using the oligonucleotide-ligand conjugates described herein. In other aspects, the oligonucleotide-ligand conjugates provided herein are used to treat cancer by regulating (e.g., inhibiting or reducing) the expression of target genes encoding immunosuppressive regulators in immune cells within the tumor microenvironment. In some aspects, this disclosure provides methods for treating cancer by reducing the expression of target genes encoding immunosuppressive regulators in immune cells within the tumor microenvironment.

[0232] definition

[0233] The publications discussed throughout this document are provided only for their disclosure prior to the filing date of this application. Nothing in this document should be construed as an admission that the inventor has no right to disclose prior to this document based on prior disclosure.

[0234] As used herein, the term “and / or” includes any and all combinations of one or more of the associated listed items. Furthermore, the singular form and the articles “a,” “an,” and “the” are intended to include the plural form as well, unless otherwise expressly stated. It should also be understood that the terms “comprising” and / or “including” as used in this specification refer to the presence of the stated features, integers, steps, operations, elements, and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. Furthermore, it should be understood that when an element including a component or subsystem is referred to and / or shown as connected or coupled to another element, it may be directly connected or coupled to that other element, or an intermediary element may be present.

[0235] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Exemplary methods and materials are described herein, but similar or equivalent methods and materials may be used in practice with the disclosed methods and compositions.

[0236] General texts describing the molecular biology techniques useful here (including the use of vectors, promoters, and many other related topics) include Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152*, (Academic Press, Inc., San Diego, Calif.) ("Berger"); Sambrook et al., *Molecular Cloning—A Laboratory Manual*, 2nd ed., Vols. 1–3, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989 ("Sambrook"); and *Current Protocols in Molecular Biology*, edited by F. Mausubel et al., *Current Protocols, A Joint Venture Between the Engelene Publication Associations*, Inc. and John Wiley and... SONS, INC. (as of 1999) ("Ausubel")Examples of protocols sufficient to guide technicians in performing in vitro amplification methods (including polymerase chain reaction (PCR), ligase chain reaction (LCR), Qβ-replicaase amplification, and other RNA polymerase-mediated techniques (e.g., NASBA), such as methods for generating homologous nucleic acids of this disclosure) can be found in Berger, Sambrook, and Ausubel, and Mullis et al., (1987) U.S. Patent No. 4,683,202; Innis et al., ed., (1990); PCR PROTOCOLS: A GUIDE TOMETHODS AND APPLICATIONS (Academic Press Inc. San Diego, Calif.) ("Innis"); Arnheim and Levinson (October 1, 1990) Cand EN 36-47; J. NIH RES. (1991) 3:81-94; Kwoh et al., (1989) PROC. NATL. ACAD. SCI. USA 86:1173; Guatelliet et al., (1990) PROC.NAT'L.ACAD.SCI.USA 87:1874; Lomell et al., (1989) J.CLIN.CHEM 35:1826; Landegren et al., (1988) SCIENCE 241:1077-80; Van Brunt (1990) BIOTECHNOLOGY 8:291-94; Wu and Wallace (1989) GENE 4:560; Barringer et al., (1990) GENE 89:117; and Sooknanan and Malek (1995) BIOTECHNOLOGY 13:563-564. An improved method for cloning in vitro amplification of nucleic acids is described in U.S. Patent No. 5,426,039 to Wallace et al. Cheng et al., (1994) NATURE 369:684-85 and the references cited therein, summarized an improved method for amplifying large nucleic acids by PCR, which generated PCR amplicones of up to 40kb.

[0237] Unless the context clearly specifies otherwise, the singular forms “a,” “an,” and “the” as used in this specification and the appended claims include plural indicators. Thus, for example, reference to “a drug carrier” includes a mixture of two or more such carriers, and so on.

[0238] A range may be expressed herein as from “about” one value and / or to “about” another value. When such a range is expressed, another embodiment includes from one value and / or to another value. Similarly, when a value is expressed as an approximation using the antecedent “about,” it should be understood that the value constitutes another embodiment. It should further be understood that the endpoints of each range are important both in relation to and independent of the other endpoint. It should also be understood that several values ​​are disclosed herein, and each value is disclosed herein as “about” the value in addition to itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It should also be understood that when a value is disclosed, “less than or equal to” the value, “greater than or equal to” the value, and possible ranges between values ​​are also disclosed, as properly understood by those skilled in the art. For example, if the value “10” is disclosed, then “less than or equal to 10” and “greater than or equal to 10” are also disclosed. It should also be understood that throughout the application, data is provided in several different formats, and this data represents a range of endpoints and starting points, as well as any combination of data points. For example, if specific data point "10" and specific data point 15 are disclosed, it should be understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15, as well as the interval between 10 and 15, are considered to be disclosed. It should also be understood that each unit between the two specific units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0239] In this specification and the accompanying claims, several terms will be referenced, and these terms shall be defined to have the following meanings:

[0240] The terms “cancer” or “tumor” include, but are not limited to, solid tumors and hematogenous tumors. These terms encompass diseases of the skin, tissues, organs, bones, cartilage, blood, and blood vessels. These terms further cover primary and metastatic cancers.

[0241] The term "PD-1" refers to a protein found on T cells that helps control the immune response. When PD-1 binds to another protein called PD-L1, it helps prevent T cells from killing other cells, including cancer cells. Some anticancer drugs, known as immune checkpoint inhibitors, are used to block PD-1. When this protein is blocked from acting on T cells, it can be used to kill cancer cells.

[0242] The term "STAT3" refers to Signal Transduction and Transcription Activator 3 (STAT3), a transcription factor encoded by the STAT3 gene (STAT3_human(Hs)NM_001369512.1 Genbank RefSeq#, or NM_139276.3) in humans. STAT3 mediates the expression of various genes in response to cellular stimuli, and therefore plays a crucial role in many cellular processes such as cell growth and apoptosis, as well as cancer growth and progression.

[0243] The term "TGF-β" refers to transforming growth factor β (TGF-β), a cytokine involved in immune and stem cell regulation and differentiation. TGF-β is an important cytokine with defined roles in many pathologies, including cancer, infectious diseases, and autoimmune diseases. Its immunosuppressive function in the tumor microenvironment contributes to tumorigenesis (Massague et al., CELL, 103(2):295-309(2000)).

[0244] The term "CXCR2" refers to CXC motif chemokine receptor 2 (CXCR2), which is the receptor for interleukin-8 (IL-8) and a member of the G protein-coupled receptor family. CXCR2 can mediate the migration of neutrophils to inflammatory areas.

[0245] The term "CCR2" refers to the type 2 CC chemokine receptor (CCR2), which is the receptor for monocyte chemoattractant protein 1 (MCP1). Inflammatory responses in some cancers may be partially mediated by the activity of MCP1.

[0246] The term “ARG1” refers to arginase-1 (ARG1), an enzyme that converts L-arginine into urea and L-ornithine. L-arginine and its downstream metabolites contribute to a suppressive tumor microenvironment by regulating T cell activity (Kim et al., FRONTIERS IN ONCOLOGY, 8:67 (2018)).

[0247] The term "PTGS2" refers to prostaglandin intraperoxidase 2 (PTGS2), also known as cyclooxygenase-2 or COX-2. PTGS2 is a key enzyme in prostaglandin synthesis. Prostaglandins can inhibit the anti-tumor activity of some immune cells and contribute to a suppressive tumor microenvironment.

[0248] The term "CTLA-4" refers to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or differentiation cluster 152 (CD152), a protein found on T cells that helps control the immune response. CTLA-4 was the first immune checkpoint target, and CTLA-4 inhibitors have been developed as breakthrough anticancer therapies.

[0249] The term "SOCS1" refers to cytokine signaling inhibitor 1 (SOCS1), a member of the STAT-induced STAT inhibitor (SSI) family. SOCS1 is a cytokine-inducible negative regulator of cytokine signaling.

[0250] As used herein, the terms "cold tumor" or "non-inflammatory tumor" refer to a tumor or tumor microenvironment in which there is minimal or no anti-tumor immune cells, such as tumor-infiltrating lymphocytes (TILs), and / or contains immunosuppressive-associated cell subsets, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and M2 macrophages. Specifically, in some embodiments, a cold tumor is characterized by a low number or even absence of infiltrating anti-tumor immune cells, such cells may be present but remain in the surrounding matrix and are therefore unable to colonize the tumor microenvironment to provide their anti-tumor function.

[0251] As used herein, “complementary” refers to a structural relationship between two nucleotides (e.g., on two opposing nucleic acids or on opposing regions of a single nucleic acid strand) that allows the two nucleotides to form base pairs with each other. For example, a purine nucleotide of a nucleic acid complementary to a pyrimidine nucleotide of an opposing nucleic acid can be base-paired together by forming hydrogen bonds with each other. In some embodiments, complementary nucleotides may be base-paired in a Watson-Crick manner or in any other manner that allows for the formation of a stable duplex. In some embodiments, the two nucleic acids may have regions of multiple nucleotides that are complementary to each other to form complementary regions, as described herein.

[0252] As used herein, a "species-cross-reactive oligonucleotide" refers to an oligonucleotide capable of inhibiting the expression of a target mRNA in more than one species. For example, in some embodiments, a species-cross-reactive oligonucleotide is capable of inhibiting the expression of a target mRNA in humans and non-human primates. Example species include, but are not limited to, humans, non-human primates, mice, and rats. In some embodiments, a species-cross-reactive oligonucleotide is capable of targeting and inhibiting mRNAs in at least two, at least three, or at least four species.

[0253] As used herein, “deoxyribonucleotide” refers to a nucleotide that, compared to a ribonucleotide, has a hydrogen atom at the 2' position of its pentose sugar instead of a hydroxyl group. A modified deoxyribonucleotide is a deoxyribonucleotide with one or more modifications or substitutions of atoms other than the 2' position, including modifications or substitutions of sugars, phosphate groups, or bases, or modifications or substitutions of these.

[0254] As used herein, "double-stranded RNA" or "dsRNA" refers to an RNA oligonucleotide that is substantially in a double-stranded form. In some embodiments, complementary base pairings of the double-stranded regions of the dsRNA oligonucleotide are formed between antiparallel nucleotide sequences of covalently separated nucleic acid strands. In some embodiments, complementary base pairings of the double-stranded regions of the dsRNA are formed between antiparallel nucleotide sequences of covalently linked nucleic acid strands. In some embodiments, complementary base pairings of the double-stranded regions of the dsRNA are formed by a single nucleic acid strand that folds (e.g., by hairpin) to provide complementary antiparallel nucleotide sequences with bases paired together. In some embodiments, the dsRNA comprises two covalently separated nucleic acid strands that completely form a double helix with each other. However, in some embodiments, the dsRNA comprises two covalently separated nucleic acid strands that partially form a double helix (e.g., with protruding ends at one or both ends). In some embodiments, the dsRNA comprises partially complementary antiparallel nucleotide sequences and may therefore have one or more mismatches, which may include internal mismatches or terminal mismatches.

[0255] As used herein, the term "double helix" in relation to nucleic acids (e.g., oligonucleotides) refers to a structure formed by the pairing of complementary bases in two antiparallel nucleotide sequences.

[0256] As used herein, “excipient” refers to a non-therapeutic agent that may be included in a composition, for example, to provide or contribute to a desired consistency or stabilizing effect.

[0257] As used in this article, the terms “hot tumor” or “inflammatory tumor” refer to a tumor or tumor microenvironment in which a large number of anti-tumor immune cells, especially TILs, are present and which are therefore usually immunostimulatory.

[0258] As used herein, a "loop" refers to an unpaired region of a nucleic acid (e.g., an oligonucleotide) flanked by two antiparallel regions of that nucleic acid that are sufficiently complementary to each other, such that under appropriate hybridization conditions (e.g., in phosphate-buffered saline, in cells), the two antiparallel regions flanking the unpaired region hybridize to form a double strand (called a "stem"). A loop containing four nucleotides can be called a tetraloop (tetraL). A loop containing three nucleotides can be called a triloop (triL).

[0259] As used herein, "modified internucleotide bonding" refers to an internucleotide bonding with one or more chemical modifications compared to a reference internucleotide bonding containing a phosphodiester bond. In some embodiments, the modified nucleotides are non-naturally occurring bonds. Typically, modified internucleotide bonding endows the nucleic acid in which the modified internucleotide bonding is present with one or more desired properties. For example, modified nucleotides can improve thermal stability, degradation resistance, nuclease resistance, solubility, bioavailability, biological activity, and reduced immunogenicity.

[0260] As used herein, a “modified nucleotide” refers to a nucleotide having one or more chemical modifications compared to a corresponding reference nucleotide selected from adenine ribonucleotide, guanine ribonucleotide, cytosine ribonucleotide, uracil ribonucleotide, adenine deoxyribonucleotide, guanine deoxyribonucleotide, cytosine deoxyribonucleotide, and thymine deoxyribonucleotide. In some embodiments, the modified nucleotide is a non-naturally occurring nucleotide. In some embodiments, the modified nucleotide has one or more chemical modifications in its sugar, nucleotide, and / or phosphate groups. In some embodiments, the modified nucleotide has one or more chemical moieties conjugated to the corresponding reference nucleotide. Generally, modified nucleotides impart one or more desired properties to nucleic acids in which the modified nucleotide is present. For example, modified nucleotides can improve thermal stability, degradation resistance, nuclease resistance, solubility, bioavailability, biological activity, reduced immunogenicity, etc.

[0261] As used herein, a “nicked tetracyclic structure” refers to the structure of an RNAi oligonucleotide characterized by separate sense (passenger) strands and antisense (guide) strands, wherein the sense strand has a complementary region that is complementary to the antisense strand, and wherein at least one strand, typically the sense strand, has a tetracyclic structure configured to stabilize an adjacent stem region formed within the at least one strand.

[0262] As used herein, “oligonucleotide” refers to a short nucleic acid (e.g., less than about 100 nucleotides in length). Oligonucleotides can be single-stranded (ss) or double-stranded (ds). Oligonucleotides may or may not have a double-stranded region. Oligonucleotides may comprise deoxyribonucleotides, ribonucleotides, or a combination of both. In some embodiments, a double-stranded oligonucleotide comprising ribonucleotides is referred to as “dsRNA.” As a set of non-limiting examples, oligonucleotides may be, but are not limited to, small interfering RNA (siRNA), microRNA (miRNA), short hairpin RNA (shRNA), enzyme substrate interfering RNA (dsiRNA), antisense oligonucleotides, short siRNA, or ss siRNA. In some embodiments, the double-stranded RNA (dsRNA) is an RNAi oligonucleotide.

[0263] The terms “RNAi oligonucleotide conjugate” and “oligonucleotide-ligand conjugate” are used interchangeably and refer to an oligonucleotide containing one or more nucleotides conjugated to one or more target ligands.

[0264] As used herein, a "protrusion" refers to a terminal unpaired nucleotide that is formed by a strand or region extending beyond the end of the complementary strand that forms a duplex with that strand or region. In some embodiments, a protrusion comprises one or more unpaired nucleotides extending from a duplex region at the 5' or 3' end of the dsRNA. In some embodiments, a protrusion is a 3' or 5' protrusion on the antisense or sense strand of the dsRNA.

[0265] As used herein, a "phosphate ester analog" refers to a chemical moiety that mimics the electrostatic and / or steric properties of a phosphate ester group. In some embodiments, the phosphate ester analog is located at the 5' terminal nucleotide of the oligonucleotide, rather than the 5'-phosphate ester that is typically readily removable by enzymatic reactions. In some embodiments, the 5'-phosphate ester analog contains a phosphatase-resistant linker. Examples of phosphate ester analogs include, but are not limited to, 5'-phosphonates such as 5'-methylenephosphonate (5'-MP) and 5'-(E)-vinylphosphonate (5'-VP). In some embodiments, the oligonucleotide has a phosphate ester analog (referred to as a "4'-phosphate ester analog") at the 4'-carbon position of the sugar at the 5'-terminal nucleotide. An example of a 4'-phosphate ester analog is an oxymethylphosphonate, wherein the oxygen atom of the oxymethyl group is bonded to the sugar moiety (e.g., at its 4'-carbon) or an analog thereof. See, for example, U.S. Provisional Patent Application No. 62 / 383,207 (filed September 2, 2016) and U.S. Provisional Patent Application No. 62 / 393,401 (filed September 12, 2016). Other modifications have been developed for the 5' end of oligonucleotides (see, for example, International Patent Application No. WO2011 / 133871; U.S. Patent No. 8,927,513; and Prakash et al. (2015) NUCLEICACIDS RES).

[0266] 43:2993-3011).

[0267] As used herein, “reduced expression” of a gene (e.g., STAT3) refers to a reduction in the amount or level of RNA transcript (e.g., STAT3 mRNA) or the protein encoded by that gene, and / or a reduction in the amount or level of the gene’s activity in a cell, cell population, sample, or subject compared to an appropriate reference (e.g., reference cells, cell population, sample, or subject). For example, the act of contacting cells with oligonucleotides of this article (e.g., oligonucleotides containing an antisense strand having a nucleotide sequence complementary to the nucleotide sequence containing STAT3 mRNA) can result in a reduction in the amount or level of STAT3 mRNA, protein, and / or activity (e.g., via degradation of STAT3 mRNA through the RNAi pathway) compared to cells not treated with dsRNA. Similarly, and as used herein, “reduced expression” refers to actions that result in a reduction in the expression of a gene (e.g., STAT3). As used herein, “decreased STAT3 expression” refers to a reduction in the amount or level of STAT3 mRNA, STAT3 protein, and / or STAT3 activity in cells, cell populations, samples, or subjects compared to an appropriate reference (e.g., reference cells, cell populations, samples, or subjects).

[0268] As used herein, a “complementary region” refers to a nucleotide sequence of a nucleic acid (e.g., dsRNA) that is sufficiently complementary to an antiparallel nucleotide sequence to allow the two nucleotide sequences to hybridize under appropriate hybridization conditions (e.g., in phosphate-buffered saline, in cells, etc.). In some embodiments, the oligonucleotides described herein contain a target sequence having a complementary region that is complementary to the mRNA target sequence.

[0269] As used herein, “ribonucleotide” refers to a nucleotide having ribose as its pentose sugar and a hydroxyl group at its 2' position. Modified ribonucleotides are ribonucleotides having one or more modified or substituted atoms other than at the 2' position, including modifications or substitutions of ribose, phosphate groups, or bases, or modifications or substitutions thereof.

[0270] As used herein, “RNAi oligonucleotide” refers to (a) a dsRNA having a sense strand and an antisense strand, wherein the antisense strand or a portion thereof is used by the Argonaute 2 (Ago2) endonuclease in the cleavage of the target mRNA, or (b) a single-stranded oligonucleotide having a single antisense strand, wherein the antisense strand (or a portion thereof) is used by the Ago2 endonuclease in the cleavage of the target mRNA.

[0271] As used herein, a “chain” refers to a single, continuous sequence of nucleotides linked together by internucleotide bonds (e.g., phosphodiester bonds or thiophosphate bonds). In some embodiments, the chain has two free ends (e.g., a 5' end and a 3' end).

[0272] As used herein, “subject” refers to any mammal, including mice, rabbits, non-human primates (NHPs), and humans. In one implementation, the subject is a human or an NHP. Furthermore, “individual” or “patient” may be used interchangeably with “subject”.

[0273] As used herein, “synthetic” means (e.g., using a machine (e.g., a solid-state nucleic acid synthesizer)) nucleic acids or other molecules that are artificially synthesized or otherwise not derived from the natural source (e.g., a cell or organism) that normally produces the molecule.

[0274] As used herein, a “targeting ligand” refers to a molecule or “part” (e.g., a carbohydrate, amino sugar, cholesterol, polypeptide, or lipid) that selectively binds to a homologous molecule (e.g., a receptor) of a tissue or cell of interest and / or can be conjugated to another substance to target that other substance to the tissue or cell of interest. For example, in some embodiments, the targeting ligand may be conjugated to an oligonucleotide to target that oligonucleotide to a specific tissue or cell of interest. In some embodiments, the targeting ligand selectively binds to a cell surface receptor. Thus, in some embodiments, when the targeting ligand is conjugated to an oligonucleotide, delivery of the oligonucleotide to a specific cell is facilitated by selective binding to a receptor expressed on the cell surface and internalization of the complex comprising the oligonucleotide, the targeting ligand, and the receptor within the cell. In some embodiments, the targeting ligand is conjugated to the oligonucleotide via a linker that is cleaved after or during cell internalization, thereby releasing the oligonucleotide from the targeting ligand within the cell.

[0275] As used in this article, "loop," "tri-loop," or "tetra-loop" refers to a loop that increases the stability of adjacent double strands formed through hybridization of nucleotide flanking sequences. This increase in stability can be detected by the melting temperature (T0) of adjacent stem double strands. m With the increase of ), the T m The T value of adjacent stem duplexes is higher than that of a set of reasonably long loops composed of randomly selected nucleotide sequences. m For example, a ring (e.g., a tetracyclic or tricyclic ring) can impart a hairpin containing a double strand of at least 2 base pairs (bp) in 10 mM NaHPO4 at at least about 50°C, at least about 55°C, at least about 56°C, at least about 58°C, at least about 60°C, at least about 65°C, or at least about 75°C. mIn some embodiments, the ring (e.g., a tetracyclic ring) can stabilize the bp in adjacent stem duplexes through stacking interactions. Additionally, interactions between nucleotides in the tetracyclic ring include, but are not limited to, non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., (1990) NATURE 346:680-82; Heus and Pardi (1991) SCIENCE 253:191-94). In some embodiments, the ring contains 3 to 6 nucleotides or is composed of 3 to 6 nucleotides, and is typically 4 to 5 nucleotides. In some embodiments, the ring contains 3, 4, 5, or 6 nucleotides or is composed of 3, 4, 5, or 6 nucleotides, and may be modified or may not be modified (e.g., it may be conjugated to a target moiety or may not be conjugated to a target moiety). In some embodiments, the tetracyclic ring contains 3 to 6 nucleotides or is composed of 3 to 6 nucleotides, and is typically 4 to 5 nucleotides. In some embodiments, the tetracyclic ring comprises or consists of 3, 4, 5, or 6 nucleotides, which may be modified or unmodified (e.g., it may be conjugated to or not to the target moiety). In one embodiment, a ring consisting of 4 nucleotides is a tetracyclic ring. Any nucleotide may be used in the ring (e.g., a tetracyclic ring), and the standard IUPAC-IUB notation for such nucleotides may be used as described by Cornish-Bowden ((1985) NUCLEIC ACIDS RES. 13:3021-3030). For example, the letter “N” may be used to indicate that any base may be present at that position, the letter “R” may be used to indicate that A (adenine) or G (guanine) may be present at that position, and “B” may be used to indicate that C (cytosine), G (guanine), or T (thymine) may be present at that position. Examples of tetracycles include tetracycles of the UNCG family (e.g., UUCG), tetracycles of the GNRA family (e.g., GAAA), and tetracycles of the CUUG family (Woese et al., (1990) PROC.NATL.ACAD.SCI.USA 87:8467-71; Antao et al., (1991) NUCLEIC ACIDS RES.19:5901-05). Examples of DNA tetracycles include tetracycles of the d(GNNA) family (e.g., d(GTTA)), tetracycles of the d(GNRA) family, tetracycles of the d(GNAB) family, tetracycles of the d(CNNG) family, and tetracycles of the d(TNCG) family (e.g., d(TTCG)). (See, for example, Nakano et al., (2002) BIOCHEM.41:4281-92; Shinji et al., (2000) NIPPON KAGAKKAI KOENYOKOSHU 78:731). In some implementations, the four rings are contained within a notched four-ring structure.

[0276] As used herein, “treatment” or “management” refers to the act of providing medical care to a subject in need, such as by administering a therapeutic agent (e.g., an oligonucleotide as described herein) to the subject to improve the subject’s health and / or well-being regarding an existing condition (e.g., disease, symptom), or to prevent or reduce the likelihood of the condition occurring. In some embodiments, treatment involves reducing the frequency or severity of at least one sign, symptom, or contributing factor to the condition experienced by the subject (e.g., disease, symptom).

[0277] As used herein, the term "tumor microenvironment" refers to the cellular environment in which any given tumor exists, including the tumor stroma, surrounding blood vessels, immune cells, fibroblasts, other cells, signaling molecules, and the ECM. It should be understood that the tumor microenvironment carries and / or surrounds tumor cells with which it interacts. Oligonucleotide conjugates are used for delivery to immune cells within the tumor microenvironment.

[0278] The tumor microenvironment (TME) plays a crucial role in maintaining tumor growth, invasion, and eventual metastasis. The complex TME is composed in part of immune cells, fibroblasts, and blood vessels. The immune cell composition within the TME is often categorized as "cold" or "hot" tumors. Cold tumors exhibit a weakened immune response, at least in part due to the presence of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Both MDSCs and Tregs attenuate the ability of T cells to infiltrate the tumor and induce antitumor responses. Hot tumors demonstrate the infiltration of anti-cancer T cells, proving a robust antitumor response. Compared to hot tumors, cold tumors generally respond poorly to immunotherapy. Therapies are needed to transform the tumor immune environment from cold to hot.

[0279] mRNA target sequence

[0280] In some embodiments, the oligonucleotide-ligand conjugate targets mRNA target sequences in immune cells associated with the tumor microenvironment via a targeting ligand. In some embodiments, the oligonucleotide-ligand conjugate, or a portion, fragment, or strand thereof (e.g., the antisense strand or guide strand of a double-stranded oligonucleotide), binds to or anneals to the target mRNA sequence, thereby reducing the expression of the target mRNA. In some embodiments, the oligonucleotide-ligand conjugate targets mRNA target sequences in immune cells associated with the tumor microenvironment via a targeting ligand to achieve the purpose of reducing the in vivo expression of the target mRNA. In some embodiments, the amount or extent to which the oligonucleotide-ligand conjugate reduces the expression of the target mRNA is related to the potency of the oligonucleotide-ligand conjugate. In some embodiments, the amount or extent to which the oligonucleotide-ligand conjugate reduces the expression of the target mRNA is related to the amount or extent of therapeutic benefit in a subject or patient with cancer treated with the oligonucleotide-ligand conjugate.

[0281] By examining the nucleotide sequences of target mRNAs, including those from multiple different species (e.g., humans, cynomolgus monkeys, mice, and rats), and as a result of in vitro and in vivo assays, certain target mRNA sequences have been found to be more susceptible to oligonucleotide-mediated downsampling than others, and therefore can be used as target sequences for the oligonucleotide-ligand conjugates described herein. In some embodiments, the sense strand or a portion or fragment thereof of the oligonucleotide-ligand conjugate described herein (e.g., RNAi oligonucleotide-lipid conjugate) contains a nucleotide sequence similar to (e.g., having no more than four mismatches) or identical to the target mRNA sequence. In some embodiments, a portion or region of the sense strand of the double-stranded oligonucleotide described herein contains the target mRNA sequence.

[0282] In some embodiments, the oligonucleotide-ligand conjugate targets and encodes the mRNA of an immunosuppressive regulator expressed by immune cells in the TME. In some embodiments, the immunosuppressive regulator directly or indirectly affects immune regulation. For example, in some embodiments, the immunosuppressive regulator is a regulatory protein, an enzyme protein, or a signaling protein. In some embodiments, the immunosuppressive regulator is a polypeptide that controls immune signaling. In some embodiments, the immunosuppressive regulator is an enzyme involved in processing the polypeptide involved in immune regulation. In some embodiments, the immunosuppressive regulator is a checkpoint inhibitor polypeptide. In some embodiments, the immunosuppressive regulator is a transcription factor. In some embodiments, the immunosuppressive regulator is a cytokine. In some embodiments, the immunosuppressive regulator is a chemokine receptor.

[0283] Both wild-type and mutant genes encoding immunomodulators can alter the immune response in the tumor-draining lymph node (TME) or tumor-draining lymph node (TdLN). In some embodiments, the oligonucleotide-ligand conjugate targets and encodes wild-type mRNA of an immunosuppressive regulator expressed by immune cells in the TME. In some embodiments, the oligonucleotide-ligand conjugate targets and encodes wild-type mRNA of an immunosuppressive regulator expressed by immune cells in the TdLN. In some embodiments, the oligonucleotide-ligand conjugate targets and encodes mutant mRNA of an immunosuppressive regulator expressed by immune cells in the TME. In some embodiments, the oligonucleotide-ligand conjugate targets and encodes mutant mRNA of an immunosuppressive regulator expressed by immune cells in the TdLN. Mutant mRNA molecules produce misfolded or highly active proteins.

[0284] In some embodiments, the oligonucleotide-ligand conjugate directly or indirectly reduces the expression of proteins that contribute to the repressive function of M-MDSCs. In some embodiments, the oligonucleotide-ligand conjugate directly or indirectly reduces the expression of proteins that contribute to the repressive function of G-MDSCs.

[0285] In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of target mRNA in the immune cells of the TME by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%. In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of immunosuppressive regulators in the immune cells of the TME by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.

[0286] In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of target mRNA in TdLN immune cells by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95%. In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of immunosuppressive regulators in TdLN immune cells by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.

[0287] Immune cells in the tumor microenvironment

[0288] In some aspects, this disclosure provides oligonucleotide-ligand conjugates that reduce the expression of target mRNAs expressed in immune cells present in the tumor and / or tumor microenvironment. In some embodiments, the oligonucleotide-ligand conjugate targets suppressive immune cells in the tumor microenvironment. In some embodiments, the targeting ligand of the conjugate delivers the oligonucleotide to immune cells present in the tumor.

[0289] In healthy individuals, immature myeloid cells produced by the bone marrow differentiate into mature granulocytes, macrophages, or dendritic cells and continue to be part of the innate immune system (Weiskopf et al., MICROBIOL SPECTR. Oct.; 4(5)(2016)). In pathological conditions such as cancer, partial blockage of differentiation of immature myeloid cells into mature myeloid cells can lead to an expansion of the population of immature myeloid cells that cannot assist in cancer surveillance or removal (Gabrilovitch et al., NATREV IMMUNOL. Mar; 9(3):162–74(2009)). Under the influence of GM-CSF secreted by cancer cells, these excess myeloid cells are recruited from the bone marrow to the tumor site (Schmid and Varner. JOURNAL OF ONCOLOGY(2010)). Once within the TME, the myeloid cell population expands, and the cells exert immunosuppressive functions, enabling them to suppress T cells and NK cells through different mechanisms (Yang et al., FRONT. IN IMMUNOL. 11:1371 (2020)), thereby directly inhibiting the response to cancer tumors.

[0290] Myeloid-derived suppressor cells (MDSCs) contribute to immunotherapy resistance by actively inhibiting the proliferation and cytotoxic activity of anti-tumor T cells and by promoting the expansion of immunosuppressive regulatory T cells (Gabrilovich et al., NATREV IMMUNOL (2009) 9(3):162-74; Law et al., CELLS (2020) 9:561). In this way, MDSCs can suppress or attenuate the host's immune response against tumors. Furthermore, these MDSCs can assist cell dissemination by promoting angiogenesis, EMT and MET transitions, and the secretion of oncogenic factors (Law et al., CELLS (2020) 9:561). Given their importance in the development, maintenance, and assisted expansion of their associated tumors, MDSCs are potential therapeutic targets for many tumor types if they can be specifically attacked. MDSCs can also be found in tumor draining lymph nodes (TdLNs), where they can suppress naive T cells also found in TdLNs (Swatz et al., NATREV CANCER (2012) 12:210-19). This suppression of naive T cells can then facilitate tumor metastasis to and from lymph nodes (Swatz et al., NATREV CANCER (2012) 12:210-19). In general, MDSCs are characterized by the co-expression of the cell surface or mRNA markers CD11b (a marker of myeloid macrophage lineage) and Gr-1 (a marker of myeloid differentiation antigen), denoted as CD11b. +Gr-1 + Cells. Gr-1 is further composed of two components: Ly6G and Ly6C. MDSCs consist of two subsets: granulocyte MDSCs (G-MDSCs), which are further characterized as CD11b. + Ly6G + Ly6C lo ; and monocyte MDSCs (M-MDSCs), which were characterized as CD11b + Ly6G - Ly6C hi The mRNA markers Ly6G, CxCr2, Slc27a2, and Ptgs2 are preferentially expressed by G-MDSCs but not by M-MDSCs. The expression of specific markers such as CxCr2, Scl27a2, and Ptgs2 suggests recruitment and inhibitory activity of G-MDSCs in the TME. Similarly, compared to G-MDSCs, M-MDSCs highly express the mRNA markers Ly6C, Scarb1, Ldlr, and Arg1. The higher expression of lipid transport receptors such as Scarb1 and Ldlr in M-MDSCs may play a crucial role in lipid uptake.

[0291] In some embodiments, the oligonucleotide-ligand conjugate targets tumor-resident immune cells. In some embodiments, the oligonucleotide-ligand conjugate targets immune cells in tumor-draining lymph nodes (TdLNs). In some embodiments, the oligonucleotide-ligand conjugate targets mRNA in tumor-resident immune cells. In some embodiments, the oligonucleotide-ligand conjugate targets mRNA in immune cells in tumor-draining lymph nodes (TdLNs).

[0292] In some embodiments, the immune cells are suppressive myeloid cells. In some embodiments, the immune cells are myeloid-derived suppressor cells (MDSCs). In some embodiments, the MDSCs are granulocyte MDSCs (G-MDSCs). In some embodiments, the MDSCs are monocyte MDSCs (M-MDSCs).

[0293] In some embodiments, the immune cell is a T cell. In some embodiments, the T cell is a CD8+ T cell. In some embodiments, the T cell is a Treg cell.

[0294] In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in tumor-resident MDSCs and / or tumor-draining lymph node MDSCs. In some embodiments, the oligonucleotide conjugate reduces target mRNA in tumor-resident G-MDSCs and / or tumor-draining lymph node G-MDSCs. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in tumor-resident M-MDSCs and / or tumor-draining lymph node M-MDSCs. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in tumor-resident Treg cells and / or tumor-draining lymph node Treg cells. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in more than one type of tumor-resident immune cell and / or tumor-draining lymph node immune cell. For example, in some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in MDSCs (e.g., M-MDSCs and / or G-MDSCs) and T cells (e.g., CD8+ T cells and / or Treg cells).

[0295] In some embodiments, the immunosuppressive activity of immune cells (e.g., MDSCs or Treg cells) is reduced upon contact with the oligonucleotide-ligand conjugate.

[0296] Immunosuppressive activity is determined using methods known in the art. In one such method, the level of arginase I in isolated tumor immune cells is measured compared to control immune cells. High levels of arginase I in tumor-resident immune cells (e.g., myeloid cells) indicate an immunosuppressive environment. Additionally, in some embodiments, the number of immunosuppressive tumor-resident cells indicates the level of suppressive activity. In some embodiments, T-cell suppression assays and / or cytokine release assays are used to determine the suppressive activity of immune cells.

[0297] cancer

[0298] In some embodiments, the oligonucleotide-ligand conjugates described herein target immune cells in a tumor. In some embodiments, the tumor is a primary tumor. In some embodiments, the tumor is a metastatic tumor. In some embodiments, the tumor is a refractory tumor. In some embodiments, the tumor is a stage I, II, III, or IV tumor. In some embodiments, the tumor is a solid tumor. A solid tumor refers to a condition where cancer forms a mass.

[0299] In some implementations, the cancer is thyroid cancer, papillary thyroid cancer, head and neck cancer, liver cancer, colorectal cancer, pancreatic cancer, breast cancer, ovarian cancer, lung cancer, carcinoma, blastoma, medulloblastoma, retinoblastoma, sarcoma, liposarcoma, synovial cell sarcoma, neuroendocrine tumor, carcinoid tumor, gastrinoma, islet cell carcinoma, mesothelioma, schwannoma, acoustic neuroma, meningioma, adenocarcinoma, lymphoid malignancy, squamous cell carcinoma, epithelial squamous cell carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal cancer, glioblastoma, cervical cancer, bladder cancer, hepatocellular carcinoma, metastatic breast cancer, colon cancer, rectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, liver cancer, anal cancer, penile cancer, Merkel cell carcinoma, testicular cancer, esophageal cancer or biliary tract tumor. In some embodiments, the cancer is refractory to anti-PD1, anti-PDL1, and / or anti-CTLA4 therapies. In some embodiments, the cancer is pancreatic cancer or lung cancer. In some embodiments, the cancer includes tumors with an immunosuppressive tumor microenvironment.

[0300] In some embodiments, the oligonucleotide-ligand conjugate is delivered to the tumor and reduces the expression of target mRNA in tumor-resident immune cells.

[0301] In some embodiments, the oligonucleotide-ligand conjugate reduces tumor volume. Tumor volume is measured using methods known to those skilled in the art. For example, the extracted tumor is manually measured using calipers. Other methods include imaging techniques such as ultrasound and MRI. In some embodiments, the oligonucleotide conjugate reduces tumor volume by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% compared to untreated tumor.

[0302] Tumor draining lymph nodes (TdLNs) are often the first site of cancer metastasis. In some embodiments, the oligonucleotide conjugate targets immune cells in the tumor draining lymph nodes. In some implementations, the tumor draining lymph nodes are subsegmental, segmental, lobar, interlobar, hilar, mediastinal, supratrochlear, deltoid, lateral, thoracic, subscapular, intermediate, subclavian, superficial inguinal, deep inguinal, popliteal, buccinator, nasolabial, prostate, mandible, submental, occipital, mastoid / postauricular, parotid, deep preauricular, deep subauricular, deep intraglandular, deep cervical, deep anterior cervical, pretracheal, paratracheal, prelarynx, thyroid, lateral deep cervical, superior deep cervical, inferior deep cervical, retropharyngeal, internal jugular vein, digastric, anterior cervical, lateral cervical, supraclavicular, postaortic, lateral aortic, abdominal, gastric, hepatic, splenic, superior mesenteric, mesenteric, ileocolic, mesocolonic, inferior mesenteric, or pararectal lymph nodes. In some implementations, the tumor draining lymph nodes are the primary tumor draining lymph nodes. In some implementations, the tumor draining lymph node is a lymph node that drains tumor metastases.

[0303] In some embodiments, the oligonucleotide-ligand conjugate does not target immune cells in non-TdLNs. In some embodiments, the oligonucleotide-ligand conjugate does not target cancer cells.

[0304] In some embodiments, the oligonucleotide-ligand conjugate targets immune cells in both the tumor and the tumor draining lymph nodes. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in immune cells within the TdLN by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0305] Structure of oligonucleotide-targeting ligand conjugates

[0306] In some embodiments, the oligonucleotide-ligand conjugates described herein comprise a nucleotide sequence and one or more target ligands, wherein the nucleotide sequence comprises one or more nucleosides (nucleic acids) conjugated to one or more target ligands, represented by formula Ia:

[0307]

[0308] Or its pharmaceutically acceptable salt.

[0309] in:

[0310] B is a nucleobase or hydrogen;

[0311] R 1 and R 2 Independently hydrogen, halogen, R A-CN, -S(O)R, -S(O)2R, -Si(OR)2R, -Si(OR)R2 or -SiR3; or

[0312] R on the same carbon 1 and R 2 Together with their intermediary atoms, they form 3-7 member saturated or partially unsaturated rings with 0-3 independent heteroatoms selected from nitrogen, oxygen and sulfur;

[0313] Each R A Independently, the optionally substituted group is selected from C. 1-6 Aliphatic group, phenyl, 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0314] Each R is independently hydrogen, a suitable protecting group, or an optionally substituted group, the optionally substituted group being selected from C. 1-6 Aliphatic group, phenyl, having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, comprising a 4-7 membered saturated or partially unsaturated heterocycle, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; or

[0315] Two R groups on the same atom, together with their intervening atoms, form a 4-7 member saturated, partially unsaturated or heteroaryl ring having 0-3 independent heteroatoms selected from nitrogen, oxygen, silicon and sulfur.

[0316] Each targeting ligand is selected from lipid conjugate moieties (LCs), carbohydrates, amino sugars, or GalNAc; and each LC is independently composed of saturated or unsaturated straight-chain or branched C. 1-50 The lipid conjugate portion of a hydrocarbon chain, wherein 0-10 methylene units of the hydrocarbon chain are independently replaced by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, -P(S)OR-;

[0317] Each -Cy- is independently a optionally substituted divalent ring selected from phenylene, 8-10 membered bicyclic arylene, 4-7 membered saturated or partially unsaturated carbocyclic, 4-11 membered saturated or partially unsaturated spirocyclic, 8-10 membered bicyclic saturated or partially unsaturated carbocyclic, 4-7 membered saturated or partially unsaturated heterocyclic with 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, 4-11 membered saturated or partially unsaturated spirocyclic with 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclic with 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, 5-6 membered heterocyclic with 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or 8-10 membered bicyclic heterocyclic with 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur.

[0318] n is 1-10;

[0319] L represents a covalent bond or a divalent saturated or unsaturated straight chain or branched chain. 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently converted by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O-, -S(O)2-, -P(O)OR-, -P(S)OR-, -V 1 CR 2 W 1 -or replace;

[0320] m is 1-50;

[0321] X 1 V 1 and W 1 Independently -C(R)2-, -OR, -O-, -S-, -Se-, or -NR-;

[0322] Y represents hydrogen, a suitable hydroxyl protecting group,

[0323] R 3 The group may be hydrogen, a suitable protecting group, a suitable prodrug, or an optionally substituted group, wherein the optionally substituted group is selected from C. 1-6 Aliphatic group, phenyl, 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0324] X 2 For O, S, or NR;

[0325] X 3 It can be -O-, -S-, -BH2- or covalent;

[0326] Y 1 A linker group attached to the 2' or 3' end of a nucleoside, nucleotide, or oligonucleotide;

[0327] Y 2 Hydrogen, a suitable protecting group, a phosphoramide analog, an internucleotide linker attached to the 5'-terminus of a nucleoside, nucleotide, or oligonucleotide, or a linker attached to a solid support; and

[0328] Z can be -O-, -S-, -NR-, or -CR2-.

[0329] In some embodiments, the oligonucleotide-ligand conjugate comprises one or more nucleic acids conjugated to a target ligand, represented by formula II-a:

[0330]

[0331] Or its pharmaceutically acceptable salt.

[0332] In some embodiments, the oligonucleotide-ligand conjugate comprises one or more nucleic acids conjugated to a target ligand, represented by formula II-b or II-c:

[0333]

[0334] Or its pharmaceutically acceptable salt, wherein:

[0335] L 1 C is a straight or branched chain that is covalent, monovalent, divalent, saturated, or unsaturated. 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently converted by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O-, -S(O)2-, -P(O)OR-, -P(S)OR- or replace;

[0336] R 4 For hydrogen, R A Or a suitable amine protecting group; and

[0337] R 5 It is an adamantyl group, or a saturated or unsaturated straight-chain or branched C group. 1-50 A hydrocarbon chain in which 0-10 methylene units are independently replaced by -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR- or -P(S)OR.

[0338] In some implementation schemes, R 5Selected from

[0339]

[0340] In some implementation schemes, R 5 Selected from:

[0341] In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementations, R 5 for

[0342] In some embodiments, the oligonucleotide-ligand conjugate comprises one or more nucleic acids conjugated to a target ligand, represented by formula II-Ib or II-Ic:

[0343]

[0344]

[0345] Or its pharmaceutically acceptable salt; wherein

[0346] B is a nucleobase or hydrogen;

[0347] m is 1-50;

[0348] X 1 It can be -O- or -S-;

[0349] Y represents hydrogen. R 3 Hydrogen or a suitable protecting group;

[0350] X 2 For O or S;

[0351] X 3 It can be -O-, -S-, or covalent;

[0352] Y 1 A linker group attached to the 2' or 3' end of a nucleoside, nucleotide, or oligonucleotide;

[0353] Y 2 It is a hydrogen, phosphoramide analogue, an internucleotide linker attached to the 5'-terminus of a nucleoside, nucleotide or oligonucleotide, or a linker attached to a solid support.

[0354] R 5 It is an adamantyl group, or a saturated or unsaturated straight-chain or branched C group. 1-50 A hydrocarbon chain wherein 0-10 methylene units are independently replaced by -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, or -P(S)OR-; and

[0355] R is hydrogen, a suitable protecting group, or an optionally substituted group, wherein the optionally substituted group is selected from C. 1-6 Aliphatic group, phenyl, 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0356] In some implementation schemes, R 5 Selected from

[0357]

[0358] In some implementation schemes, R 5 for

[0359]

[0360] In some implementation schemes, R 5 for

[0361] In some embodiments, the oligonucleotide sequence contains 1-10 targeting ligands. In some embodiments, the nucleotide sequence contains 1, 2, or 3 targeting ligands.

[0362] In some embodiments, the oligonucleotide of the oligonucleotide-ligand conjugate is a double-stranded molecule. In some embodiments, the oligonucleotide is an RNAi molecule. In some embodiments, the double-stranded oligonucleotide includes a stem-loop. In some embodiments, the ligand is conjugated to any nucleotide in the stem-loop. In some embodiments, the ligand is conjugated to a first nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to a second nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to a third nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to a fourth nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to one, two, three, or four nucleotides in the stem-loop. In some embodiments, the ligand is conjugated to three nucleotides in the stem-loop.

[0363] In some embodiments, the oligonucleotide-ligand conjugate comprises a 36-nucleotide sense chain, with positions from 5' to 3' numbered 1-36. In some embodiments, the oligonucleotide-ligand conjugate comprises a lipid conjugated to position 27 of the 36-nucleotide sense chain. In some embodiments, the oligonucleotide-ligand conjugate comprises a lipid conjugated to position 28 of the 36-nucleotide sense chain. In some embodiments, the oligonucleotide conjugate comprises a lipid conjugated to position 29 of the 36-nucleotide sense chain. In some embodiments, the oligonucleotide conjugate comprises a lipid conjugated to position 30 of the 36-nucleotide sense chain.

[0364] In some embodiments, the oligonucleotide-ligand conjugate comprises an antisense strand of 15 to 30 nucleotides and a sense strand of 15 to 40 nucleotides, wherein the sense strand and the antisense strand form a double-stranded region, wherein the antisense strand comprises a complementary region complementary to a target sequence expressed in tumor microenvironment-associated immune cells, and wherein the sense strand comprises a stem-loop at its 3' end, the stem-loop comprising a tetracycle containing four nucleotides, wherein one or more of the four nucleotides are represented by formula II-Ib:

[0365]

[0366] Where B is selected from adenine and guanine nucleobases, and where R... 5 It is a hydrocarbon chain. In some embodiments, m is 1, X1 is O, Y2 is an internucleotide linker attached to the 5' end of the nucleoside, and Y is composed of... In this designation, Y1 is a linker group attached to the 2' or 3' end of the nucleotide, X2 is O, X3 is O, and R3 is H. In some embodiments, the hydrocarbon chain is a C8-C30 hydrocarbon chain. In some embodiments, the hydrocarbon chain is a C16 hydrocarbon chain. In some embodiments, the C16 hydrocarbon chain is composed of... The four nucleotides of the tetracycle are numbered 1-4 from 5' to 3', and position 1 is represented by formula II-Ib. In some embodiments, position 2 is represented by formula II-Ib. In some embodiments, position 3 is represented by formula II-Ib. In some embodiments, position 4 is represented by formula II-Ib. In some embodiments, the sense strand is 36 nucleotides, which are numbered 1-36 from 5' to 3', wherein the stem-loop contains nucleotides at positions 21-36, and wherein one or more nucleotides at positions 27-30 are represented by formula II-Ib. In some embodiments, the antisense strand is 22 nucleotides.

[0367] In some aspects, this disclosure provides oligonucleotide-ligand conjugates for targeting target mRNAs (e.g., target mRNAs that regulate immunosuppression) and inhibiting or reducing the expression of target genes (e.g., via the RNAi pathway), wherein the oligonucleotide-ligand conjugate is a double-stranded (ds) nucleic acid molecule comprising a sense strand (also referred to herein as a guest strand) and an antisense strand (also referred herein as a guide strand). In some embodiments, the sense and antisense strands are separate strands and are not covalently linked. In some embodiments, the sense and antisense strands are covalently linked. In some embodiments, the sense and antisense strands form a double-stranded region, wherein the sense and antisense strands, or portions thereof, bind or anneal to each other in a complementary manner (e.g., by Watson-Crick base pairing).

[0368] In some embodiments, the sense strand has a first region (R1) and a second region (R2), wherein R2 comprises a first subregion (S1), a ring (L) such as a tetraL or triL, and a second subregion (S2), wherein L or triL is located between S1 and S2, and wherein S1 and S2 form a second double strand (D2). D2 can have different lengths. In some embodiments, the length of D2 is about 1-6 bp. In some embodiments, the length of D2 is 2-6, 3-6, 4-6, 5-6, 1-5, 2-5, 3-5, or 4-5 bp. In some embodiments, the length of D2 is 1, 2, 3, 4, 5, or 6 bp. In some embodiments, the length of D2 is 6 bp.

[0369] In some embodiments, the sense strand R1 and the antisense strand form a first double helix (D1). In some embodiments, the length of D1 is at least about 15 nucleotides (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21). In some embodiments, the length of D1 is in the range of about 12 to 30 nucleotides (e.g., 12 to 30, 12 to 27, 15 to 22, 18 to 22, 18 to 25, 18 to 27, 18 to 30, or 21 to 30 nucleotides). In some embodiments, the length of D1 is at least 12 nucleotides (e.g., at least 12, at least 15, at least 20, at least 25, or at least 30 nucleotides). In some embodiments, the length of D1 is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the length of D1 is 19 nucleotides. In some embodiments, the length of D1 is 20 nucleotides. In some embodiments, D1 containing both sense and antisense strands does not span the entire length of the sense and / or antisense strands. In some embodiments, D1 containing both sense and antisense strands spans the entire length of the sense or antisense strand, or both. In some embodiments, D1 containing both sense and antisense strands spans the entire length of both the sense and antisense strands.

[0370] It should be understood that in some embodiments, the sequence presented in the sequence listing may be referenced when describing the structure of an oligonucleotide (e.g., an oligonucleotide-ligand conjugate) or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides (e.g., RNA counterparts of DNA nucleotides or DNA counterparts of RNA nucleotides) and / or one or more modified nucleotides and / or one or more modified internucleotide bonds and / or one or more other modifications, compared to the specified sequence, while still retaining complementary properties substantially the same or similar to those of the specified sequence.

[0371] In some embodiments, the oligonucleotide-ligand conjugates described herein comprise a 25-nucleotide sense strand and a 27-nucleotide antisense strand, which, upon cleavage, generates an antisense strand incorporated into the mature RISC. In some embodiments, the sense strand of the oligonucleotide-ligand conjugate is longer than 27 nucleotides (e.g., 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides). In some embodiments, the sense strand of the oligonucleotide-ligand conjugate is longer than 25 nucleotides (e.g., 26, 27, 28, 29, or 30 nucleotides).

[0372] In some embodiments, the oligonucleotide-ligand conjugates described herein have a 5' end that is thermodynamically less stable compared to the other 5' end. In some embodiments, asymmetric oligonucleotide-ligand conjugates are provided, which include a blunt end at the 3' end of the sense strand and a 3'-protrusion at the 3' end of the antisense strand. In some embodiments, the 3'-protrusion on the antisense strand is about 1-8 nucleotides long (e.g., 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides). Typically, the oligonucleotide-ligand conjugate has a two-nucleotide protrusion at the 3' end of the antisense (guide) strand. However, other protrusions are also possible. In some embodiments, the overhang is a 3' overhang containing 1 to 6 nucleotides, optionally 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to 4, 4 to 6, 4 to 5, 5 to 6 nucleotides, or a length of 1, 2, 3, 4, 5, or 6 nucleotides. However, in some embodiments, the overhang is a 5' overhang containing 1 to 6 nucleotides, optionally 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to 4, 4 to 6, 4 to 5, 5 to 6 nucleotides, or a length of 1, 2, 3, 4, 5, or 6 nucleotides.

[0373] In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand are modified. In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand are complementary to the target mRNA (e.g., a target mRNA regulating immunosuppression). In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand are not complementary to the target mRNA. In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand of the oligonucleotide-ligand conjugate described herein are unpaired. In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand of the oligonucleotide-ligand conjugate described herein contain unpaired GG. In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand of the oligonucleotide-ligand conjugate described herein are not complementary to the target mRNA. In some embodiments, each of the two terminal nucleotides at the 3' end of the oligonucleotide-ligand conjugate is GG. Typically, one or both of the two terminal GG nucleotides at the 3' end of each double-stranded oligonucleotide (e.g., an RNAi oligonucleotide conjugate) are not complementary to the target mRNA.

[0374] In some embodiments, one or more (e.g., 1, 2, 3, 4, or 5) mismatches exist between the sense and antisense strands. If more than one mismatch exists between the sense and antisense strands, they may be sequentially located (e.g., two, three, or more consecutively) or scattered throughout the complementary region. In some embodiments, the 3' end of the sense strand contains one or more mismatches. In one embodiment, two mismatches are incorporated at the 3' end of the sense strand. In some embodiments, base mismatches or segment destabilization at the 3' end of the sense strand of the oligonucleotide-ligand conjugate described herein improves or increases the potency and / or efficacy of the oligonucleotide-ligand conjugate.

[0375] In some embodiments, the targeting ligand is GalNAc as described herein. In some embodiments, the targeting ligand is a carbohydrate. In some embodiments, the targeting ligand is an amino sugar.

[0376] In some embodiments, the oligonucleotide-ligand conjugate comprises two or more targeting ligands, wherein the targeting ligands are different. In some embodiments, the oligonucleotide-ligand conjugate comprises two or more targeting ligands, wherein the targeting ligands are the same.

[0377] Exemplary oligonucleotides

[0378] In some embodiments, the oligonucleotide-ligand conjugate comprises an oligonucleotide conjugated to a fatty acid. In some embodiments, the fatty acid is a saturated fatty acid. In some embodiments, the fatty acid is an unsaturated fatty acid. In some embodiments, the oligonucleotide is conjugated to a lipid. In some embodiments, the lipid is a carbon chain. In some embodiments, the carbon chain is saturated. In some embodiments, the carbon chain is unsaturated. In some embodiments, the oligonucleotide is conjugated to a 16-carbon (C16) lipid. In some embodiments, the C16 lipid contains at least one double bond. In some embodiments, the oligonucleotide is conjugated to an 18-carbon (C18) lipid. In some embodiments, the C18 lipid contains at least one double bond. In some embodiments, the oligonucleotide is conjugated to a 22-carbon (C22) lipid. In some embodiments, the C22 lipid contains at least one double bond. In some embodiments, the oligonucleotide is conjugated to a 24-carbon (C24) lipid. In some embodiments, the C24 lipid contains at least one double bond.

[0379] In some embodiments, the oligonucleotide-ligand conjugate comprises a ring, wherein at least one nucleotide of the ring is conjugated to a C16 lipid. In some embodiments, a second nucleotide of the ring is conjugated to a C16 lipid. In some embodiments, the oligonucleotide-ligand conjugate comprises a ring, wherein at least one nucleotide of the ring is conjugated to a C18 lipid. In some embodiments, a second nucleotide of the ring is conjugated to a C18 lipid. In some embodiments, the oligonucleotide-ligand conjugate comprises a ring, wherein at least one nucleotide of the ring is conjugated to a C22 lipid. In some embodiments, a second nucleotide of the ring is conjugated to a C22 lipid. In some embodiments, the oligonucleotide-ligand conjugate comprises a ring, wherein at least one nucleotide of the ring is conjugated to a C24 lipid. In some embodiments, a second nucleotide of the ring is conjugated to a C24 lipid.

[0380] In some embodiments, the oligonucleotide-ligand conjugate comprises a tetracyclic ring, wherein at least one nucleotide of the tetracyclic ring is conjugated to a C16 lipid. In some embodiments, the second nucleotide of the tetracyclic ring is conjugated to a C16 lipid. In some embodiments, the oligonucleotide-ligand conjugate comprises a tetracyclic ring, wherein at least one nucleotide of the tetracyclic ring is conjugated to a C18 lipid. In some embodiments, the second nucleotide of the tetracyclic ring is conjugated to a C18 lipid. In some embodiments, the oligonucleotide-ligand conjugate comprises a tetracyclic ring, wherein at least one nucleotide of the tetracyclic ring is conjugated to a C22 lipid. In some embodiments, the second nucleotide of the tetracyclic ring is conjugated to a C22 lipid. In some embodiments, the oligonucleotide-ligand conjugate comprises a tetracyclic ring, wherein at least one nucleotide of the tetracyclic ring is conjugated to a C24 lipid. In some embodiments, the second nucleotide of the tetracyclic ring is conjugated to a C24 lipid.

[0381] In some embodiments, the oligonucleotide-ligand conjugate comprises a nucleotide sequence having at least one modified nucleoside. In some embodiments, the oligonucleotide-ligand conjugate comprises an antisense strand and a sense strand, wherein each strand comprises at least one modified nucleoside.

[0382] In some embodiments, the oligonucleotide-ligand conjugate is represented by the following formula:

[0383] There is a chain of righteousness:

[0384] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][

[0385] mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][ademX-TL]

[0386] [mX][mX][mX][mX][mX][mX][mX][mX]

[0387] hybridization to

[0388] Antonym chain: [MePhosphonate-4O-mXs][fXs][fX][fX][fX][mX][fX][mX][mX]

[0389] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0390] or

[0391] There is a chain of righteousness:

[0392] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][

[0393] mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][mX][ademX-C#]

[0394] [mX][mX][mX][mX][mX][mX][mX][mX]

[0395] hybridization to

[0396] Antonym chain: [MePhosphonate-4O-mXs][fXs][fX][fX][fX][mX][fX][mX][mX]

[0397] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0398] In some embodiments, the oligonucleotide-ligand conjugate is represented by the following formula:

[0399] There is a chain of righteousness:

[0400] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][mX][mX][mX][m X][mX][mX][mX][mX][mX][mX][mX][mX][ademX-TL][mX][mX][mX][mX][mX][mX][mX][mX]

[0401] hybridization to

[0402] Antisense strand: [MePhosphonate-4O-mXs][fXs][fXs][fX][fX][mX][fX][mX][mX][fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0403] or

[0404] There is a chain of righteousness:

[0405] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][mX][mX][mX][m X][mX][mX][mX][mX][mX][mX][mX][mX][ademX-C#][mX][mX][mX][mX][mX][mX][mX][mX]

[0406] hybridization to

[0407] Antisense strand: [MePhosphonate-4O-mXs][fXs][fXs][fX][fX][mX][fX][mX][mX][fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0408] Table 1. Modifying Keywords

[0409]

[0410]

[0411] In some embodiments, the oligonucleotide of the oligonucleotide-ligand conjugate is conjugated to a C16 lipid as shown below:

[0412]

[0413] In some embodiments, the oligonucleotide of the oligonucleotide-ligand conjugate is conjugated to a C18 lipid as shown below:

[0414]

[0415] In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in immune cells of the TME or TdLN, but does not reduce mRNA in tumor epithelial cells.

[0416] How to use

[0417] i. Reduce target gene expression

[0418] In some embodiments, this disclosure provides methods for contacting or delivering to immune cells or populations of immune cells (e.g., tumor-resident immune cells) in the tumor microenvironment an effective amount of any oligonucleotide-ligand conjugate described herein to reduce target gene expression (e.g., reduce the expression of a target gene encoding an immunosuppressive regulator). In some embodiments, the reduction in target gene expression is determined by measuring a decrease in the amount or level of activity of a target mRNA, a protein encoded by the target mRNA, or a target gene (mRNA or protein) in the cell. These methods include those described herein and those known to those skilled in the art.

[0419] The methods provided herein can be used for any suitable tumor-resident immune cell type. In some embodiments, the cells are any cells expressing the target mRNA. In some embodiments, the cells are primary cells obtained from a subject. In some embodiments, the primary cells have undergone a limited number of passages, such that the cells substantially retain their native phenotypic properties. In some embodiments, the oligonucleotide-ligand conjugates delivered to the cells are ex vivo or in vitro (i.e., can be delivered to cells in culture or the organism in which the cells reside).

[0420] In some embodiments, the oligonucleotide-ligand conjugates disclosed herein are delivered to immune cells or populations of immune cells in the tumor microenvironment using nucleic acid delivery methods known in the art. These methods include, but are not limited to, injecting a solution or pharmaceutical composition containing the oligonucleotide-ligand conjugate, bombarding with particles coated with the oligonucleotide-ligand conjugate, exposing cells or populations of cells to a solution containing the oligonucleotide-ligand conjugate, or electroporating the cell membrane in the presence of the oligonucleotide-ligand conjugate. Other methods known in the art for delivering oligonucleotides to cells can be used, such as lipid-mediated carrier transport, chemically mediated transport, and cationic liposome transfection such as calcium phosphate.

[0421] In some embodiments, the reduction in target gene expression is determined by an assay or technique evaluating one or more molecules, properties, or characteristics of cells or cell populations associated with target gene expression, or by an assay or technique evaluating molecules (e.g., target mRNA or protein) that directly indicate target gene expression in cells or cell populations. In some embodiments, the extent to which the oligonucleotide-ligand conjugates provided herein reduce target gene expression (e.g., reduce the expression of a target gene encoding an immunosuppressive regulator) is evaluated by comparing target gene expression in cells or cell populations contacted with the oligonucleotide-ligand conjugate with control cells or cell populations (e.g., cells or cell populations not contacted with the oligonucleotide-ligand conjugate or contacted with a control oligonucleotide-ligand conjugate). In some embodiments, a control amount or level of target gene expression in control cells or cell populations is predetermined, so that it is not necessary to measure the control amount or level each time the assay or technique is performed. The predetermined level or value can take many forms. In some embodiments, the predetermined level or value can be a single cutoff value, such as a median or average.

[0422] mRNA in immune cells can be measured using techniques known to those skilled in the art. For example, after tumor extraction, the tissue is manually or chemically dissociated into single cells. Cells of interest (e.g., MDSCs) are then separated using MACS sorting, the cells are collected, and prepared for RNA analysis. In some embodiments, the oligonucleotide conjugate reduces the expression of target mRNA in immune cells of the TME or TdLN for 1 day to at least 4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of target mRNA in immune cells of the TME or TdLN for 1 day, 3 days, 7 days, 14 days, 21 days, 28 days, or 34 days. In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of target mRNA in immune cells of the TME or TdLN for at least 1-4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of target mRNA in immune cells of the TME or TdLN for up to 2 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces the expression of target mRNA in immune cells of the TME or TdLN for up to 4 weeks.

[0423] In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in M-MDSCs for 1 day to at least 4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in M-MDSCs for 1 day, 3 days, 7 days, 14 days, 21 days, 28 days, or 34 days. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in M-MDSCs for at least 1-4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in M-MDSCs for up to 2 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in immune cells of M-MDSCs for up to 4 weeks.

[0424] In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in G-MDSCs for 1 day to at least 4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in G-MDSCs for 1 day, 3 days, 7 days, 14 days, 21 days, 28 days, or 34 days. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in G-MDSCs for at least 1-4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in G-MDSCs for up to 2 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in immune cells of G-MDSCs for up to 4 weeks.

[0425] In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in Tregs for 1 day to at least 4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in Tregs for 1 day, 3 days, 7 days, 14 days, 21 days, 28 days, or 34 days. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in M-MDSCs for at least 1-4 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in Tregs for up to 2 weeks. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA expression in immune cells of Tregs for up to 4 weeks.

[0426] In some embodiments, contact or delivery of the oligonucleotide-ligand conjugate described herein to immune cells or populations of immune cells (e.g., tumor-resident immune cells) in the tumor microenvironment results in a reduction in target gene expression. In some embodiments, the reduction in target gene expression is relative to a control amount or level of target gene expression in cells or populations that have not been contacted with the oligonucleotide-ligand conjugate or have been contacted with a control oligonucleotide-ligand conjugate. In some embodiments, the reduction in target gene expression is relative to a control amount or level of target gene expression of about 1% or less, about 5% or less, about 10% or less, about 15% or less, about 20% or less, about 25% or less, about 30% or less, about 35% or less, about 40% or less, about 45% or less, about 50% or less, about 55% or less, about 60% or less, about 70% or less, about 80% or less, or about 90% or less. In some implementations, the reduction in target gene expression in immune cells within the TME is approximately 1% or less, approximately 5% or less, approximately 10% or less, approximately 15% or less, approximately 20% or less, approximately 25% or less, approximately 30% or less, approximately 35% or less, approximately 40% or less, approximately 45% or less, approximately 50% or less, approximately 55% or less, approximately 60% or less, approximately 70% or less, approximately 80% or less, or approximately 90% or less, relative to the control level of target gene expression. In some implementations, the reduction in target gene expression in immune cells in TdLN is about 1% or less, about 5% or less, about 10% or less, about 15% or less, about 20% or less, about 25% or less, about 30% or less, about 35% or less, about 40% or less, about 45% or less, about 50% or less, about 55% or less, about 60% or less, about 70% or less, about 80% or less, or about 90% or less, relative to the control level of target gene expression. In some implementations, the reduction in target gene expression in M-MDSC is approximately 1% or less, approximately 5% or less, approximately 10% or less, approximately 15% or less, approximately 20% or less, approximately 25% or less, approximately 30% or less, approximately 35% or less, approximately 40% or less, approximately 45% or less, approximately 50% or less, approximately 55% or less, approximately 60% or less, approximately 70% or less, approximately 80% or less, or approximately 90% or less, relative to the control level of target gene expression. In some implementations, the reduction in target gene expression in G-MDSC is approximately 1% or less, approximately 5% or less, approximately 10% or less, approximately 15% or less, approximately 20% or less, approximately 25% or less, approximately 30% or less, approximately 35% or less, approximately 40% or less, approximately 45% or less, approximately 50% or less, approximately 55% or less, approximately 60% or less, approximately 70% or less, approximately 80% or less, or approximately 90% or less, relative to the control level of target gene expression.In some embodiments, the reduction in target gene expression in Tregs is defined as approximately 1% or less, approximately 5% or less, approximately 10% or less, approximately 15% or less, approximately 20% or less, approximately 25% or less, approximately 30% or less, approximately 35% or less, approximately 40% or less, approximately 45% or less, approximately 50% or less, approximately 55% or less, approximately 60% or less, approximately 70% or less, approximately 80% or less, or approximately 90% or less, relative to a control level of target gene expression. In some embodiments, the control level of target gene expression is the amount or level of target mRNA and / or protein in cells or cell populations that have not yet been contacted with the oligonucleotide-ligand conjugates described herein. In some embodiments, the effectiveness of delivering the oligonucleotide-ligand conjugates according to the methods described herein to immune cells or immune cell populations (e.g., tumor-resident immune cells) in the tumor microenvironment is evaluated after any limited time period or time quantity (e.g., minutes, hours, days, weeks, months). For example, in some embodiments, target gene expression is measured in immune cells or populations of immune cells in the tumor microenvironment (e.g., tumor-resident immune cells) at least about 4 hours, about 8 hours, about 12 hours, about 18 hours, or about 24 hours after contacting or delivering the oligonucleotide-ligand conjugate to cells or cell populations; or at least about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 21 days, about 28 days, about 35 days, about 42 days, about 49 days, about 56 days, about 63 days, about 70 days, about 77 days, or about 84 days or longer. In some implementations, target gene expression is measured in immune cells or populations of immune cells (e.g., tumor-resident immune cells) in the tumor microenvironment at least about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, or about 6 months or longer after contacting or delivering the oligonucleotide-ligand conjugate to cells or populations of cells.

[0427] Reducing the activity of immunosuppressive cells such as Tregs or MDSCs in tumors is a potential strategy for converting cold tumors into hot tumors. In some embodiments, the oligonucleotide-ligand conjugate converts cold tumors into hot tumors. In some embodiments, the oligonucleotide-ligand conjugate enhances antitumor-inducing immune activity by reducing immunosuppressive activity. In some embodiments, the oligonucleotide-ligand conjugate enhances antitumor-inducing T cell activity by reducing the activity of immunosuppressive cells (e.g., MDSCs).

[0428] In some embodiments, the oligonucleotide-ligand conjugate enhances antitumor activity by reducing the immunosuppressive activity of MDSCs. In some embodiments, the oligonucleotide-ligand conjugate enhances antitumor activity by reducing the immunosuppressive activity of M-MDSCs. In some embodiments, the oligonucleotide-ligand conjugate enhances antitumor activity by reducing the immunosuppressive activity of G-MDSCs. In some embodiments, the oligonucleotide-ligand conjugate enhances antitumor activity by reducing the immunosuppressive activity of Tregs. In some embodiments, methods for measuring antitumor activity include, but are not limited to, measuring the number of tumor-infiltrating lymphocytes in the tumor.

[0429] In some embodiments, the oligonucleotide-ligand conjugate reduces the immunosuppressive activity of M-MDSCs to an amount sufficient to convert a cold tumor into a hot tumor. In some embodiments, the oligonucleotide-ligand conjugate reduces the immunosuppressive activity of G-MDSCs to an amount sufficient to convert a cold tumor into a hot tumor. In some embodiments, the oligonucleotide-ligand conjugate reduces the immunosuppressive activity of Tregs to an amount sufficient to convert a cold tumor into a hot tumor. Methods for determining whether a cold tumor has converted into a hot tumor include, but are not limited to, measuring the tumor's response to immunotherapy (e.g., a checkpoint inhibitor peptide).

[0430] ii. Treatment methods and medicinal uses

[0431] In some aspects, this disclosure provides oligonucleotide-ligand conjugates for or modified for treating a subject (e.g., a human) with cancer, who will benefit from a reduction in target genes (e.g., target genes encoding immunosuppressive regulators). In some aspects, this disclosure provides oligonucleotide-ligand conjugates for or modified for treating a subject with cancer. In some aspects, this disclosure provides oligonucleotide-ligand conjugates for or modified for treating a subject with cancer associated with immunosuppressive TME. This disclosure also provides oligonucleotide-ligand conjugates for or modified for preparing medicaments or pharmaceutical compositions for treating cancer. In some embodiments, the oligonucleotide-ligand conjugate used or modified for use targets immunosuppressive regulators (e.g., transcription factors or checkpoint inhibitor peptides). In some embodiments, the oligonucleotide-ligand conjugate used or modified for use targets immunosuppressive regulators and reduces the amount or level of the regulator's mRNA or protein and / or activity.

[0432] As detailed below, the method may also include steps such as: measuring or obtaining a baseline value of a biomarker of an immunosuppressive regulator, and then comparing such a value with one or more other baseline values ​​or values ​​obtained after administration of an oligonucleotide to assess the effectiveness of treatment.

[0433] In some embodiments, this disclosure provides oligonucleotide-ligand conjugates for reducing immunosuppression in the tumor microenvironment. In some embodiments, the reduction in immunosuppression is determined by an appropriate assay or technique evaluating one or more properties or characteristics of immunosuppression in the tumor (e.g., the presence of suppressive cells such as MDSCs), or by an assay or technique evaluating molecules that directly indicate immunosuppression (e.g., high expression of Arg1). In some embodiments, the extent to which the oligonucleotide-ligand conjugates reduce immunosuppression is evaluated by comparing the immunosuppression in the TME contacted with the oligonucleotide-ligand conjugate to an appropriate control (e.g., an appropriate tumor not contacted with the oligonucleotide or contacted with a control oligonucleotide). In some embodiments, the appropriate control level of mRNA expressed as protein can be a predetermined level or value, such that it is not necessary to measure the control level every time. The predetermined level or value can take many forms. In some embodiments, the predetermined level or value can be a single cutoff value, such as a median or average.

[0434] In some embodiments, administration of the oligonucleotide-ligand conjugates described herein results in a reduction of target mRNA in tumor-resident immune cells. In some embodiments, the reduction in target mRNA is approximately 1% or less, approximately 5% or less, approximately 10% or less, approximately 15% or less, approximately 20% or less, approximately 25% or less, approximately 30% or less, approximately 35% or less, approximately 40% or less, approximately 45% or less, approximately 50% or less, approximately 55% or less, approximately 60% or less, approximately 70% or less, approximately 80% or less, or approximately 90% or less compared to an appropriate control level of mRNA. An appropriate control level may be the level of mRNA expression and / or protein translation in cells or cell populations that have not yet been contacted with the oligonucleotide-ligand conjugates described herein. In some embodiments, the effectiveness of delivering the oligonucleotide-ligand conjugates to cells according to the methods described herein is evaluated after a limited time period. For example, the level of mRNA in cells can be analyzed at least about 8 hours, about 12 hours, about 18 hours, or about 24 hours after the oligonucleotide-ligand conjugate is introduced into the tumor; or at least about 1, 2, 3, 4, 5, 6, 7 days or even up to 14 days after the tumor is introduced.

[0435] In some embodiments, the oligonucleotide-ligand conjugate is delivered in the form of a transgene engineered to express the oligonucleotide-ligand conjugate or a strand constituting the oligonucleotide-ligand conjugate (e.g., its sense and antisense strands) in cells. In some embodiments, the oligonucleotide-ligand conjugate is delivered using a transgene engineered to express any of the oligonucleotide-ligand conjugates disclosed herein. The transgene can be delivered using a viral vector (e.g., adenovirus, retrovirus, vaccinia virus, poxvirus, adeno-associated virus, or herpes simplex virus) or a non-viral vector (e.g., plasmid or synthetic mRNA). In some embodiments, the transgene can be injected directly into a subject.

[0436] In some aspects, this disclosure provides methods for treating subjects who have, are suspected of having, or are at risk of developing cancer. In some embodiments, this disclosure provides methods for treating or attenuating the onset or progression of cancer using the oligonucleotide-ligand conjugates described herein. In some embodiments of the methods herein, the subject is treated by administering a therapeutically effective amount of any one or more of the oligonucleotide-ligand conjugates described herein. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0437] In some embodiments of the methods described herein, one or more oligonucleotide-ligand conjugates of this invention, or a pharmaceutical composition comprising one or more oligonucleotide-ligand conjugates, are administered to a subject with cancer. In some embodiments, the oligonucleotide-ligand conjugate reduces target mRNA in the tumor (e.g., immune cells in the tumor microenvironment). In some embodiments, the amount of target mRNA and / or protein is reduced in the subject.

[0438] In some embodiments of the methods described herein, the oligonucleotide-ligand conjugates of this invention or pharmaceutical compositions comprising the oligonucleotide-ligand conjugates are administered to a subject with cancer, and the expression of a target gene (e.g., a regulator of immunosuppression) in the subject is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the expression of the target prior to administration of one or more oligonucleotide-ligand conjugates or pharmaceutical compositions. In some embodiments, the target mRNA expression in a subject (e.g., a reference or control subject) is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the target mRNA expression in a subject who has not received the oligonucleotide-ligand conjugate or pharmaceutical composition or has received a control oligonucleotide-ligand conjugate or pharmaceutical composition or treatment.

[0439] In some embodiments of the methods described herein, one or more oligonucleotide-ligand conjugates of this invention or pharmaceutical compositions comprising such oligonucleotide-ligand conjugates are administered to a subject with cancer such that the amount or level of target mRNA (e.g., a gene encoding an immunosuppressive regulator) in the subject's tumor-resident immune cells is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the amount or level of target mRNA prior to administration of the oligonucleotide-ligand conjugate or pharmaceutical composition. In some embodiments of the methods described herein, one or more oligonucleotide-ligand conjugates of this invention or a pharmaceutical composition comprising the oligonucleotide-ligand conjugate are administered to a subject with cancer such that the amount or level of target mRNA (e.g., a gene encoding an immunosuppressive regulator) in the subject's TdLN immune cells is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the amount or level of target mRNA prior to administration of the oligonucleotide-ligand conjugate or pharmaceutical composition. In some embodiments, the amount or level of target mRNA in the subject is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the amount or level of target mRNA in a subject who has not received the one or more oligonucleotide-ligand conjugates or pharmaceutical compositions or who has received one or more control oligonucleotide-ligand conjugates, pharmaceutical compositions, or treatments.

[0440] In some embodiments of the methods described herein, one or more oligonucleotide-ligand conjugates of this invention or a pharmaceutical composition comprising the oligonucleotide-ligand conjugate are administered to a cancer-stricken subject in an immunosuppressive environment such that the amount or level of the immunosuppressive target protein in the subject is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the amount or level of the immunosuppressive protein prior to administration of the oligonucleotide-ligand conjugate or pharmaceutical composition. In some embodiments, the amount or level of immunosuppressive proteins in subjects (e.g., reference or control subjects) is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the amount or level of immunosuppressive proteins in subjects who did not receive the oligonucleotide-ligand conjugate or pharmaceutical composition or who received a control oligonucleotide-ligand conjugate or pharmaceutical composition or treatment.

[0441] In some embodiments of the methods described herein, one or more oligonucleotide-ligand conjugates of this invention or a pharmaceutical composition comprising one or more oligonucleotide-ligand conjugates are administered to a cancer-stricken subject with an immunosuppressive TME, such that the amount or level of immunosuppressive mRNA or protein in the subject is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% compared to the amount or level of immunosuppressive mRNA or protein in the subject prior to administration of the oligonucleotide-ligand conjugate or pharmaceutical composition. In some embodiments, the amount or level of target mRNA regulating immunosuppression is reduced by at least about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or more than 99% in subjects who have not received the oligonucleotide-ligand conjugate or pharmaceutical composition or have received a control oligonucleotide-ligand conjugate, pharmaceutical composition, or treatment (e.g., reference or control subjects).

[0442] Due to its high specificity, the oligonucleotide-ligand conjugates described herein specifically target the mRNA of target genes in diseased cells and tissues. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to target cells. In some embodiments, the target cells are immune cells found in the tumor microenvironment. In some embodiments, the target cells are immune cells found in an immunosuppressive tumor microenvironment. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to one or more MDSC cell populations. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to G-MDSCs. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to M-MDSCs. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to both G-MDSCs and M-MDSCs. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to T cells in the tumor microenvironment. In some embodiments, the oligonucleotide-ligand conjugates deliver oligonucleotides to Treg cells.

[0443] As described herein, oligonucleotide-ligand conjugates for targeting mRNAs encoding immunosuppressive regulators can transform cold tumors into hot tumors. Hot tumors enable other treatment methods to treat the disease more effectively. Therefore, in some embodiments, the oligonucleotide-ligand conjugates described herein are administered in combination with a second therapeutic agent. In some embodiments, the second therapeutic agent is selected from, but is not limited to, chemotherapy, targeted anticancer therapy, oncolytic agents, cytotoxic agents, immunotherapy, cytokines, surgery, radiation procedures, activators of co-stimulatory molecules, inhibitors of inhibitory molecules, vaccines, or cellular immunotherapy, or combinations thereof.

[0444] The methods described herein generally involve administering to a subject an effective amount of one or more oligonucleotide-ligand conjugates, i.e., an amount capable of producing the desired therapeutic outcome. A therapeutically acceptable amount may be an amount capable of therapeutically treating a disease or condition. The appropriate dose for any subject will depend on several factors, including the subject's body size, body surface area, age, the specific composition to be administered, the active ingredient in the composition, the time and route of administration, general health condition, and any other medications administered concurrently.

[0445] In some embodiments, any of the compositions herein are administered to a subject via the enteral (e.g., orally, via a gastric feeding tube, via a duodenal feeding tube, via a gastrostomy, or via the rectum), parenteral (e.g., subcutaneously, intravenously, intra-arterially, intraosseously, intramuscularly, intracerebrally, intraventricularly, or intrathecally), topical (e.g., epidermis, inhalation, via eye drops, or via mucous membranes), or by direct injection into a target organ (e.g., the subject's liver). In some embodiments, the oligonucleotide-ligand conjugate or pharmaceutical composition thereof is administered intravenously or subcutaneously.

[0446] As a set of non-limiting examples, in some embodiments, the oligonucleotide-ligand conjugate described herein is administered quarterly (every three months), every two months (every two months), monthly, or weekly. For example, the oligonucleotide-ligand conjugate may be administered weekly or at two- or three-week intervals. Alternatively, the oligonucleotide-ligand conjugate may be administered daily. In some embodiments, a loading dose of one or more oligonucleotide-ligand conjugates is administered to a subject, followed by one or more maintenance doses of the oligonucleotide-ligand conjugate.

[0447] In some embodiments, the oligonucleotide-ligand conjugates described herein are administered alone or in combination. In some embodiments, the oligonucleotides described herein are administered simultaneously, sequentially (in any order), or intermittently in combination. For example, two oligonucleotide-ligand conjugates may be administered simultaneously. Alternatively, one oligonucleotide-ligand conjugate may be administered, and a second oligonucleotide-ligand conjugate may be administered after any time period (e.g., one hour, one day, one week, or one month).

[0448] In some implementations, the subjects to be treated are human or non-human primates or other mammal subjects. Other exemplary subjects include domestic animals such as dogs and cats; livestock such as horses, cattle, pigs, sheep, goats, and chickens; and animals such as mice, rats, guinea pigs, and hamsters.

[0449] Types of oligonucleotides

[0450] Various oligonucleotide types and / or structures can be used to target sequences in the methods described herein, including but not limited to RNAi oligonucleotides, antisense oligonucleotides, miRNAs, etc. Any oligonucleotide type described herein or elsewhere is intended to be used as a framework to incorporate the target sequence described herein.

[0451] In some embodiments, the oligonucleotides described herein inhibit the expression of a target sequence by incorporating an RNA interference (RNAi) pathway upstream or downstream of a cleavage enzyme (Dicer). For example, RNAi oligonucleotides have been developed having a size of about 19-25 nucleotides per strand and having at least one 3' overhang of 1 to 5 nucleotides (see, for example, U.S. Patent No. 8,372,968). Longer oligonucleotides have also been developed, which are processed by cleavage enzymes to generate active RNAi products (see, for example, U.S. Patent No. 8,883,996). Further work has yielded extended dsRNAs in which at least one end of at least one strand extends beyond the double-stranded target region, including structures in which one strand comprises a thermodynamically stable tetracyclic structure (see, for example, U.S. Patents Nos. 8,513,207 and 8,927,705, and International Patent Application Publication No. WO 2010 / 033225). Such structures may include single-strand extensions (on one or both sides of the molecule) and double-strand extensions.

[0452] In some embodiments, the oligonucleotides described herein are added downstream of the cleavage enzyme (e.g., cleavage enzyme cleavage) into the RNAi pathway. In some embodiments, the oligonucleotides described herein are cleavage enzyme substrates. In some embodiments, after processing with an endogenous cleavage enzyme, a double-stranded nucleic acid of 19-23 nucleotides in length is produced, capable of reducing the expression of the target mRNA. In some embodiments, the oligonucleotide has a 3' overhang (e.g., 1, 2, or 3 nucleotides in length) at the sense strand. In some embodiments, the oligonucleotide (e.g., siRNA) comprises a 21-nucleotide guide strand antisense to the target RNA and a complementary guest strand, wherein these two strands are annealed to form a 19-bp double helix and a 2-nucleotide overhang at either or both 3' ends. Longer oligonucleotide designs are also possible, including oligonucleotides with a 23-nucleotide guiding strand and a 21-nucleotide guest strand, wherein there is a blunt end on the right side of the molecule (3' end of the guest strand / 5' end of the guiding strand) and a two-nucleotide 3'-guiding strand overhang on the left side of the molecule (5' end of the guest strand / 3' end of the guiding strand). In such molecules, a 21 bp double-stranded region is present. See, for example, U.S. Patents 9,012,138, 9,012,621, and 9,193,753.

[0453] In some embodiments, the oligonucleotides described herein comprise a sense strand and an antisense strand, both in length ranging from about 17 to 26 nucleotides (e.g., 17 to 26, 20 to 25, or 21-23). ​​In some embodiments, the oligonucleotides described herein comprise a sense strand and an antisense strand, both in length ranging from about 17 to 36 nucleotides (e.g., 17 to 36, 20 to 25, or 21-23). ​​In some embodiments, the oligonucleotides described herein comprise an antisense strand of 19-30 nucleotides and a sense strand of 19-50 nucleotides, wherein the antisense strand and the sense strand are separate strands forming an asymmetric double-stranded region with a 1-4 nucleotide overhang at the 3' end of the antisense strand. In some embodiments, the oligonucleotides described herein comprise a sense strand and an antisense strand, both in length ranging from about 19-22 nucleotides. In some embodiments, the sense strand and the antisense strand are of equal length. In some embodiments, the oligonucleotides described herein comprise a sense strand and an antisense strand, such that a 3'-protrusion is present on the sense strand or the antisense strand, or on both the sense strand and the antisense strand. In some embodiments, for oligonucleotides having a sense strand and an antisense strand, each with a length in the range of about 21-23 nucleotides, the 3'-protrusion on the sense strand, the antisense strand, or both the sense strand and the antisense strand is 1 or 2 nucleotides in length. In some embodiments, the oligonucleotide has a 22-nucleotide guiding strand and a 20-nucleotide guest strand, wherein it has a blunt end on the right side of the molecule (3' end of the guest strand / 5' end of the guiding strand) and a 2-nucleotide 3'-guiding strand protrusion on the left side of the molecule (5' end of the guest strand / 3' end of the guiding strand). In such molecules, a 20 bp double-stranded region is present.

[0454] Other oligonucleotide designs used with the compositions and methods described herein include: 16-meric siRNAs (see, for example, NUCLEIC ACIDS IN CHEMISTRY AND BIOLOGY, Blackburn (ed.), Royal Society of Chemistry, 2006), shRNAs (e.g., with a stem of 19 bp or less; see, for example, Moore et al. (2010) METHODS MOL. BIOL. 629:141-58), and blunt-ended siRNAs (e.g., 19 bp in length; see, for example, Kraynack and Baker (2006) RNA). 12:163-76), asymmetric siRNA (aiRNA; see, e.g., Sun et al. (2008) Nat. Biotechnol. 26:1379-82), asymmetric short double-stranded siRNA (see, e.g., Chang et al. (2009) Mol. Ther. 17:725-32), forked siRNA (see, e.g., Hohjoh (2004) FEBS Lett. 557:193-98), single-stranded siRNA (Elsner (2012) Nat. Biotechnol. 30:1063), dumbbell-shaped circular siRNA (see, e.g., Abe et al. (2007) J. Am. Chem. Soc. 129:15108-09), and small internal segmented interfering RNA (siRNA; see, e.g., Bramsen et al. (2007) Nucleic Acids Res. 35:5886-97). Other non-limiting examples of oligonucleotide structures that can be used in some embodiments to reduce or inhibit STAT3 expression are microRNAs (miRNAs), short hairpin RNAs (shRNAs), and short siRNAs (see, for example, Hamilton et al. (2002) EMBO J.21:4671-79; see also U.S. Patent Application Publication No. 2009 / 0099115).

[0455] Additionally, in some embodiments, the oligonucleotides used to reduce or inhibit the expression of the target sequence herein are single-stranded. Such structures may include, but are not limited to, single-stranded RNAi molecules. Recent efforts have demonstrated the activity of single-stranded RNAi molecules (see, for example, Matsui et al., (2016) MOL.THER.24:946-55). However, in some embodiments, the oligonucleotides herein are antisense oligonucleotides (ASOs). An antisense oligonucleotide is a single-stranded oligonucleotide having a nucleobase sequence that, when written in the 5' to 3' orientation, contains the inverse complementary sequence of the targeted segment of a specific nucleic acid and is appropriately modified (e.g., as a gapmer) to induce RNase H-mediated cleavage of its target RNA in the cell, or (e.g., as a mixmer) to inhibit the translation of the target mRNA in the cell. The ASO used herein may be modified in any suitable manner known in the art, including, for example, as shown in U.S. Patent No. 9,567,587 (including, for example, changes in length, sugar moiety of nucleobases (pyrimidine, purine), and heterocyclic moiety of nucleobases). Furthermore, ASO has been used for decades to reduce the expression of specific target genes (see, for example, Bennett et al., (2017) ANNU. REV. PHARMACOL. 57:81-105).

[0456] In some embodiments, the antisense oligonucleotide shares a complementary region with the target mRNA. In some embodiments, the antisense oligonucleotide is 15-50 nucleotides long. In some embodiments, the antisense oligonucleotide is 15-25 nucleotides long. In some embodiments, the antisense oligonucleotide is 22 nucleotides long. In some embodiments, the antisense oligonucleotide is at least 15 consecutive nucleotides long. In some embodiments, the antisense oligonucleotide is at least 19 consecutive nucleotides long. In some embodiments, the antisense oligonucleotide is at least 20 consecutive nucleotides long. In some embodiments, the antisense oligonucleotide differs from the target sequence by 1, 2, or 3 nucleotides.

[0457] Double-stranded oligonucleotides

[0458] In some embodiments, this disclosure provides a double-stranded dsRNA for targeting and inhibiting the expression of a target sequence (e.g., via the RNAi pathway), comprising a sense strand (also referred to herein as a guest strand) and an antisense strand (also referred herein as a guide strand). In some embodiments, the sense and antisense strands are separate strands and are not covalently linked. In some embodiments, the sense and antisense strands are covalently linked. In some embodiments, the sense and antisense strands form a double-stranded region, wherein the sense and antisense strands, or portions thereof, bind to each other in a complementary manner (e.g., via Watson-Crick base pairing).

[0459] In some embodiments, the sense strand has a first region (R1) and a second region (R2), wherein R2 comprises a first subregion (S1), a ring (L) such as a tetraL or triL, and a second subregion (S2), wherein the L, tetraL, or triL is located between S1 and S2, and wherein S1 and S2 form a second double strand (D2). D2 can have different lengths. In some embodiments, the length of D2 is about 1-6 bp. In some embodiments, the length of D2 is 2-6, 3-6, 4-6, 5-6, 1-5, 2-5, 3-5, or 4-5 bp. In some embodiments, the length of D2 is 1, 2, 3, 4, 5, or 6 bp. In some embodiments, the length of D2 is 6 bp.

[0460] In some embodiments, the sense strand R1 and the antisense strand form a first double helix (D1). In some embodiments, the length of D1 is at least about 15 nucleotides (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21). In some embodiments, the length of D1 is in the range of about 12 to 30 nucleotides (e.g., 12 to 30, 12 to 27, 15 to 22, 18 to 22, 18 to 25, 18 to 27, 18 to 30, or 21 to 30 nucleotides). In some embodiments, the length of D1 is at least 12 nucleotides (e.g., at least 12, at least 15, at least 20, at least 25, or at least 30 nucleotides). In some embodiments, the length of D1 is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the length of D1 is 20 nucleotides. In some embodiments, D1 containing both sense and antisense strands does not span the entire length of the sense and / or antisense strands. In some embodiments, D1 containing both sense and antisense strands spans the entire length of the sense or antisense strand, or both. In some embodiments, D1 containing both sense and antisense strands spans the entire length of both the sense and antisense strands.

[0461] It should be understood that in some embodiments, the sequence presented in the sequence listing may be referenced when describing the structure of an oligonucleotide or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides (e.g., RNA counterparts of DNA nucleotides or DNA counterparts of RNA nucleotides) and / or one or more modified nucleotides and / or one or more modified internucleotide bonds and / or one or more other modifications, compared to the specified sequence, while still retaining complementary properties substantially the same or similar to those of the specified sequence.

[0462] In some embodiments, the double-stranded RNA (dsRNA) of this invention comprises a 25-nucleotide sense strand and a 27-nucleotide antisense strand, which, upon exposure to a cleavage enzyme, produces an antisense strand incorporated into the mature RISC. In some embodiments, the sense strand of the dsRNA is longer than 27 nucleotides (e.g., 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides). In some embodiments, the sense strand of the dsRNA is longer than 27 nucleotides (e.g., 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides). In some embodiments, the sense strand of the dsRNA is longer than 25 nucleotides (e.g., 26, 27, 28, 29, or 30 nucleotides).

[0463] In some embodiments, the oligonucleotides described herein have a 5' end that is thermodynamically less stable compared to the other 5' end. In some embodiments, asymmetric oligonucleotides are provided that include a blunt end at the 3' end of the sense strand and a 3'-protrusion at the 3' end of the antisense strand. In some embodiments, the 3'-protrusion on the antisense strand is about 1-8 nucleotides long (e.g., 1, 2, 3, 4, 5, 6, 7, or 8 nucleotides). Typically, oligonucleotides for RNAi have a two-nucleotide protrusion at the 3' end of the antisense (guide) strand. However, other protrusions are also possible. In some embodiments, the protrusion is a 3'-protrusion containing 1 to 6 nucleotides, optionally 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to 4, 4 to 6, 4 to 5, 5 to 6 nucleotides, or 1, 2, 3, 4, 5, or 6 nucleotides in length. However, in some embodiments, the overhang is a 5'-overhang containing 1 to 6 nucleotides, optionally 1 to 5, 1 to 4, 1 to 3, 1 to 2, 2 to 6, 2 to 5, 2 to 4, 2 to 3, 3 to 6, 3 to 5, 3 to 4, 4 to 6, 4 to 5, 5 to 6 nucleotides, or 1, 2, 3, 4, 5 or 6 nucleotides in length.

[0464] In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand are modified. In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand are complementary to the target mRNA. In some embodiments, the two terminal nucleotides at the 3' end of the antisense strand of the oligonucleotide described herein contain unpaired GG. In some embodiments, the two (2) terminal nucleotides at the 3' end of the antisense strand of the oligonucleotide described herein are not complementary to the target mRNA. In some embodiments, the two terminal nucleotides at the 3' end of each oligonucleotide in the nicked tetracyclic structure are GG. In some embodiments, one or both of the two (2) terminal GG nucleotides at the 3' end of each oligonucleotide described herein are not complementary to the target mRNA. Typically, one or both of the two terminal GG nucleotides at the 3' end of each oligonucleotide are not complementary to the target.

[0465] In some embodiments, one or more (e.g., 1, 2, 3, 4, or 5) mismatches exist between the sense and antisense strands. If more than one mismatch exists between the sense and antisense strands, they may be sequentially located (e.g., two, three, or more consecutively) or scattered throughout the complementary region. In some embodiments, the 3' end of the sense strand contains one or more mismatches. In one embodiment, two mismatches are incorporated at the 3' end of the sense strand. In some embodiments, base mismatches or segment destabilization at the 3' end of the oligonucleotide's sense strand improve the efficiency of bistrand synthesis in RNAi, which may be achieved by facilitating cleavage enzyme processing.

[0466] a. antisense chain

[0467] In some embodiments, the dsRNA comprises an antisense strand of up to about 40 nucleotides in length (e.g., up to 40, up to 35, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, the oligonucleotides herein (e.g., RNAi oligonucleotides) comprise an antisense strand of up to about 50 nucleotides in length (e.g., up to 50, up to 40, up to 35, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, the oligonucleotide may have an antisense strand of at least about 12 nucleotides in length (e.g., at least 12, at least 15, at least 19, at least 21, at least 22, at least 25, at least 27, at least 30, at least 35, or at least 38 nucleotides in length). In some embodiments, the oligonucleotide may have an antisense strand of about 12 to about 40 nucleotides (e.g., 12 to 40, 12 to 36, 12 to 32, 12 to 28, 15 to 40, 15 to 36, 15 to 32, 15 to 28, 17 to 22, 17 to 25, 19 to 27, 19 to 30, 20 to 40, 22 to 40, 25 to 40, or 32 to 40). In some embodiments, the oligonucleotide comprises an antisense strand of 15 to 30 nucleotides in length. In some implementations, the oligonucleotide may have an antisense strand of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 nucleotides in length.

[0468] In some implementations, the antisense strand of the oligonucleotide may be referred to as the "guide strand." For example, if the antisense strand is capable of binding to an RNA-induced silencing complex (RISC) and an Argonaute protein such as Ago2, or binding to one or more similar factors, and guides the silencing of a target gene, it may be referred to as the guide strand. In some implementations, the sense strand complementary to the guide strand may be referred to as the "passenger strand."

[0469] b. A chain of meaning

[0470] In some embodiments, the oligonucleotide comprises a sense strand (or guest strand) of up to about 40 nucleotides in length (e.g., up to 40, up to 36, up to 30, up to 27, up to 25, up to 21, up to 19, up to 17, or up to 12 nucleotides in length). In some embodiments, the oligonucleotide may have a sense strand of at least about 12 nucleotides in length (e.g., at least 12, at least 15, at least 19, at least 21, at least 25, at least 27, at least 30, at least 36, or at least 38 nucleotides in length). In some embodiments, the oligonucleotide may have a sense strand of about 12 to about 40 nucleotides (e.g., 12 to 40, 12 to 36, 12 to 32, 12 to 28, 15 to 40, 15 to 36, 15 to 32, 15 to 28, 17 to 21, 17 to 25, 19 to 27, 19 to 30, 20 to 40, 22 to 40, 25 to 40, or 32 to 40). In some embodiments, the oligonucleotides herein comprise a sense strand of 15 to 50 nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand of 18 to 36 nucleotides. In some embodiments, the oligonucleotide may have a sense strand of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length. In some embodiments, the oligonucleotide comprises a sense strand of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some implementations, the oligonucleotides described herein comprise a sense strand of 36 nucleotides in length.

[0471] In some embodiments, the oligonucleotides provided herein (e.g., RNAi oligonucleotides) comprise a sense strand with a stem-loop structure at its 3' end. In some embodiments, the stem-loop is formed by intra-chain base pairing. In some embodiments, the sense strand comprises a stem-loop structure at its 5' end. In some embodiments, the stem of the stem-loop comprises a double strand of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a double strand of 2 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a double strand of 3 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a double strand of 4 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a double strand of 5 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a double strand of 6 nucleotides in length. In some embodiments, the stem of the stem-loop comprises a double strand of 7 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 8 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 9 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 10 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 11 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 12 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 13 nucleotides in length. In some embodiments, the stem of the stem-loop contains a double strand of 14 nucleotides in length.

[0472] In some embodiments, the stem-loop provides protection against degradation (e.g., enzymatic degradation) of the oligonucleotide, promotes or improves targeting and / or delivery to target cells, tissues, or organs (e.g., the liver), or both. For example, in some embodiments, the loop of the stem-loop consists of one or more modified nucleotides that promote, improve, or increase targeting, inhibition of target gene expression, and / or delivery, uptake, and / or penetration into target cells, tissues, or organs (e.g., the liver), or combinations thereof. In some embodiments, the stem-loop itself or modifications to the stem-loop do not affect or substantially do not affect the inherent gene expression repressive activity of the oligonucleotide, but promote, improve, or increase the stability of the oligonucleotide (e.g., provide protection against degradation) and / or its delivery, uptake, and / or penetration into target cells, tissues, or organs. In some embodiments, the oligonucleotides herein comprise a sense chain containing (e.g., at its 3' end) a stem-loop as follows: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a single-stranded loop of nucleotides linking S1 and S2 with a length of up to about 10 nucleotides (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides). In some embodiments, the loop (L) is 3 nucleotides long (referred to herein as a "tri-loop"). In some embodiments, the loop (L) is 4 nucleotides long (referred to herein as a "tetra-loop"). In some embodiments, the loop (L) is 5 nucleotides long. In some embodiments, the loop (L) is 6 nucleotides long. In some embodiments, the loop (L) is 7 nucleotides long. In some embodiments, the loop (L) is 8 nucleotides long. In some embodiments, the loop (L) is 9 nucleotides long. In some embodiments, the loop (L) is 10 nucleotides long.

[0473] In some embodiments, the quadruple loop comprises the sequence 5'-GAAA-3'. In some embodiments, the stem-loop comprises the sequence 5'-GCAGCCGAAAGGCUGC-3' (SEQ ID NO:86).

[0474] In some embodiments, the sense strand includes a stem-loop structure at its 3' end. In some embodiments, the sense strand includes a stem-loop structure at its 5' end. In some embodiments, the stem is a double strand of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 bp in length. In some embodiments, the stem-loop provides protection against degradation (e.g., enzymatic degradation) and promotes targeting properties for delivery to target cells. For example, in some embodiments, the loop provides an added nucleotide that can be modified thereon without substantially affecting the gene expression repressive activity of the oligonucleotide. In some embodiments, oligonucleotides are provided herein in which the sense strand includes (e.g., at its 3' end) a stem-loop as shown: S1-L-S2, wherein S1 is complementary to S2, and wherein L forms a loop of up to about 10 nucleotides in length (e.g., 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length) between S1 and S2. Figure 1 depicts a non-limiting example of such an oligonucleotide.

[0475] In some embodiments, the ring (L) having the stem-loop structure S1-L-S2 as described herein is a tricyclic ring. In some embodiments, the tricyclic ring comprises ribonucleotides, deoxyribonucleotides, modified nucleotides, ligands (e.g., delivery ligands), and combinations thereof.

[0476] In some implementations, the stem-loop is a tetracyclic ring (e.g., within a notched tetracyclic structure). The tetracyclic ring may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Typically, the tetracyclic ring has 4 to 5 nucleotides.

[0477] Double chain length

[0478] In some embodiments, the length of the double strand formed between the sense and antisense strands is at least 12 nucleotides (e.g., at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides). In some embodiments, the length of the double strand formed between the sense and antisense strands is in the range of 12-30 nucleotides (e.g., 12-30, 12-27, 12-22, 15-25, 18-30, 18-22, 18-25, 18-27, 18-30, 19-30, or 21-30 nucleotides). In some embodiments, the length of the double strand formed between the sense and antisense strands is 12, 13, 14, 15, 16, 17, 18, 19, 29, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 12 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 13 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 14 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 15 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 16 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 17 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 18 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 19 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 20 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 21 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 22 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 23 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 24 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 25 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 26 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 27 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 28 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 29 nucleotides. In some embodiments, the length of the duplex formed between the sense and antisense strands is 30 nucleotides.In some embodiments, the double strand formed between the sense and antisense chains does not span the entire length of the sense and / or antisense chains. In some embodiments, the double strand between the sense and antisense chains spans the entire length of either the sense or antisense chain. In some embodiments, the double strand between the sense and antisense chains spans the entire length of both the sense and antisense chains.

[0479] oligonucleotide ends

[0480] In some embodiments, the oligonucleotides disclosed herein (e.g., RNAi oligonucleotides) comprise a sense strand and an antisense strand, wherein the ends of any one or both strands comprise blunt ends. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, which are separate strands forming an asymmetric double-stranded region with a protruding end at the 3' end of the antisense strand. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the ends of any one or both strands comprise a protruding end containing one or more nucleotides. In some embodiments, the one or more nucleotides constituting the protruding end are unpaired nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the 3' end of the sense strand and the 5' end of the antisense strand comprise blunt ends. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the 5' end of the sense strand and the 3' end of the antisense strand comprise blunt ends.

[0481] In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the 3' end of any one or both strands comprises a 3'-protrusion containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the sense strand comprises a 3'-protrusion containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the antisense strand comprises a 3'-protrusion containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein both the sense strand and the antisense strand comprise a 3'-protrusion containing one or more nucleotides.

[0482] In some implementations, the length of the 3'-protrusion is about one (1) to twenty (20) nucleotides (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or about 20 nucleotides). In some embodiments, the length of the 3' overhang is about one (1) to nineteen (19), one (1) to eighteen (18), one (1) to seventeen (17), one (1) to sixteen (16), one (1) to fifteen (15), one (1) to fourteen (14), one (1) to thirteen (13), one (1) to twelve (12), one (1) to eleven (11), one (1) to ten (10), one (1) to nine (9), one (1) to eight (8), one (1) to seven (7), one (1) to six (6), one (1) to five (5), one (1) to four (4), one (1) to three (3), or about one (1) to two (2) nucleotides. In some embodiments, the length of the 3' overhang is (1) nucleotide. In some embodiments, the length of the 3' overhang is two (2) nucleotides. In some embodiments, the length of the 3' overhang is three (3) nucleotides. In some embodiments, the 3'-overhead is four (4) nucleotides long. In some embodiments, the 3'-overhead is five (5) nucleotides long. In some embodiments, the 3'-overhead is six (6) nucleotides long. In some embodiments, the 3'-overhead is seven (7) nucleotides long. In some embodiments, the 3'-overhead is eight (8) nucleotides long. In some embodiments, the 3'-overhead is nine (9) nucleotides long. In some embodiments, the 3'-overhead is ten (10) nucleotides long. In some embodiments, the 3'-overhead is eleven (11) nucleotides long. In some embodiments, the 3'-overhead is twelve (12) nucleotides long. In some embodiments, the 3'-overhead is thirteen (13) nucleotides long. In some embodiments, the 3'-overhead is fourteen (14) nucleotides long. In some embodiments, the 3'-overhead is fifteen (15) nucleotides long. In some embodiments, the 3'-overhead is sixteen (16) nucleotides long. In some embodiments, the 3'-protrusion is seventeen (17) nucleotides long. In some embodiments, the 3'-protrusion is eighteen (18) nucleotides long. In some embodiments, the 3'-protrusion is nineteen (19) nucleotides long. In some embodiments, the 3'-protrusion is twenty (20) nucleotides long.

[0483] In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the 5' end of any one or both strands comprises a 5'-protrusion containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the sense strand comprises a 5'-protrusion containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein the antisense strand comprises a 5'-protrusion containing one or more nucleotides. In some embodiments, the oligonucleotides herein comprise a sense strand and an antisense strand, wherein both the sense strand and the antisense strand comprise a 5'-protrusion containing one or more nucleotides.

[0484] In some implementations, the 5'-protrusion is about one (1) to twenty (20) nucleotides long (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or about 20 nucleotides long). In some embodiments, the length of the 5' overhang is about one (1) to nineteen (19), one (1) to eighteen (18), one (1) to seventeen (17), one (1) to sixteen (16), one (1) to fifteen (15), one (1) to fourteen (14), one (1) to thirteen (13), one (1) to twelve (12), one (1) to eleven (11), one (1) to ten (10), one (1) to nine (9), one (1) to eight (8), one (1) to seven (7), one (1) to six (6), one (1) to five (5), one (1) to four (4), one (1) to three (3), or about one (1) to two (2) nucleotides. In some embodiments, the length of the 5' overhang is (1) nucleotide. In some embodiments, the length of the 5' overhang is two (2) nucleotides. In some embodiments, the length of the 5' overhang is three (3) nucleotides. In some embodiments, the 5'-overhead is four (4) nucleotides long. In some embodiments, the 5'-overhead is five (5) nucleotides long. In some embodiments, the 5'-overhead is six (6) nucleotides long. In some embodiments, the 5'-overhead is seven (7) nucleotides long. In some embodiments, the 5'-overhead is eight (8) nucleotides long. In some embodiments, the 5'-overhead is nine (9) nucleotides long. In some embodiments, the 5'-overhead is ten (10) nucleotides long. In some embodiments, the 5'-overhead is eleven (11) nucleotides long. In some embodiments, the 5'-overhead is twelve (12) nucleotides long. In some embodiments, the 5'-overhead is thirteen (13) nucleotides long. In some embodiments, the 5'-overhead is fourteen (14) nucleotides long. In some embodiments, the 5'-overhead is fifteen (15) nucleotides long. In some embodiments, the 5'-overhead is sixteen (16) nucleotides long. In some embodiments, the 5'-overhead is seventeen (17) nucleotides long. In some embodiments, the 5'-overhead is eighteen (18) nucleotides long. In some embodiments, the 5'-overhead is nineteen (19) nucleotides long. In some embodiments, the 5'-overhead is twenty (20) nucleotides long.

[0485] In some embodiments, one or more (e.g., 2, 3, 4, 5 or more) nucleotides constituting the 3' or 5' end of the sense strand and / or antisense strand are modified. For example, in some embodiments, one or both terminal nucleotides of the 3' end of the antisense strand are modified. In some embodiments, the last nucleotide of the 3' end of the antisense strand is modified such that it contains a 2' modification or contains 2'-O-methoxyethyl. In some embodiments, the last or two terminal nucleotides of the 3' end of the antisense strand are complementary to the target. In some embodiments, the last or two nucleotides of the 3' end of the antisense strand are not complementary to the target.

[0486] In some embodiments, the oligonucleotides disclosed herein (e.g., RNAi oligonucleotides) comprise a sense strand and an antisense strand, wherein the 3' end of the sense strand comprises a stem-loop as described herein, and the 3' end of the antisense strand comprises a 3'-protrusion as described herein. In some embodiments, the oligonucleotides herein (e.g., RNAi oligonucleotides) comprise a sense strand and an antisense strand forming a notched tetracyclic structure as described herein, wherein the 3' end of the sense strand comprises a stem-loop, wherein the loop is a tetracyclic structure as described herein, and wherein the 3' end of the antisense strand comprises a 3'-protrusion as described herein. In some embodiments, the 3'-protrusion is two (2) nucleotides in length. In some embodiments, both (2) nucleotides constituting the 3'-protrusion contain guanine (G) nucleotides. Typically, one or both nucleotides constituting the 3'-protrusion of the antisense strand are not complementary to the target.

[0487] Oligonucleotide modification

[0488] a. Sugar modification

[0489] In some embodiments, the modified sugar (also referred to herein as a sugar analogue) comprises a modified deoxyribose or ribose moiety, wherein, for example, one or more modifications occur at the 2', 3', 4' and / or 5' carbon positions of the sugar. In some embodiments, the modified sugar may also comprise non-natural alternative carbon structures, such as those present in locked nucleic acids (“LNA”; see, for example, Koshkin et al., (1998) TETRAHEDON 54:3607-3630), unlocked nucleic acids (“UNA”; see, for example, Snead et al., (2013) MOL.THER-NUCL.ACIDS2:e103), and bridging nucleic acids (“BNA”; see, for example, Imanishi and Obika (2002) CHEM COMMUN.(CAMB)21:1653-1659).

[0490] In some embodiments, the nucleotide modification of the sugar includes a 2'-modification. In some embodiments, the 2'-modification may be 2'-O-propargyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-fluoro(2'-F), 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl](2'-O-NMA), or 2'-deoxy-2'-fluoro-β-d-arabinose (2'-FANA). In some embodiments, the modification is 2'-F, 2'-OMe, or 2'-MOE. In some embodiments, the modification of the sugar includes modification of the sugar ring, which may include modification of one or more carbons of the sugar ring. For example, modification of the sugar in a nucleotide may include linking the 2'-oxygen of the sugar to the 1'-carbon or 4'-carbon of the sugar, or linking the 2'-oxygen to the 1'-carbon or 4'-carbon via an ethylene or methylene bridge. In some embodiments, the modified nucleotide has an acyclic sugar lacking the 2'-carbon to 3'-carbon bond. In some embodiments, the modified nucleotide has a thiol group, for example, at the 4' position of the sugar.

[0491] In some embodiments, the oligonucleotide described herein comprises at least about one modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60 or more). In some embodiments, the sense strand of the oligonucleotide comprises at least about one modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35 or more). In some embodiments, the antisense strand of the oligonucleotide comprises at least about one modified nucleotide (e.g., at least 1, at least 5, at least 10, at least 15, at least 20 or more).

[0492] In some embodiments, all nucleotides of the sense strand of the oligonucleotide are modified. In some embodiments, all nucleotides of the antisense strand of the oligonucleotide are modified. In some embodiments, all nucleotides of the oligonucleotide (i.e., both the sense and antisense strands) are modified. In some embodiments, the modified nucleotides contain 2'-modifications (e.g., 2'-F or 2'-OMe, 2'-MOE, and 2'-deoxy-2'-fluoro-β-d-arabinose). In some embodiments, the modified nucleotides contain 2'-modifications (e.g., 2'-F or 2'-OMe).

[0493] In some embodiments, this disclosure provides oligonucleotides with different modification patterns. In some embodiments, the oligonucleotides herein comprise a sense strand having the modification patterns as illustrated in the examples and sequence listing, and an antisense strand having the modification patterns as illustrated in the examples and sequence listing.

[0494] In some embodiments, the oligonucleotides disclosed herein (e.g., RNAi oligonucleotides) comprise an antisense strand having a nucleotide modified with 2'-F. In some embodiments, the oligonucleotides disclosed herein comprise an antisense strand having a nucleotide modified with both 2'-F and 2'-OMe. In some embodiments, the oligonucleotides disclosed herein comprise a sense strand having a nucleotide modified with 2'-F. In some embodiments, the oligonucleotides disclosed herein comprise a sense strand having a nucleotide modified with both 2'-F and 2'-OMe.

[0495] In some embodiments, the oligonucleotides described herein comprise a sense strand in which about 10-15%, 10%, 11%, 12%, 13%, 14%, or 15% of the nucleotides contain a 2'-fluorine modification. In some embodiments, about 11% of the nucleotides in the sense strand contain a 2'-fluorine modification. In some embodiments, the oligonucleotides described herein comprise an antisense strand in which about 25-35%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35% of the nucleotides contain a 2'-fluorine modification. In some embodiments, about 32% of the nucleotides in the antisense strand contain a 2'-fluorine modification. In some embodiments, about 15-25%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25% of the nucleotides in the oligonucleotide contain a 2'-fluorine modification. In some embodiments, about 19% of the nucleotides in the dsRNAi oligonucleotide contain a 2'-fluorine modification.

[0496] In some embodiments, the modified oligonucleotide comprises a sense strand sequence having the modification pattern illustrated in Figure 1 or Example 12 and an antisense strand having the modification pattern illustrated in Figure 1 or Example 12. In some embodiments, for these oligonucleotides, one or more of positions 8, 9, 10, or 11 of the sense strand are modified with a 2'-F group. In other embodiments, for these oligonucleotides, the sugar moiety at each nucleotide at positions 1-7 and 12-20 of the sense strand is modified with 2'-OMe.

[0497] In some embodiments, the antisense strand has three nucleotides modified with 2'-F at the 2'-position of the sugar moiety. In some embodiments, the sugar moiety at positions 2, 5, and 14 of the antisense strand, and optionally up to three nucleotides at positions 1, 3, 7, and 10, are modified with 2'-F. In some embodiments, the sugar moiety at positions 2, 5, and 14 of the antisense strand, and optionally up to three nucleotides at positions 3, 4, 7, and 10, are modified with 2'-F. In other embodiments, the sugar moiety at each position 2, 5, and 14 of the antisense strand is modified with 2'-F. In other embodiments, the sugar moiety at each position 1, 2, 5, and 14 of the antisense strand is modified with 2'-F. In still other embodiments, the sugar moiety at each position 1, 2, 3, 5, 7, and 14 of the antisense strand is modified with 2'-F. In other embodiments, the sugar portion at each of positions 2, 3, 4, 5, 7, and 14 of the antisense chain is modified with 2'-F. In yet another embodiment, the sugar portion at each of positions 1, 2, 3, 5, 10, and 14 of the antisense chain is modified with 2'-F. In other embodiments, the sugar portion at each of positions 2, 3, 4, 5, 10, and 14 of the antisense chain is modified with 2'-F. In yet another embodiment, the sugar portion at each of positions 2, 3, 5, 7, 10, and 14 of the antisense chain is modified with 2'-F. In yet another embodiment, the sugar portion at each of positions 2, 3, 4, 5, 7, 10, and 14 of the antisense chain is modified with 2'-F.

[0498] In some embodiments, the oligonucleotides provided herein comprise an antisense strand in which the sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21 or position 22 is modified with 2'-F.

[0499] In some embodiments, the oligonucleotides provided herein comprise an antisense strand in which the sugar moiety at position 1, position 2, position 3, position 4, position 5, position 6, position 7, position 8, position 9, position 10, position 11, position 12, position 13, position 14, position 15, position 16, position 17, position 18, position 19, position 20, position 21 or position 22 is modified with 2'-OMe.

[0500] In some embodiments, the oligonucleotides provided herein comprise an antisense strand whose sugar moiety at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22 is modified with a sugar moiety selected from 2'-O-propynyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinose (2'-FANA).

[0501] In some embodiments, the oligonucleotides provided herein include a sense strand in which the sugar moiety at positions 8-11 is modified with 2'-F. In some embodiments, the oligonucleotides provided herein include a sense strand in which the sugar moiety at positions 3, 8, 9, 10, 12, 13, and 17 is modified with 2'-F. In some embodiments, the oligonucleotides provided herein include a sense strand in which the sugar moiety at positions 1-7 and 12-17 or 12-20 is modified with 2'OMe. In some embodiments, the oligonucleotides provided herein include a sense strand in which the sugar moiety at positions 1-7, 12-27, and 31-36 is modified with 2'OMe. In some embodiments, the oligonucleotides provided herein comprise a sense strand in which the sugar moiety of each nucleotide at positions 1-7 and 12-17 or 12-20 is modified with a modification selected from 2'-O-propynyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinose (2'-FANA). In some embodiments, the oligonucleotides provided herein comprise a sense strand in which the sugar moiety at positions 1-2, 4-7, 11, 14-16, and 18-20 is modified with 2'OMe. In some embodiments, the oligonucleotides provided herein comprise a sense strand in which the sugar moiety of each nucleotide at positions 1-2, 4-7, 11, 14-16, and 18-20 is modified with a modification selected from 2'-O-propynyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinose (2'-FANA).

[0502] In some embodiments, the oligonucleotides provided herein comprise a sense strand in which the sugar moiety at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 is modified with 2'-F.

[0503] In some embodiments, the oligonucleotides provided herein comprise a sense strand in which the sugar moiety at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 is modified with 2'-OMe.

[0504] In some embodiments, the oligonucleotides provided herein comprise a sense strand at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, and 25. The sugar moiety at positions 32, 33, 34, 35, or 36 is modified by a group selected from 2'-O-propynyl, 2'-O-propylamino, 2'-amino, 2'-ethyl, 2'-aminoethyl (EA), 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), 2'-O-[2-(methylamino)-2-oxoethyl] (2'-O-NMA), and 2'-deoxy-2'-fluoro-β-d-arabinose (2'-FANA).

[0505] b.5' terminal phosphate

[0506] In some embodiments, the 5'-terminal phosphate group of the oligonucleotide enhances its interaction with Ago2. However, oligonucleotides containing a 5'-phosphate group may be readily degraded by phosphatases or other enzymes, which may limit their bioavailability in vivo. In some embodiments, the oligonucleotide comprises a 5'-phosphate analog resistant to such degradation. In some embodiments, the phosphate analog may be an oxymethylphosphonate, vinylphosphonate, or malonylphosphonate. In some embodiments, the 1' end of the oligonucleotide chain is attached to a chemical moiety that mimics the electrostatic and steric properties of the native 5'-phosphate group ("phosphate analog").

[0507] In some embodiments, the oligonucleotide has a phosphate ester analog (referred to as a "4'-phosphate ester analog") at the 4'-carbon position of the sugar. See, for example, International Patent Application Publication No. WO 2018 / 045317. In some embodiments, the oligonucleotide herein contains a 4'-phosphate ester analog at the 5'-terminal nucleotide. In some embodiments, the phosphate ester analog is an oxymethylphosphonate, wherein the oxygen atom of the oxymethyl group is bonded to the sugar moiety (e.g., at its 4'-carbon position) or an analog thereof. In other embodiments, the 4'-phosphate ester analog is a thiomethylphosphonate or an aminomethylphosphonate, wherein the sulfur atom of the thiomethyl group or the nitrogen atom of the aminomethyl group is bonded to the 4'-carbon of the sugar moiety or an analog thereof. In some embodiments, the 4'-phosphate ester analog is an oxymethylphosphonate. In some embodiments, the oxymethylphosphonate is represented by the formula –O–CH2–PO(OH)2 or –O–CH2–PO(OR)2, wherein R is independently selected from H, CH3, alkyl, CH2CH2CN, CH2OCOC(CH3)3, CH2OCH2CH2Si(CH3)3, or a protecting group. In some embodiments, the alkyl group is CH2CH3. More typically, R is independently selected from H, CH3, or CH2CH3.

[0508] In some embodiments, the oligonucleotides provided herein comprise an antisense strand containing a 4'-phosphate analog at the 5'-terminal nucleotide, wherein the 5'-terminal nucleotide comprises the following structure:

[0509]

[0510] 4'-O-monomethylphosphonate-2'-O-methyluridine thiophosphate [MePhosphonate-4O-mUs].

[0511] Chemical Formula 1

[0512] c. Modified nucleotide interbonding

[0513] In some embodiments, the oligonucleotide may comprise a modified internucleotide bond. In some embodiments, phosphate modification or substitution may produce an oligonucleotide comprising at least one (e.g., at least one, at least two, at least three, or at least five) modified internucleotide bonds. In some embodiments, any oligonucleotide disclosed herein comprises about one to about ten (e.g., 1 to 10, 2 to 8, 4 to 6, 3 to 10, 5 to 10, 1 to 5, 1 to 3, or 1 to 2) modified internucleotide bonds. In some embodiments, any oligonucleotide disclosed herein comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 modified internucleotide bonds.

[0514] The modified internucleotide bonds can be dithiophosphate bonds, 4′-O-methylene phosphate bonds, thiophosphate bonds, phosphate triester bonds, thioalkylphosphonate bonds, thioalkylphosphonate bonds, phosphoramide bonds, phosphonate bonds, or boranophosphate bonds. In some embodiments, at least one modified internucleotide bond of any oligonucleotide disclosed herein is a thiophosphate bond. In some embodiments, at least one modified internucleotide bond of any oligonucleotide disclosed herein is a 4′-O-methylene phosphate bond.

[0515] In some embodiments, the oligonucleotide described herein has a phosphate thioester bond between one or more of the sense strand positions 1 and 2, antisense strand positions 1 and 2, antisense strand positions 2 and 3, antisense strand positions 3 and 4, antisense strand positions 20 and 21, and antisense strand positions 21 and 22. In some embodiments, the oligonucleotide described herein has a phosphate thioester bond between each of the sense strand positions 1 and 2, antisense strand positions 1 and 2, antisense strand positions 2 and 3, antisense strand positions 20 and 21, and antisense strand positions 21 and 22.

[0516] d. Base modification

[0517] In some embodiments, the oligonucleotides described herein have one or more modified nucleobases. In some embodiments, the modified nucleobase (also referred to herein as a base analog) is linked at the 1' position of the nucleotide sugar moiety. In some embodiments, the modified nucleobase is a nitrogenous base. In some embodiments, the modified nucleobase does not contain a nitrogen atom. See, for example, U.S. Patent Application Publication No. 2008 / 0274462. In some embodiments, the modified nucleotide contains a universal base. However, in some embodiments, the modified nucleotide does not contain a nucleobase (base-free).

[0518] In some embodiments, the universal base is a heterocyclic moiety located at the 1' position of the nucleotide sugar moiety in the modified nucleotide, or at an equivalent position in a nucleotide sugar moiety substitution, such that when present in a duplex, it can be positioned opposite more than one type of base without substantially altering the duplex structure. In some embodiments, a single-stranded nucleic acid containing the universal base forms a duplex with the target nucleic acid with a lower Tm than a duplex formed with a complementary nucleic acid, compared to a reference single-stranded nucleic acid (e.g., an oligonucleotide) that is fully complementary to the target nucleic acid. However, in some embodiments, a single-stranded nucleic acid containing the universal base forms a duplex with the target nucleic acid with a higher Tm than a duplex formed with a nucleic acid containing the mismatched base, compared to a reference single-stranded nucleic acid in which the universal base has been substituted to generate a single mismatched base.

[0519] Non-limiting examples of general binding nucleotides include, but are not limited to, inosine, 1-β-D-furanosyl-5-nitroindole and / or 1-β-D-furanosyl-3-nitropyrrole (see, U.S. Patent Application Publication No. 2007 / 0254362; Van Aerschot et al. (1995) NUCLEIC ACIDS RES. 23:4363-4370; Loakes et al. (1995) Nucleic Acids Res. 23:2361-66; and Loakes and Brown (1994) Nucleic Acids Res. 22:4039-43).

[0520] e. Reversible modification

[0521] While certain modifications can be made to protect oligonucleotides from the effects of the in vivo environment before they reach target cells, these modifications may reduce their potency or activity once they reach the cytosol of the target cells. Reversible modifications can be made, allowing the molecule to retain the desired properties outside the cell and then be removed upon entering the cytoplasmic environment of the cell. For example, reversible modifications can be removed by the action of intracellular enzymes or by intracellular chemical conditions (e.g., by the reduction of intracellular glutathione).

[0522] In some embodiments, the reversibly modified nucleotides contain a glutathione-sensitive moiety. Typically, nucleic acid molecules are chemically modified with a cyclic disulfide moiety to mask the negative charge generated by the internucleotide diphosphate bond and improve cellular uptake and nuclease resistance. See U.S. Patent Application Publication No. 2011 / 0294869, International Patent Application Publications Nos. WO 2014 / 088920 and WO 2015 / 188197, and Meade et al., (2014) NAT. BIOTECHNOL. 32:1256-63. This reversible modification of the internucleotide diphosphate bond is designed to cleave within the cell via a reducing environment in the cytosol (e.g., glutathione). Earlier examples include neutralizing phosphotriester modifications that have been reported to cleave within the cell (see Dellinger et al., (2003) J. AM. CHEM. SOC. 125:940-50).

[0523] In some embodiments, such reversible modification allows for protection during in vivo administration (e.g., via lysosomal / endosome compartment transport in blood and / or cells), where the oligonucleotide will be exposed to nucleases and other harsh environmental conditions (e.g., pH). This modification is reversed when released into the cytosol of cells where glutathione levels are higher than the extracellular space, resulting in the cleaved oligonucleotide. Using a reversible glutathione-sensitive moiety may allow for the introduction of larger chemical groups into the oligonucleotide of interest, compared to available options using irreversible chemical modifications. This is because these larger chemical groups will be removed in the cytosol and therefore will not interfere with the biological activity of the oligonucleotide within the cellular cytosol. Therefore, these larger chemical groups can be engineered to confer various advantages on the nucleotide or oligonucleotide, such as nuclease resistance, lipophilicity, charge, thermal stability, specificity, and reduced immunogenicity. In some embodiments, the structure of the glutathione-sensitive moiety can be engineered to alter its release kinetics.

[0524] In some embodiments, the glutathione-sensitive moiety is attached to the sugar of the nucleotide. In some embodiments, the glutathione-sensitive moiety is attached to the 2'-carbon of the sugar of the modified nucleotide. In some embodiments, the glutathione-sensitive moiety is located at the 5'-carbon of the sugar, particularly when the modified nucleotide is the 5'-terminal nucleotide of an oligonucleotide. In some embodiments, the glutathione-sensitive moiety is located at the 3'-carbon of the sugar, particularly when the modified nucleotide is the 3'-terminal nucleotide of an oligonucleotide. In some embodiments, the glutathione-sensitive moiety comprises a sulfonyl group. See, for example, U.S. Provisional Patent Application No. 62 / 378,635, filed August 23, 2016, entitled Compositions Comprising Reversibly Modified Oligonucleotides and Uses Thereof.

[0525] Oligonucleotide inhibitors of STAT3

[0526] In some aspects, this disclosure particularly provides oligonucleotides that reduce or inhibit STAT3 expression. In some embodiments, the oligonucleotides that inhibit STAT3 expression herein target STAT3 mRNA. The sequence of human STAT3 mRNA (NM_001369512.1) is shown in SEQ ID NO:85 or NM_139276.3 (SEQ ID NO:1217). STAT3 is a known target of conventional cancer therapies.

[0527] Tolerogenic activity of MDSCs is controlled by the oncogenic transcription factor STAT3 (Su et al., INT J. MOL SCI (2018) 19(6):1803). STAT3 is also known to be highly expressed in a range of cancer types and in in vitro and in vivo preclinical models (Huynh et al., NAT. REV. CANCER (2019) 19:82-96). Inhibition of STAT3 leads to selective apoptosis and tumor growth inhibition of tumor cells through regulation of downstream target genes (Wang et al., INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 15(3):668–79 (2019)). STAT3 has received particular attention in immuno-oncology due to its well-established contribution to the immunosuppressive tumor microenvironment. STAT3 contributes to the immunosuppressive tumor microenvironment by upregulating the expression of inhibitory receptors expressed by T cells and by increasing IFNγ secretion through the expression of its ligands (PD-1 / PD-L1) (Bu et al., JOURNAL OF DENTAL RESEARCH, 96(9):1027–34(2017)). It has long been known that inhibition of STAT3 signaling in antigen-presenting cells (APCs) leads to antigen-specific CD4+ T cells responding to other tolerogenic stimuli (Cheng et al., IMMUNITY, 19:425–36(2003)). In addition, phosphorylated STAT3 on MDSCs directly contributes to the regulation of the immunosuppressive tumor microenvironment by regulating inhibitory components such as the amino acid arginine through transcriptional control (Vasques-Dunndel et al., J.CLIN. INVEST., 15(3):668–79(2013)). Over the years, several approaches have been explored to therapeutically target STAT3. While direct protein targeting is attractive, the real target is protein-protein interaction, which has been considered a prime example of an "undrugable" target due to historical data showing that many compounds have failed to effectively inhibit its activity (Lau et al., CANCERS (2019) 11(11):1681, Zou et al., MOL CANCER (2020) 19:145). In addition, the widespread expression of STAT3 in several tissues has raised concerns about serious on-target toxicity (Wong et al., EXPERT OPINION ONINVESTIGATIONAL DRUGS, 26(8):883-87 (2017), Kortylewski et al., CANCER IMMUNOLIMMUNOTHER (2017) 66(8):979-88).

[0528] STAT3 target sequence

[0529] In some embodiments, the oligonucleotide targets a target sequence containing STAT3 mRNA. In some embodiments, the oligonucleotide, or a portion, fragment, or strand thereof (e.g., the antisense strand or guide strand of dsRNA), binds to or anneals to a target sequence containing STAT3 mRNA, thereby inhibiting STAT3 expression. In some embodiments, the oligonucleotide targets a STAT3 target sequence for the purpose of inhibiting STAT3 expression in vivo. In some embodiments, the amount or extent to which the oligonucleotide targeting the STAT3 target sequence inhibits STAT3 expression is related to the potency of the oligonucleotide. In some embodiments, the amount or extent to which the oligonucleotide targeting the STAT3 target sequence inhibits STAT3 expression is related to the amount or extent of treatment benefit in a subject or patient suffering from a disease, condition, or status associated with STAT3 expression treated with the oligonucleotide.

[0530] By examining the nucleotide sequences of mRNA encoding STAT3, including those of mRNAs from multiple different species (e.g., humans, cynomolgus monkeys, mice, and rats; see, for example, Example 11), and as a result of in vitro and in vivo assays (see, for example, Examples 12 and 13), certain nucleotide sequences of STAT3 mRNA have been found to be more susceptible to oligonucleotide-based repression than other sequences, and therefore can be used as target sequences for the oligonucleotides described herein. In some embodiments, the sense strand of the oligonucleotide (e.g., dsRNA) described herein contains the STAT3 target sequence. In some embodiments, a portion or region of the sense strand of the dsRNA described herein contains the STAT3 target sequence. In some embodiments, the STAT3 mRNA target sequence contains, or is composed of, the sequence of SEQ ID NO:85. In some embodiments, the STAT3 mRNA target sequence contains, or is composed of, the sequence of SEQ ID NO:1217. In some embodiments, the STAT3 mRNA target sequence comprises, or consists of, any one of the sequences in SEQ ID NO: 89-280. In some embodiments, the STAT3 mRNA target sequence comprises, or consists of, the sequence in SEQ ID NO: 108. In some embodiments, the STAT3 mRNA target sequence comprises, or consists of, the sequence in SEQ ID NO: 140. In some embodiments, the STAT3 mRNA target sequence comprises, or consists of, the sequence in SEQ ID NO: 141. In some embodiments, the STAT3 mRNA target sequence comprises, or consists of, the sequence in SEQ ID NO: 147.

[0531] STAT3 target sequence

[0532] In some embodiments, the oligonucleotides described herein have a complementary region that is complementary to STAT3 mRNA (e.g., within the target sequence of STAT3 mRNA) for the purpose of targeting mRNA in cells and reducing or inhibiting its expression. In some embodiments, the oligonucleotides described herein contain a STAT3 target sequence (e.g., the antisense strand or guide strand of dsRNA) having a complementary region that binds to or anneals to the STAT3 target sequence via complementary (Watson-Crick) base pairing. The target sequence or complementary region typically has an appropriate length and base content such that the oligonucleotide (or a strand thereof) can bind to or anneal to STAT3 mRNA, thereby inhibiting its expression. In some embodiments, the length of the target sequence or complementary region is at least about 12, at least about 13, at least about 14, at least about 15, at least about 16, at least about 17, at least about 18, at least about 19, at least about 20, at least about 21, at least about 22, at least about 23, at least about 24, at least about 25, at least about 26, at least about 27, at least about 28, at least about 29, or at least about 30 nucleotides. In some embodiments, the length of the target sequence or complementary region is about 12 to about 30 (e.g., 12 to 30, 12 to 22, 15 to 25, 17 to 21, 18 to 27, 19 to 27, or 15 to 30) nucleotides. In some embodiments, the length of the target sequence or complementary region is about 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides. In some embodiments, the target sequence or complementary region is 18 nucleotides long. In some embodiments, the target sequence or complementary region is 19 nucleotides long. In some embodiments, the target sequence or complementary region is 20 nucleotides long. In some embodiments, the target sequence or complementary region is 21 nucleotides long. In some embodiments, the target sequence or complementary region is 22 nucleotides long. In some embodiments, the target sequence or complementary region is 23 nucleotides long. In some embodiments, the target sequence or complementary region is 24 nucleotides long. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to the sequence of any one of SEQ ID NO:89-280, and the target sequence or complementary region is 18 nucleotides long. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to the sequence of any one of SEQ ID NO:89-280, and the target sequence or complementary region is 19 nucleotides long. In some embodiments, the oligonucleotide includes a target sequence or complementary region that is complementary to the sequence of any one of SEQ ID NO:473-664, and the target sequence or complementary region is 20 nucleotides in length.In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to the sequence of any one of SEQ ID NO:473-664, and the target sequence or complementary region is 21 nucleotides in length. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to the sequence of any one of SEQ ID NO:473-664, and the target sequence or complementary region is 22 nucleotides in length. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to the sequence of any one of SEQ ID NO:473-664, and the target sequence or complementary region is 23 nucleotides in length. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to the sequence of any one of SEQ ID NO:473-664, and the target sequence or complementary region is 24 nucleotides in length.

[0533] In some embodiments, the oligonucleotides herein comprise a target sequence or complementary region that is completely complementary to the STAT3 target sequence (e.g., the antisense strand or guide strand of a double-stranded oligonucleotide). In some embodiments, the target sequence or complementary region is partially complementary to the STAT3 target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region that is completely complementary to STAT3 or a sequence of STAT3. In some embodiments, the oligonucleotide comprises a target sequence or complementary region that is partially complementary to STAT3 or a sequence of STAT3.

[0534] In some embodiments, the oligonucleotide comprises a target sequence or complementary region that is completely complementary to the sequence of any one of SEQ ID NO: 89-280. In some embodiments, the oligonucleotide comprises a target sequence or complementary region that is completely complementary to the sequence shown in SEQ ID NO: 108, 140, 141, and 147. In some embodiments, the oligonucleotide comprises a target sequence or complementary region that is partially complementary to the sequence of any one of SEQ ID NO: 89-280. In some embodiments, the oligonucleotide comprises a target sequence or complementary region that is partially complementary to the sequence shown in SEQ ID NO: 108, 140, 141, and 147.

[0535] In some embodiments, the oligonucleotide herein comprises a target sequence or complementary region complementary to a continuous nucleotide sequence containing STAT3 mRNA, wherein the length of said continuous nucleotide sequence is about 12 to about 30 nucleotides (e.g., 12 to 30, 12 to 28, 12 to 26, 12 to 24, 12 to 20, 12 to 18, 12 to 16, 14 to 22, 16 to 20, 18 to 20, or 18 to 19 nucleotides). In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a continuous nucleotide sequence containing STAT3 mRNA, wherein the length of said continuous nucleotide sequence is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a continuous nucleotide sequence containing STAT3 mRNA, wherein said continuous nucleotide sequence is 19 nucleotides long.

[0536] In some embodiments, the oligonucleotides herein (e.g., RNAi oligonucleotides) comprise a target sequence or complementary region complementary to a sequential nucleotide sequence of any one of SEQ ID NO: 89-280, optionally wherein the sequential nucleotide sequence is 19 nucleotides in length. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequential nucleotide sequence of any one of SEQ ID NO: 108, 140, 141, and 147, wherein the sequential nucleotide sequence is 19 nucleotides in length. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequential nucleotide sequence of any one of SEQ ID NO: 473-664, wherein the sequential nucleotide sequence is 20 nucleotides in length. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequential nucleotide sequence of any one of SEQ ID NO: 492, 524, 525, and 531, wherein the sequential nucleotide sequence is 20 nucleotides in length.

[0537] In some embodiments, the target sequence or complementary region of the oligonucleotide complementary to a consecutive nucleotide sequence of STAT3 or a STAT3 target sequence spans the entire length of the antisense strand. In some embodiments, the complementary region of the oligonucleotide complementary to a consecutive nucleotide sequence of STAT3 or a STAT3 target sequence spans a portion of the entire length of the antisense strand. In some embodiments, the oligonucleotide herein includes a complementary region (e.g., on the antisense strand of dsRNA) that is at least partially (e.g., completely) complementary to a consecutive nucleotide segment of nucleotides 1-20 spanning the target sequence of STAT3 or STAT3.

[0538] In some embodiments, the target sequence or complementary region of the oligonucleotide described herein (e.g., RNAi oligonucleotide) is complementary to a consecutive nucleotide sequence of any one of SEQ ID NO:89-280 and spans the entire length of the antisense strand. In some embodiments, the target sequence or complementary region of the oligonucleotide is complementary to a consecutive nucleotide sequence of SEQ ID NO:89-280 and spans a portion of the entire length of the antisense strand. In some embodiments, the oligonucleotide described herein (e.g., RNAi oligonucleotide) includes a complementary region (e.g., on the antisense strand of dsRNA) that is at least partially (e.g., completely) complementary to a consecutive nucleotide segment of nucleotides 1-19 or 1-20 spanning the sequence shown in any one of SEQ ID NO:473-664.

[0539] In some embodiments, the oligonucleotides herein comprise a target sequence or complementary region having one or more bp mismatches with the corresponding STAT3 target sequence. In some embodiments, the target sequence or complementary region may have up to about one, up to about two, up to about three, up to about four, up to about five mismatches with the corresponding STAT3 target sequence, provided that the ability of the target sequence or complementary region to bind or anneal to STAT3 mRNA under appropriate hybridization conditions and / or the ability of the oligonucleotide to inhibit STAT3 expression is maintained. Alternatively, the target sequence or complementary region may have no more than one, no more than two, no more than three, no more than four, or no more than five mismatches with the corresponding STAT3 target sequence, provided that the ability of the target sequence or complementary region to bind or anneal to STAT3 mRNA under appropriate hybridization conditions and / or the ability of the oligonucleotide to inhibit STAT3 expression is maintained. In some embodiments, the oligonucleotide comprises a target sequence or complementary region having one mismatch with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region having two mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region having three mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region having four mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region having five mismatches with the corresponding target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region having more than one mismatch (e.g., 2, 3, 4, 5, or more mismatches) with the corresponding target sequence, wherein at least two (e.g., all) mismatches are sequentially located (e.g., consecutive 2, 3, 4, 5, or more mismatches), or wherein the mismatches are scattered throughout the target sequence or complementary region. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a sequential nucleotide sequence of any one of SEQ ID NO:89-280, wherein the target sequence or complementary region may have up to about 1, up to about 2, up to about 3, up to about 4, up to about 5 mismatches with the corresponding STAT3 target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a consecutive nucleotide sequence of any one of SEQ ID NO:89-280, wherein the target sequence or complementary region may have no more than 1, 2, 3, 4, or 5 mismatches with the corresponding STAT3 target sequence. In some embodiments, the oligonucleotide comprises a target sequence or complementary region complementary to a consecutive nucleotide sequence of any one of SEQ ID NO:108, 140, 141, and 147, wherein the target sequence or complementary region may have up to about 1, 2, 3, 4, or 5 mismatches with the corresponding STAT3 target sequence.In some embodiments, the oligonucleotide includes a target sequence or complementary region that is complementary to a consecutive nucleotide sequence of any one of SEQ ID NO: 108, 140, 141 and 147, wherein the target sequence or complementary region may have no more than 1, no more than 2, no more than 3, no more than 4 or no more than 5 mismatches with the corresponding STAT3 target sequence.

[0540] Targeted ligands

[0541] In some embodiments, it is desirable to target the STAT3-targeting oligonucleotides of this disclosure to one or more cells or organs. Such a strategy can help avoid adverse effects in other organs or prevent excessive loss of the oligonucleotide to cells, tissues, or organs from which it would not benefit. Targeting oligonucleotides to one or more cells or organs can be achieved through a variety of methods. Conjugation of oligonucleotides to tissue- or cell-specific antibodies, small molecules, or targeting ligands can facilitate delivery of the oligonucleotide to one or more target cells or tissues and alter the accumulation of the oligonucleotide in one or more target cells or tissues (Chernolovskaya et al., (2019) FRONT PHARMACOL. 10:444). For example, conjugation of oligonucleotides to saturated fatty acids (e.g., C22) can facilitate delivery to cells or tissues such as adipose tissue or immune cells, as such ligands are more readily taken up than conventional oligonucleotide ligands. Therefore, in some embodiments, the oligonucleotides disclosed herein are modified to facilitate targeting and / or delivery to tissues, cells, or organs (e.g., facilitating delivery of the oligonucleotide to the liver). In some embodiments, the oligonucleotides disclosed herein are modified to facilitate delivery of the oligonucleotide to cells of the immune system. In some embodiments, the oligonucleotides disclosed herein are modified to facilitate delivery of the oligonucleotide to myeloid-derived suppressor cells. In some embodiments, the oligonucleotide comprises at least one nucleotide (e.g., 1, 2, 3, 4, 5, 6 or more nucleotides) conjugated to one or more target ligands.

[0542] In some embodiments, the targeting ligand comprises a carbohydrate, amino sugar, cholesterol, peptide, polypeptide, protein, or a portion of a protein (e.g., an antibody or antibody fragment), or lipid. In some embodiments, the targeting ligand is an aptamer. For example, the targeting ligand may be an RGD peptide for targeting the tumor vascular system or glioma cells, a CREKA peptide for targeting the tumor vascular system or stoma, transferrin, lactoferrin, or an aptamer for targeting the transferrin receptor expressed on the CNS vascular system, or an anti-EGFR antibody for targeting EGFR on glioma cells. In some embodiments, the targeting ligand is one or more GalNAc portions.

[0543] In some embodiments, one or more (e.g., 1, 2, 3, 4, 5, or 6) nucleotides of the oligonucleotide are each conjugated to a separate target ligand. In some embodiments, 2 to 4 nucleotides of the oligonucleotide are each conjugated to a separate target ligand. In some embodiments, the target ligand is conjugated to 2 to 4 nucleotides at either end of the sense or antisense strand (e.g., the target ligand is conjugated to a bulge or extension of 2 to 4 nucleotides at the 5' or 3' end of the sense or antisense strand), such that the target ligand is analogous to the bristles of a toothbrush, and the oligonucleotide is analogous to the toothbrush. For example, the oligonucleotide may include a stem-loop at the 5' or 3' end of the sense strand, and 1, 2, 3, or 4 nucleotides of the loop may be conjugated to the target ligand individually. In some embodiments, the oligonucleotides (e.g., dsRNA) provided in this disclosure include a stem-loop at the 3' end of the sense strand, wherein the loop of the stem-loop comprises a tricyclic or tetracyclic ring, and wherein the three or four nucleotides constituting the tricyclic or tetracyclic ring are individually conjugated to a target ligand. In some embodiments, the oligonucleotides (e.g., RNAi oligonucleotides) provided in this disclosure include a stem-loop at the 3' end of the sense strand, wherein the loop of the stem-loop comprises a tetracyclic ring, and wherein the three nucleotides of the tetracyclic ring are individually conjugated to a target ligand.

[0544] GalNAc is a high-affinity ligand for ASGPR, which is primarily expressed on the sinusoidal surface of hepatocytes and plays a major role in the binding, internalization, and subsequent clearance of circulating glycoproteins (desialidinic glycoproteins) containing terminal galactose or GalNAc residues. Conjugation (indirectly or directly) of the GalNAc moiety to the oligonucleotides of this disclosure can be used to target these oligonucleotides to ASGPR expressed on cells. In some embodiments, the oligonucleotides of this disclosure are conjugated to at least one or more GalNAc moieties, wherein the GalNAc moieties target the oligonucleotide to ASGPR expressed on human liver cells (e.g., human hepatocytes). In some embodiments, the GalNAc moieties target the oligonucleotide to the liver.

[0545] In some embodiments, the oligonucleotide of this disclosure is conjugated directly or indirectly to a monovalent GalNAc. In some embodiments, the oligonucleotide is conjugated directly or indirectly to more than one monovalent GalNAc (i.e., conjugated to 2, 3, or 4 monovalent GalNAc portions, and typically to 3 or 4 monovalent GalNAc portions). In some embodiments, the oligonucleotide is conjugated to one or more divalent, trivalent, or tetravalent GalNAc portions.

[0546] In some embodiments, one or more (e.g., 1, 2, 3, 4, 5, or 6) nucleotides of the oligonucleotide are each conjugated to a GalNAc moiety. In some embodiments, 2 to 4 nucleotides of the tetracyclic ring are each conjugated to a single GalNAc. In some embodiments, 1 to 3 nucleotides of the tricyclic ring are each conjugated to a single GalNAc. In some embodiments, the targeting ligand is conjugated to 2 to 4 nucleotides at either end of the sense or antisense strand (e.g., the ligand is conjugated to a 2 to 4 nucleotide overhang or extension at the 5' or 3' end of the sense or antisense strand), such that the GalNAc moiety resembles the bristles of a toothbrush, and the oligonucleotide resembles the toothbrush. In some embodiments, the GalNAc moiety is conjugated to a nucleotide of the sense strand. For example, four GalNAc moieties may be conjugated to nucleotides in the tetracyclic ring of the sense strand, with each GalNAc moiety conjugated to one nucleotide.

[0547] In some embodiments, the tetracycle is any combination of adenine and guanine nucleotides.

[0548] In some embodiments, the tetracycle (tetraL) has a monovalent GalNAc moiety attached to any one or more guanine nucleotides of the tetracycle via any linker described herein, as shown in the following chemical formula 2 (X = heteroatom):

[0549]

[0550] In some embodiments, the tetracycle (tetraL) has a monovalent GalNAc attached to any one or more adenine nucleotides of the tetracycle via any linker described herein, as in the following chemical formula.

[0551] As shown in Equation 3 (X = heteroatom):

[0552]

[0553] In some embodiments, the oligonucleotides described herein comprise a monovalent GalNAc attached to a guanine nucleotide, referred to as [ademG-GalNAc] or 2'-aminodiethoxymethanol-guanine-GalNAc, as shown in the following chemical formula 4:

[0554]

[0555] In some embodiments, the oligonucleotides described herein comprise a monovalent GalNAc attached to an adenine nucleotide, referred to as [ademA-GalNAc] or 2'-aminodiethoxymethanol-adenine-GalNAc, as shown in the following chemical formula 5:

[0556]

[0557] Below is an example of such conjugation (Formula 6) (L = linker, X = heteroatom) for a ring containing the nucleotide sequence GAAA from 5' to 3', showing the stem junction. For example, such a ring can exist at positions 27-30 of the sense strand as shown in Figure 1. In the chemical formula, Used to describe the linking point (chemical formula 6) to the oligonucleotide chain.

[0558]

[0559] Targeting ligands can be linked to nucleotides using appropriate methods or chemistry (e.g., click chemistry). In some embodiments, click linkers are used to conjugate the targeting ligand to a nucleotide. In some embodiments, acetal-based linkers are used to conjugate the targeting ligand to a nucleotide of any of the oligonucleotides described herein. Acetal-based linkers are disclosed, for example, in International Patent Application Publication No. WO 2016 / 100401. In some embodiments, the linker is an unstable linker. However, in other embodiments, the linker is stable. An example of a ring from 5' to 3' containing the nucleotide GAAA is shown below, wherein the GalNAc moiety is attached to the nucleotide of the ring (Formulas 7 and 8) using an acetal linker. For example, such a ring can exist at positions 27-30 of either sense strand as shown in Figure 1. In the chemical formula, It is the linker point that connects to the oligonucleotide chain (Chemical Formula 7 and Chemical Formula 8).

[0560] Formula 8).

[0561]

[0562]

[0563] As mentioned, various suitable methods or chemical synthesis techniques (e.g., click chemistry) can be used to link the target ligand to a nucleotide. In some embodiments, a click linker is used to conjugate the target ligand to a nucleotide. In some embodiments, an acetal-based linker is used to conjugate the target ligand to a nucleotide of any of the oligonucleotides described herein. An acetal-based linker is disclosed, for example, in International Patent Application Publication No. WO 2016 / 100401. In some embodiments, the linker is an unstable linker. However, in other embodiments, the linker is a stable linker.

[0564] In some embodiments, a double-stranded extension (e.g., up to 3, 4, 5, or 6 bp in length) is provided between the targeting ligand (e.g., the GalNAc moiety) and the dsRNA. In some embodiments, the oligonucleotides herein do not have a GalNAc conjugated thereto.

[0565] Structure of conjugated STAT3-targeting oligonucleotides

[0566] In some embodiments, the STAT3-targeting oligonucleotides described herein comprise a nucleotide sequence having a complementary region complementary to the STAT3 mRNA target sequence and one or more targeting ligands, wherein the nucleotide sequence comprises one or more nucleosides (nucleic acids) conjugated to one or more targeting ligands, represented by Formula Ia:

[0567]

[0568] Or its pharmaceutically acceptable salt.

[0569] in:

[0570] B is a nucleobase or hydrogen;

[0571] R 1 and R 2 Independently hydrogen, halogen, R A -CN, -S(O)R, -S(O)2R, -Si(OR)2R, -Si(OR)R2 or -SiR3; or

[0572] R on the same carbon 1 and R 2 Together with their intermediary atoms, they form 3-7 member saturated or partially unsaturated rings with 0-3 independent heteroatoms selected from nitrogen, oxygen and sulfur;

[0573] Each R A Independently, the optionally substituted group is selected from C. 1-6 Aliphatic group, phenyl, 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0574] Each R is independently hydrogen, a suitable protecting group, or an optionally substituted group, the optionally substituted group being selected from C. 1-6 Aliphatic group, phenyl, having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, comprising a 4-7 membered saturated or partially unsaturated heterocycle, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; or

[0575] Two R groups on the same atom, together with their intervening atoms, form a 4-7 member saturated, partially unsaturated or heteroaryl ring having 0-3 independent heteroatoms selected from nitrogen, oxygen, silicon and sulfur.

[0576] Each targeting ligand is selected from lipid conjugate moieties (LCs), carbohydrates, amino sugars, or GalNAc; and each LC is independently composed of saturated or unsaturated straight-chain or branched C. 1-50 The lipid conjugate portion of a hydrocarbon chain, wherein 0-10 methylene units of the hydrocarbon chain are independently replaced by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, -P(S)OR-;

[0577] Each -Cy- is independently a optionally substituted divalent ring selected from phenylene, 8-10 membered bicyclic arylene, 4-7 membered saturated or partially unsaturated carbocyclic, 4-11 membered saturated or partially unsaturated spirocyclic, 8-10 membered bicyclic saturated or partially unsaturated carbocyclic, 4-7 membered saturated or partially unsaturated heterocyclic with 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 4-11 membered saturated or partially unsaturated spirocyclic with 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 8-10 membered bicyclic saturated or partially unsaturated heterocyclic with 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5-6 membered heterocyclic with 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 8-10 membered bicyclic with 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0578] Cyclohexaaryl;

[0579] n is 1-10;

[0580] L represents a covalent bond or a divalent saturated or unsaturated straight chain or branched chain. 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently converted by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O-, -S(O)2-, -P(O)OR-, -P(S)OR-, -V 1 CR 2 W 1 -or replace;

[0581] m is 1-50;

[0582] X 1 V 1 and W 1 Independently -C(R)2-, -OR, -O-, -S-, -Se-, or -NR-;

[0583] Y represents hydrogen, a suitable hydroxyl protecting group,

[0584] R 3The group may be hydrogen, a suitable protecting group, a suitable prodrug, or an optionally substituted group, wherein the optionally substituted group is selected from C. 1-6 Aliphatic group, phenyl, 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur;

[0585] X 2 For O, S, or NR;

[0586] X 3 It can be -O-, -S-, -BH2- or covalent;

[0587] Y 1 A linker group attached to the 2' or 3' end of a nucleoside, nucleotide, or oligonucleotide;

[0588] Y 2 Hydrogen, a suitable protecting group, a phosphoramide analog, an internucleotide linker attached to the 5'-terminus of a nucleoside, nucleotide, or oligonucleotide, or a linker attached to a solid support; and

[0589] Z can be -O-, -S-, -NR-, or -CR2-.

[0590] In some embodiments, the STAT3-targeting oligonucleotide comprises one or more nucleic acids conjugated to a targeting ligand, represented by formula II-a:

[0591]

[0592] Or its pharmaceutically acceptable salt.

[0593] In some embodiments, the STAT3-targeting oligonucleotide comprises one or more nucleic acids conjugated to a targeting ligand, represented by formula II-b or II-c:

[0594]

[0595] Or its pharmaceutically acceptable salt, wherein:

[0596] L 1 C is a straight or branched chain that is covalent, monovalent, divalent, saturated, or unsaturated. 1-50 A hydrocarbon chain wherein 0-10 methylene units of the hydrocarbon chain are independently converted by -Cy-, -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O-, -S(O)2-, -P(O)OR-, -P(S)OR- or replace;

[0597] R 4 For hydrogen, RA Or a suitable amine protecting group; and

[0598] R 5 It is an adamantyl group, or a saturated or unsaturated straight-chain or branched C group. 1-50 A hydrocarbon chain in which 0-10 methylene units are independently replaced by -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR- or -P(S)OR.

[0599] In some implementation schemes, R 5 Selected from

[0600]

[0601] In some implementation schemes, R 5 Selected from:

[0602] In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementation schemes, R 5 for In some implementations, R 5 for

[0603] In some embodiments, the STAT3-targeting oligonucleotide comprises one or more nucleic acids conjugated to a targeting ligand, represented by formula II-Ib or II-Ic:

[0604]

[0605]

[0606] Or its pharmaceutically acceptable salt; wherein

[0607] B is a nucleobase or hydrogen;

[0608] m is 1-50;

[0609] X 1 It can be -O- or -S-;

[0610] Y represents hydrogen. R 3 Hydrogen or a suitable protecting group;

[0611] X 2 For O or S;

[0612] X 3 It can be -O-, -S-, or covalent;

[0613] Y 1 A linker group attached to the 2' or 3' end of a nucleoside, nucleotide, or oligonucleotide;

[0614] Y 2 It is a hydrogen, phosphoramide analogue, an internucleotide linker attached to the 5'-terminus of a nucleoside, nucleotide or oligonucleotide, or a linker attached to a solid support.

[0615] R 5 It is an adamantyl group, or a saturated or unsaturated straight-chain or branched C group. 1-50 A hydrocarbon chain wherein 0-10 methylene units are independently replaced by -O-, -C(O)NR-, -NR-, -S-, -C(O)-, -C(O)O-, -S(O)-, -S(O)2-, -P(O)OR-, or -P(S)OR-; and

[0616] R is hydrogen, a suitable protecting group, or an optionally substituted group, wherein the optionally substituted group is selected from C. 1-6 Aliphatic group, phenyl, 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.

[0617] In some implementation schemes, R 5 Selected from

[0618]

[0619] In some implementation schemes, R 5 for

[0620]

[0621] In some implementation schemes, R 5 for

[0622] In some embodiments, the nucleotide sequence of the STAT3-targeting oligonucleotide contains 1-10 targeting ligands. In some embodiments, the nucleotide sequence contains 1, 2, or 3 targeting ligands.

[0623] In some embodiments, the STAT3-targeting oligonucleotide is a double-stranded molecule. In some embodiments, the STAT3-targeting oligonucleotide is an RNAi molecule. In some embodiments, the STAT3-targeting double-stranded oligonucleotide includes a stem-loop. In some embodiments, the ligand is conjugated to any nucleotide in the stem-loop. In some embodiments, the ligand is conjugated to a first nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to a second nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to a third nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to a fourth nucleotide from 5' to 3' in the stem-loop. In some embodiments, the ligand is conjugated to one, two, three, or four nucleotides in the stem-loop. In some embodiments, the ligand is conjugated to three nucleotides in the stem-loop.

[0624] In some embodiments, the STAT3-targeting double-stranded oligonucleotide includes a stem loop, wherein one or more lipids are conjugated to one or more nucleotides of the stem loop. In some embodiments, the STAT3-targeting double-stranded oligonucleotide includes a stem loop, wherein one or more C16 lipids are conjugated to one or more nucleotides of the stem loop. In some embodiments, the STAT3-targeting double-stranded oligonucleotide includes a stem loop, wherein one or more C18 lipids are conjugated to one or more nucleotides of the stem loop.

[0625] In some embodiments, the STAT3-targeting oligonucleotide comprises a 36-nucleotide sense chain, with positions numbered 1-36 from 5' to 3'. In some embodiments, the STAT3-targeting oligonucleotide comprises a lipid conjugated to position 27 of the 36-nucleotide sense chain. In some embodiments, the STAT3-targeting oligonucleotide comprises a lipid conjugated to position 28 of the 36-nucleotide sense chain. In some embodiments, the STAT3-targeting oligonucleotide comprises a lipid conjugated to position 29 of the 36-nucleotide sense chain. In some embodiments, the STAT3-targeting oligonucleotide comprises a lipid conjugated to position 30 of the 36-nucleotide sense chain. In some embodiments, the 36-nucleotide sense chain forms a stem-loop with loops at positions 27-30. In some embodiments, the lipid conjugates to more than one position of the loop (e.g., positions 27 and 28 of the 36-nucleotide sense chain).

[0626] In some embodiments, the STAT3-targeting oligonucleotide comprises a C16 lipid conjugated to position 27 of the sense strand of the 36 nucleotides. In some embodiments, the STAT3-targeting oligonucleotide comprises a C16 lipid conjugated to position 28 of the sense strand of the 36 nucleotides. In some embodiments, the STAT3-targeting oligonucleotide comprises a C16 lipid conjugated to position 29 of the sense strand of the 36 nucleotides. In some embodiments, the STAT3-targeting oligonucleotide comprises a C16 lipid conjugated to position 30 of the sense strand of the 36 nucleotides. In some embodiments, the 36 nucleotides of the sense strand form a stem-loop with loops at positions 27-30. In some embodiments, the C16 lipid conjugates to more than one position of the loop (e.g., positions 27 and 28 of the sense strand of the 36 nucleotides).

[0627] In some embodiments, the STAT3-targeting oligonucleotide comprises a C18 lipid conjugated to position 27 of the sense strand of the 36 nucleotides. In some embodiments, the STAT3-targeting oligonucleotide comprises a C18 lipid conjugated to position 28 of the sense strand of the 36 nucleotides. In some embodiments, the STAT3-targeting oligonucleotide comprises a C18 lipid conjugated to position 29 of the sense strand of the 36 nucleotides. In some embodiments, the STAT3-targeting oligonucleotide comprises a C18 lipid conjugated to position 30 of the sense strand of the 36 nucleotides. In some embodiments, the 36 nucleotides of the sense strand form a stem-loop with loops at positions 27-30. In some embodiments, the C18 lipid conjugates to more than one position of the loop (e.g., positions 27 and 28 of the sense strand of the 36 nucleotides).

[0628] In some embodiments, the STAT3-targeting oligonucleotide comprises an antisense strand of 15 to 30 nucleotides and a sense strand of 15 to 40 nucleotides, wherein the sense strand and the antisense strand form a double-stranded region, wherein the antisense strand contains a complementary region complementary to the STAT3 mRNA target sequence expressed in tumor microenvironment-associated immune cells, and wherein the sense strand comprises a stem-loop at its 3' end, the stem-loop comprising a tetracycle containing four nucleotides, wherein one or more of the four nucleotides are represented by formula II-Ib:

[0629]

[0630] Where B is selected from adenine and guanine nucleobases, and where R... 5 It is a hydrocarbon chain. In some embodiments, m is 1, X1 is O, Y2 is an internucleotide linker attached to the 5' end of the nucleoside, and Y is composed of... This indicates that Y1 is a linker group attached to the 2' or 3' end of the nucleotide, X2 is O, X3 is O, and R3 is H.

[0631] In some embodiments, the hydrocarbon chain is a C8-C30 hydrocarbon chain. In some embodiments, the hydrocarbon chain is a C16 hydrocarbon chain. In some embodiments, the C16 hydrocarbon chain is composed of… This indicates that, in some embodiments, the hydrocarbon chain is a C18 hydrocarbon chain. In some embodiments, the C18 hydrocarbon chain is composed of... express.

[0632] In some embodiments, the oligonucleotide comprises a sense chain containing a sequence selected from SEQ ID NO:89-280, wherein the sense chain comprises a C18 lipid. In some embodiments, the four nucleotides of the tetracyclic ring are numbered 1-4 from 5' to 3', and position 1 is represented by formula II-Ib. In some embodiments, position 2 is represented by formula II-Ib. In some embodiments, position 3 is represented by formula II-Ib. In some embodiments, position 4 is represented by formula II-Ib. In some embodiments, the sense chain is 36 nucleotides, which are numbered 1-36 from 5' to 3', wherein the stem-loop contains nucleotides at positions 21-36, and wherein one or more nucleotides at positions 27-30 are represented by formula II-Ib. In some embodiments, the antisense chain is 22 nucleotides.

[0633] Exemplary STAT3-targeted oligonucleotides

[0634] In some embodiments, the STAT3-targeting oligonucleotide comprises a sense strand and an antisense strand as shown in Tables 3, 4, 5, 10, 11, 12, 13, and 14, wherein the oligonucleotide comprises a stem-loop structure having a double-stranded stem of about 2-6 base pairs and a loop of 3-4 nucleotides, and wherein the sense strand and antisense strand comprise the modification patterns shown in Figure 1 or Example 12. In some embodiments, the STAT3-targeting oligonucleotide comprises a sense strand and an antisense strand as shown in Tables 3, 4, 5, 10, 11, 12, 13, and 14, wherein the oligonucleotide comprises a stem-loop structure having a double-stranded stem of about 2-6 base pairs and a loop of 3-4 nucleotides, wherein the sense strand and antisense strand comprise the modification patterns shown in Figure 1, and wherein the antisense strand is modified with an oxymethylphosphonate at the 4' carbon of the 5' terminal nucleotide. In some embodiments, the oligonucleotide comprises a stem-loop comprising the nucleotide sequence of SEQ ID NO:86. In some embodiments, the oligonucleotide comprises a 6-base-pair double-stranded stem and a 4-nucleotide stem-loop, the stem-loop containing 1, 2, 3, or 4 GalNAc-conjugated nucleotides. In some embodiments, the GalNAc-conjugated nucleotide is a monovalent GalNAc conjugated to an adenine nucleotide, referred to as [ademA-GalNAc] or 2'-aminodiethoxymethanol-adenine-GalNAc, as shown below:

[0635]

[0636] In some embodiments, the stem-loop comprises a double-stranded stem of 6 base pairs and a loop containing the nucleotide sequence GAAA, wherein each adenine nucleotide is ademA-GalNAc.

[0637] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0638] (a) are SEQ ID NO:9 and 10, respectively;

[0639] (b) are SEQ ID NO:37 and 38, respectively;

[0640] (c) are SEQ ID NO: 65 and 66 respectively; and

[0641] (d) are SEQ ID NO:69 and 70, respectively.

[0642] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0643] (a) are SEQ ID NO:9 and 10, respectively;

[0644] (b) are SEQ ID NO:37 and 38, respectively;

[0645] (c) are SEQ ID NO: 65 and 66 respectively; and

[0646] (d) are SEQ ID NO:69 and 70, respectively.

[0647] The semantic and antisemantic chains are modified based on the following pattern.

[0648] There is a chain of righteousness:

[0649] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][mX][mX][mX][m X][mX][mX][mX][mX][mX][mX][mX][mX][ademX-C#][mX][mX][mX][mX][mX][mX][mX][mX]

[0650] hybridization to

[0651] Antonym chain: [MePhosphonate-4O-mXs][fXs][fX][fX][fX][mX][fX][mX][mX]

[0652] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0653] (Keywords are provided in Table 1). In some implementations, C# is C16 or C18.

[0654] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0655] (a) are SEQ ID NO: 862 and 952, respectively;

[0656] (b) are SEQ ID NO: 875 and 965, respectively;

[0657] (c) are SEQ ID NO: 876 and 966 respectively; and

[0658] (d) are SEQ ID NO:920 and 1010, respectively.

[0659] The semantic and antisemantic chains are modified based on the following pattern.

[0660] There is a chain of righteousness:

[0661] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][mX][mX][mX][m X][mX][mX][mX][mX][mX][mX][mX][mX][ademX-C#][mX][mX][mX][mX][mX][mX][mX][mX]

[0662] hybridization to

[0663] Antonym chain: [MePhosphonate-4O-mXs][fXs][fX][fX][fX][mX][fX][mX][mX]

[0664] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0665] (Keywords are provided in Table 1). In some implementations, C# is C16 or C18.

[0666] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0667] (a) are SEQ ID NO: 862 and 952, respectively;

[0668] (b) are SEQ ID NO: 875 and 965, respectively;

[0669] (c) are SEQ ID NO: 876 and 966 respectively; and

[0670] (d) are SEQ ID NO:920 and 1010, respectively.

[0671] The semantic and antisemantic chains are modified based on the following pattern.

[0672] There is a chain of righteousness:

[0673] [mXs][mX][mX][mX][mX][mX][mX][fX][fX][fX][fX][mX][mX][mX][mX][mX][mX][mX][m X][mX][mX][mX][mX][mX][mX][mX][mX][ademX-C#][mX][mX][mX][mX][mX][mX][mX][mX]

[0674] hybridization to

[0675] Antonym chain: [MePhosphonate-4O-mXs][fXs][fXs][fX][fX][mX][fX][mX][mX]

[0676] [fX][mX][mX][mX][fX][mX][mX][mX][mX][mX][mXs][mXs][mX]

[0677] (Keywords are provided in Table 1). In some implementations, C# is C16 or C18.

[0678] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0679] (a) are SEQ ID NO: 11 and 12, respectively;

[0680] (b) are SEQ ID NO:39 and 40, respectively;

[0681] (c) are SEQ ID NO: 67 and 68 respectively; and

[0682] (d) are SEQ ID NO:71 and 72, respectively.

[0683] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sequence shown in SEQ ID NO:81. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sequence shown in SEQ ID NO:82. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sequence shown in SEQ ID NO:83. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sequence shown in SEQ ID NO:84.

[0684] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand and an antisense strand having the nucleotide sequences shown in SEQ ID NO:87 and 68, respectively. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand and an antisense strand having the nucleotide sequences shown in SEQ ID NO:88 and 71, respectively.

[0685] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO: 89-280. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO: 857-946. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO: 857-888. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO: 889-912. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO: 913-934. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO: 935-946.

[0686] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:947-1036. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:947-978. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:979-1002. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1003-1024. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1025-1036.

[0687] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:857-946 and an antisense strand selected from SEQ ID NO:947-1036. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:857-888 and an antisense strand selected from SEQ ID NO:947-978. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:889-912 and an antisense strand selected from SEQ ID NO:979-1002. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:913-934 and an antisense strand selected from SEQ ID NO:1003-1024. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA comprise a sense strand sequence selected from SEQ ID NO:935-946 and an antisense strand selected from SEQ ID NO:1025-1036.

[0688] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO:1037-1126. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO:1037-1068. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO:1069-1092. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO:1093-1114. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense sequence selected from SEQ ID NO:1115-1126.

[0689] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1127-1216. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1127-1158. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1159-1182. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1183-1204. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises an antisense sequence selected from SEQ ID NO:1205-1216.

[0690] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:1037-1126 and an antisense strand selected from SEQ ID NO:1127-1216. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:1037-1068 and an antisense strand selected from SEQ ID NO:1127-1182. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:1069-1092 and an antisense strand selected from SEQ ID NO:1159-1182. In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises a sense strand sequence selected from SEQ ID NO:1093-1114 and an antisense strand selected from SEQ ID NO:1183-1204. In some embodiments, the oligonucleotides used to reduce the expression of STAT3 mRNA comprise a sense strand sequence selected from SEQ ID NO:1115-1126 and an antisense strand selected from SEQ ID NO:1205-1216.

[0691] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0692] (a) are SEQ ID NO: 857 and 947, respectively;

[0693] (b) are SEQ ID NO: 858 and 948, respectively;

[0694] (c) are SEQ ID NO: 859 and 949, respectively;

[0695] (d) are SEQ ID NO: 860 and 950, respectively;

[0696] (e) are SEQ ID NO: 862 and 952, respectively;

[0697] (f) are SEQ ID NO: 867 and 957, respectively;

[0698] (g) are SEQ ID NO: 875 and 965 respectively; and

[0699] (h) are SEQ ID NO:876 and 966, respectively.

[0700] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0701] (a) are SEQ ID NO: 901 and 991, respectively;

[0702] (b) are SEQ ID NO: 910 and 1000, respectively;

[0703] (c) are SEQ ID NO: 899 and 989, respectively;

[0704] (d) are SEQ ID NO: 896 and 986, respectively;

[0705] (e) are SEQ ID NO: 892 and 982, respectively;

[0706] (f) are SEQ ID NO: 890 and 980 respectively; and

[0707] (g) are SEQ ID NO:889 and 979, respectively.

[0708] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0709] (a) are SEQ ID NO: 940 and 1030, respectively;

[0710] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0711] (c) are SEQ ID NO:939 and 1029, respectively.

[0712] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0713] (a) are SEQ ID NO:915 and 1005, respectively;

[0714] (b) are SEQ ID NO:924 and 1014, respectively;

[0715] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0716] (d) are SEQ ID NO:920 and 1010, respectively.

[0717] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0718] (a) are SEQ ID NO: 862 and 952, respectively;

[0719] (b) are SEQ ID NO: 875 and 965, respectively;

[0720] (c) are SEQ ID NO: 876 and 966 respectively; and

[0721] (d) are SEQ ID NO:920 and 1010, respectively.

[0722] In some implementations, the sense strand contains the sequence of SEQ ID NO:862 and the antisense strand contains the sequence of SEQ ID NO:952.

[0723] In some implementations, the sense strand contains the sequence of SEQ ID NO:875 and the antisense strand contains the sequence of SEQ ID NO:965.

[0724] In some implementations, the sense strand contains the sequence of SEQ ID NO:876 and the antisense strand contains the sequence of SEQ ID NO:966.

[0725] In some implementations, the sense strand contains the sequence of SEQ ID NO:920 and the antisense strand contains the sequence of SEQ ID NO:1010.

[0726] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0727] (a) are SEQ ID NO: 1037 and 1127, respectively;

[0728] (b) are SEQ ID NO: 1038 and 1128, respectively;

[0729] (c) are SEQ ID NO: 1039 and 1129, respectively;

[0730] (d) are SEQ ID NO: 1040 and 1130, respectively;

[0731] (e) are SEQ ID NO: 1042 and 1132, respectively;

[0732] (f) are SEQ ID NO: 1047 and 1137, respectively;

[0733] (g) are SEQ ID NO: 1055 and 1145 respectively; and

[0734] (h) are SEQ ID NO:1056 and 1146, respectively.

[0735] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0736] (a) are SEQ ID NO: 1081 and 1171, respectively;

[0737] (b) are SEQ ID NO: 1090 and 1180, respectively;

[0738] (c) are SEQ ID NO: 1079 and 1169, respectively;

[0739] (d) are SEQ ID NO: 1076 and 1166, respectively;

[0740] (e) are SEQ ID NO: 1072 and 1162, respectively;

[0741] (f) are SEQ ID NO: 1070 and 1160 respectively; and

[0742] (g) are SEQ ID NO:1069 and 1159, respectively.

[0743] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0744] (a) are SEQ ID NO: 1120 and 1210, respectively;

[0745] (b) are SEQ ID NO: 1117 and 1207 respectively; and

[0746] (c) are SEQ ID NO:1119 and 1209, respectively.

[0747] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0748] (a) are SEQ ID NO: 1095 and 1185, respectively;

[0749] (b) are SEQ ID NO: 1104 and 1194, respectively;

[0750] (c) are SEQ ID NO: 1093 and 1183 respectively; and

[0751] (d) are SEQ ID NO:1100 and 1190, respectively.

[0752] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0753] (a) are SEQ ID NO: 1042 and 1132, respectively;

[0754] (b) are SEQ ID NO: 1055 and 1145, respectively;

[0755] (c) are SEQ ID NO: 1056 and 1146 respectively; and

[0756] (d) are SEQ ID NO:1100 and 1190, respectively.

[0757] In some implementations, the sense strand contains the sequence of SEQ ID NO:1042 and the antisense strand contains the sequence of SEQ ID NO:1132.

[0758] In some implementations, the sense strand contains the sequence of SEQ ID NO:1055 and the antisense strand contains the sequence of SEQ ID NO:1145.

[0759] In some implementations, the sense strand contains the sequence of SEQ ID NO:1056 and the antisense strand contains the sequence of SEQ ID NO:1146.

[0760] In some implementations, the sense strand contains the sequence of SEQ ID NO:1100 and the antisense strand contains the sequence of SEQ ID NO:1190.

[0761] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands, which contain nucleotide sequences selected from the following:

[0762] (a) are SEQ ID NO: 1042 and 1225, respectively;

[0763] (b) are SEQ ID NO: 1055 and 1226, respectively;

[0764] (c) are SEQ ID NO: 1056 and 1227 respectively; and

[0765] (d) are SEQ ID NO:1100 and 1228, respectively.

[0766] In some embodiments, the oligonucleotides described herein for reducing STAT3 mRNA expression contain minimal off-target effects. For example, in some embodiments, the oligonucleotides described herein reduce STAT3 expression without reducing STAT1 expression, or reduce STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence shown in SEQ ID NO:862, and the antisense strand comprising the nucleotide sequence shown in SEQ ID NO:952, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence shown in SEQ ID NO:1042, and the antisense strand comprising the nucleotide sequence shown in SEQ ID NO:1132, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than reducing STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence shown in SEQ ID NO:875, and the antisense strand comprising the nucleotide sequence shown in SEQ ID NO:965, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than it reduces STAT3 expression. In some embodiments, the oligonucleotide comprises a sense strand and an antisense strand, the sense strand comprising the nucleotide sequence shown in SEQ ID NO:1055, and the antisense strand comprising the nucleotide sequence shown in SEQ ID NO:1145, wherein the oligonucleotide reduces STAT3 expression without reducing STAT1 expression, or reduces STAT1 expression to a lesser extent than it reduces STAT3 expression.

[0767] In some embodiments, the oligonucleotides described herein for reducing STAT3 mRNA expression are species-cross-reactive oligonucleotides. In some embodiments, the oligonucleotides described herein are capable of reducing the expression of STAT3 mRNA in at least two different species. In some embodiments, the oligonucleotides described herein are capable of reducing the expression of STAT3 mRNA in at least two different species, but do not cross-react with non-STAT3 mRNA (e.g., STAT1). In some embodiments, the oligonucleotides described herein for reducing STAT3 mRNA expression are cross-reactive between at least two species. In some embodiments, the oligonucleotides for reducing STAT3 expression cross-react with human, non-human primate, and mouse STAT3 mRNA. In some embodiments, the oligonucleotides for reducing STAT3 mRNA expression cross-react with human and mouse STAT3 mRNA. In some embodiments, the oligonucleotides for reducing STAT3 mRNA expression cross-react with human and non-human primate STAT3 mRNA.

[0768] In some embodiments, the oligonucleotides used to reduce STAT3 mRNA expression reduce STAT3 mRNA expression by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.

[0769] In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 50% to at least 75%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 80%, at least 85%, at least 90%, or at least 95%.

[0770] In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in human and non-human primates (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 50% to at least 75%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in human and non-human primates (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in human and non-human primates (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 80%, at least 85%, at least 90%, or at least 95%.

[0771] In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in humans and mice (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 50% to at least 75%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in humans and mice (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or at least 75%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression reduces STAT3 mRNA in humans and mice (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, the oligonucleotide used to reduce STAT3 mRNA expression comprises a sense strand and an antisense strand selected from the following:

[0772] (a) are SEQ ID NO: 901 and 991, respectively;

[0773] (b) are SEQ ID NO: 910 and 1000, respectively;

[0774] (c) are SEQ ID NO: 899 and 989, respectively;

[0775] (d) are SEQ ID NO: 896 and 986, respectively;

[0776] (e) are SEQ ID NO: 892 and 982, respectively;

[0777] (f) are SEQ ID NO: 890 and 980 respectively; and

[0778] (g) are SEQ ID NO: 889 and 979, respectively.

[0779] This oligonucleotide reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., this oligonucleotide is a species-cross-reactive oligonucleotide).

[0780] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0781] (a) are SEQ ID NO: 940 and 1030, respectively;

[0782] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0783] (c) are SEQ ID NO:939 and 1029, respectively.

[0784] This oligonucleotide reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., this oligonucleotide is a species-cross-reactive oligonucleotide).

[0785] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0786] (a) are SEQ ID NO:915 and 1005, respectively;

[0787] (b) are SEQ ID NO:924 and 1014, respectively;

[0788] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0789] (d) are SEQ ID NO:920 and 1010, respectively.

[0790] This oligonucleotide reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., this oligonucleotide is a species-cross-reactive oligonucleotide).

[0791] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:862 and the antisense strand sequence of SEQ ID NO:952, wherein the oligonucleotide reduces STAT3 mRNA in human and non-human primates (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide).

[0792] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:875 and the antisense strand sequence of SEQ ID NO:965, wherein the oligonucleotide reduces human STAT3 mRNA.

[0793] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:876 and the antisense strand sequence of SEQ ID NO:966, wherein the oligonucleotide reduces human STAT3 mRNA.

[0794] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:920 and the antisense strand sequence of SEQ ID NO:1010, wherein the oligonucleotide reduces human STAT3 mRNA.

[0795] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0796] (a) are SEQ ID NO: 857 and 947, respectively;

[0797] (b) are SEQ ID NO: 858 and 948, respectively;

[0798] (c) are SEQ ID NO: 859 and 949, respectively;

[0799] (d) are SEQ ID NO: 860 and 950, respectively;

[0800] (e) are SEQ ID NO: 862 and 952, respectively;

[0801] (f) are SEQ ID NO: 867 and 957, respectively;

[0802] (g) are SEQ ID NO: 875 and 965 respectively; and

[0803] (h) are SEQ ID NO: 876 and 966, respectively.

[0804] This oligonucleotide reduces STAT3 mRNA by at least 75%.

[0805] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0806] (a) are SEQ ID NO: 901 and 991, respectively;

[0807] (b) are SEQ ID NO: 910 and 1000, respectively;

[0808] (c) are SEQ ID NO: 899 and 989, respectively;

[0809] (d) are SEQ ID NO: 896 and 986, respectively;

[0810] (e) are SEQ ID NO: 892 and 982, respectively;

[0811] (f) are SEQ ID NO: 890 and 980 respectively; and

[0812] (g) are SEQ ID NO: 889 and 979, respectively.

[0813] This oligonucleotide reduces STAT3 mRNA by at least 75%.

[0814] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0815] (a) are SEQ ID NO: 940 and 1030, respectively;

[0816] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0817] (c) are SEQ ID NO:939 and 1029, respectively.

[0818] This oligonucleotide reduces STAT3 mRNA by at least 75%.

[0819] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0820] (a) are SEQ ID NO:915 and 1005, respectively;

[0821] (b) are SEQ ID NO:924 and 1014, respectively;

[0822] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0823] (d) are SEQ ID NO:920 and 1010, respectively.

[0824] This oligonucleotide reduces STAT3 mRNA by at least 75%.

[0825] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0826] (a) are SEQ ID NO: 862 and 952, respectively;

[0827] (b) are SEQ ID NO: 875 and 965, respectively;

[0828] (c) are SEQ ID NO: 876 and 966 respectively; and

[0829] (d) are SEQ ID NO:920 and 1010, respectively.

[0830] This oligonucleotide reduces STAT3 mRNA by at least 75%.

[0831] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:862 and the antisense strand sequence of SEQ ID NO:952, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.

[0832] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:875 and the antisense strand sequence of SEQ ID NO:965, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.

[0833] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:876 and the antisense strand sequence of SEQ ID NO:966, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.

[0834] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:920 and the antisense strand sequence of SEQ ID NO:1010, wherein the oligonucleotide reduces STAT3 mRNA by at least 75%.

[0835] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0836] (a) are SEQ ID NO: 857 and 947, respectively;

[0837] (b) are SEQ ID NO: 858 and 948, respectively;

[0838] (c) are SEQ ID NO: 859 and 949, respectively;

[0839] (d) are SEQ ID NO: 860 and 950, respectively;

[0840] (e) are SEQ ID NO: 862 and 952, respectively;

[0841] (f) are SEQ ID NO: 867 and 957, respectively;

[0842] (g) are SEQ ID NO: 875 and 965 respectively; and

[0843] (h) are SEQ ID NO: 876 and 966, respectively.

[0844] The oligonucleotide is conjugated with lipids.

[0845] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0846] (a) are SEQ ID NO: 901 and 991, respectively;

[0847] (b) are SEQ ID NO: 910 and 1000, respectively;

[0848] (c) are SEQ ID NO: 899 and 989, respectively;

[0849] (d) are SEQ ID NO: 896 and 986, respectively;

[0850] (e) are SEQ ID NO: 892 and 982, respectively;

[0851] (f) are SEQ ID NO: 890 and 980 respectively; and

[0852] (g) are SEQ ID NO: 889 and 979, respectively.

[0853] The oligonucleotide is conjugated to a lipid on its sense chain.

[0854] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0855] (a) are SEQ ID NO: 940 and 1030, respectively;

[0856] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0857] (c) are SEQ ID NO:939 and 1029, respectively.

[0858] The oligonucleotide is conjugated to a lipid on its sense chain.

[0859] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0860] (a) are SEQ ID NO:915 and 1005, respectively;

[0861] (b) are SEQ ID NO:924 and 1014, respectively;

[0862] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0863] (d) are SEQ ID NO:920 and 1010, respectively.

[0864] The oligonucleotide is conjugated to a lipid on its sense chain.

[0865] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0866] (a) are SEQ ID NO: 862 and 952, respectively;

[0867] (b) are SEQ ID NO: 875 and 965, respectively;

[0868] (c) are SEQ ID NO: 876 and 966 respectively; and

[0869] (d) are SEQ ID NO:920 and 1010, respectively.

[0870] The oligonucleotide is conjugated to a lipid on its sense chain.

[0871] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO:862 and an antisense strand sequence of SEQ ID NO:952, wherein the oligonucleotide is conjugated to a lipid on the sense strand.

[0872] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:875 and the antisense strand sequence of SEQ ID NO:965, wherein the oligonucleotide is conjugated to a lipid on the sense strand.

[0873] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:876 and the antisense strand sequence of SEQ ID NO:966, wherein the oligonucleotide is conjugated to a lipid on the sense strand.

[0874] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:920 and the antisense strand sequence of SEQ ID NO:1010, wherein the oligonucleotide is conjugated to a lipid on the sense strand.

[0875] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0876] (a) are SEQ ID NO: 857 and 947, respectively;

[0877] (b) are SEQ ID NO: 858 and 948, respectively;

[0878] (c) are SEQ ID NO: 859 and 949, respectively;

[0879] (d) are SEQ ID NO: 860 and 950, respectively;

[0880] (e) are SEQ ID NO: 862 and 952, respectively;

[0881] (f) are SEQ ID NO: 867 and 957, respectively;

[0882] (g) are SEQ ID NO: 875 and 965 respectively; and

[0883] (h) are SEQ ID NO: 876 and 966, respectively.

[0884] The oligonucleotide is conjugated to a C18 lipid on its sense chain.

[0885] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0886] (a) are SEQ ID NO: 901 and 991, respectively;

[0887] (b) are SEQ ID NO: 910 and 1000, respectively;

[0888] (c) are SEQ ID NO: 899 and 989, respectively;

[0889] (d) are SEQ ID NO: 896 and 986, respectively;

[0890] (e) are SEQ ID NO: 892 and 982, respectively;

[0891] (f) are SEQ ID NO: 890 and 980 respectively; and

[0892] (g) are SEQ ID NO: 889 and 979, respectively.

[0893] The oligonucleotide is conjugated to a C18 lipid on its sense chain.

[0894] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0895] (a) are SEQ ID NO: 940 and 1030, respectively;

[0896] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0897] (c) are SEQ ID NO:939 and 1029, respectively.

[0898] The oligonucleotide is conjugated to a C18 lipid on its sense chain.

[0899] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0900] (a) are SEQ ID NO:915 and 1005, respectively;

[0901] (b) are SEQ ID NO:924 and 1014, respectively;

[0902] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0903] (d) are SEQ ID NO:920 and 1010, respectively.

[0904] The oligonucleotide is conjugated to a C18 lipid on its sense chain.

[0905] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0906] (a) are SEQ ID NO: 862 and 952, respectively;

[0907] (b) are SEQ ID NO: 875 and 965, respectively;

[0908] (c) are SEQ ID NO: 876 and 966 respectively; and

[0909] (d) are SEQ ID NO:920 and 1010, respectively.

[0910] The oligonucleotide is conjugated to a C18 lipid on its sense chain.

[0911] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises a sense strand sequence of SEQ ID NO:862 and an antisense strand sequence of SEQ ID NO:952, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.

[0912] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:875 and the antisense strand sequence of SEQ ID NO:965, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.

[0913] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:876 and the antisense strand sequence of SEQ ID NO:966, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.

[0914] In some embodiments, the oligonucleotide used to reduce the expression of STAT3 mRNA comprises the sense strand sequence of SEQ ID NO:920 and the antisense strand sequence of SEQ ID NO:1010, wherein the oligonucleotide is conjugated to a C18 lipid on the sense strand.

[0915] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0916] (a) are SEQ ID NO: 901 and 991, respectively;

[0917] (b) are SEQ ID NO: 910 and 1000, respectively;

[0918] (c) are SEQ ID NO: 899 and 989, respectively;

[0919] (d) are SEQ ID NO: 896 and 986, respectively;

[0920] (e) are SEQ ID NO: 892 and 982, respectively;

[0921] (f) are SEQ ID NO: 890 and 980 respectively; and

[0922] (g) are SEQ ID NO: 889 and 979, respectively.

[0923] This oligonucleotide reduces STAT3 mRNA (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 75% in humans, non-human primates, and mice.

[0924] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0925] (a) are SEQ ID NO: 940 and 1030, respectively;

[0926] (b) are SEQ ID NO: 937 and 1027 respectively; and

[0927] (c) are SEQ ID NO:939 and 1029, respectively.

[0928] This oligonucleotide reduces STAT3 mRNA (i.e., it is a species-cross-reactive oligonucleotide) by at least 75% in humans and mice.

[0929] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0930] (a) are SEQ ID NO:915 and 1005, respectively;

[0931] (b) are SEQ ID NO:924 and 1014, respectively;

[0932] (c) are SEQ ID NO: 913 and 1003 respectively; and

[0933] (d) are SEQ ID NO:920 and 1010, respectively.

[0934] This oligonucleotide reduces human STAT3 mRNA by at least 75%.

[0935] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:862 and the antisense strand sequence of SEQ ID NO:952, wherein the oligonucleotide reduces STAT3 mRNA in human and non-human primates (i.e., the oligonucleotide is a species-cross-reactive oligonucleotide) by at least 75%.

[0936] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:875 and the antisense strand sequence of SEQ ID NO:965, wherein the oligonucleotide reduces human STAT3 mRNA by at least 75%.

[0937] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:876 and the antisense strand sequence of SEQ ID NO:966, wherein the oligonucleotide reduces human STAT3 mRNA by at least 75%.

[0938] In some embodiments, the oligonucleotide for reducing STAT3 mRNA expression comprises the sense strand sequence of SEQ ID NO:920 and the antisense strand sequence of SEQ ID NO:1010, wherein the oligonucleotide reduces human STAT3 mRNA by at least 75%.

[0939] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0940] (a) are SEQ ID NO: 901 and 991, respectively;

[0941] (b) are SEQ ID NO: 910 and 1000, respectively;

[0942] (c) are SEQ ID NO: 899 and 989, respectively;

[0943] (d) are SEQ ID NO: 896 and 986, respectively;

[0944] (e) are SEQ ID NO: 892 and 982, respectively;

[0945] (f) are SEQ ID NO: 890 and 980 respectively; and

[0946] (g) are SEQ ID NO: 889 and 979, respectively.

[0947] This oligonucleotide is conjugated to lipids on its sense strand and reduces STAT3 mRNA in humans, non-human primates, and mice (i.e., this oligonucleotide is a species-cross-reactive oligonucleotide).

[0948] In some implementations, the oligonucleotides used to reduce STAT3 mRNA expression comprise sense and antisense strands selected from the following:

[0949] (a) are SEQ I...

Claims

1. An oligonucleotide for reducing STAT3 expression, comprising an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence of SEQ ID NO: 965, the sense strand comprising the nucleotide sequence of SEQ ID NO: 875, wherein the oligonucleotide comprises an antisense strand of 15 to 30 nucleotides in length and a sense strand of 15 to 40 nucleotides in length, wherein the sense strand comprises a C18 saturated fatty acid moiety conjugated to the sense strand, and wherein each of the antisense strand and the sense strand comprises at least one 2'-modified nucleotide and at least one modified nucleotide inter-bonding.

2. The oligonucleotide of claim 1, comprising an antisense strand and a sense strand, the antisense strand comprising the nucleotide sequence of SEQ ID NO: 1145, and the sense strand comprising the nucleotide sequence of SEQ ID NO: 1055.

3. The oligonucleotide according to claim 1 or 2, wherein the sense strand comprises a stem-loop at its 3' end as follows: S1-L-S2, wherein S1 and S2 are complementary, and wherein L forms a loop of 3 to 5 nucleotides in length between S1 and S2.

4. The oligonucleotide according to claim 3, wherein L is a tetracyclic ring, and optionally L has a length of 4 nucleotides.

5. The oligonucleotide of claim 4, wherein L comprises a sequence represented as GAAA.

6. The oligonucleotide according to claim 1, wherein the 2'-modification comprises 2'-aminoethyl, 2'-fluoro, 2'-O-methyl, 2'-O-methoxyethyl, or 2'-deoxy-2'-fluoro-β-d-arabinose.

7. The oligonucleotide according to any one of claims 1 or 4-6, wherein the sense strand comprises 36 nucleotides at positions 1-36 from 5' to 3', and wherein: a) One or more of positions 8-11 contain a 2'-fluorinated modification; and / or b) Each of positions 1-7 and 12-36 contains a 2'-O-methyl modification.

8. The oligonucleotide of claim 7, wherein positions 8-11 all contain a 2'-fluorinated modification.

9. The oligonucleotide according to any one of claims 1 or 4-6, wherein the antisense strand comprises 22 nucleotides at positions 1-22 from 5' to 3', and wherein: a) Positions 2, 3, 4, 5, 7, 10, and 14 contain a 2'-fluorinated modification; and / or b) Positions 1, 6, 8, 9, 11-13, and 15-22 contain 2'-O-methyl modifications.

10. The oligonucleotide according to any one of claims 1-2 and 4-6, wherein the 4'-carbon of the sugar of the 5'-nucleotide of the antisense strand comprises a phosphate ester analog.

11. The oligonucleotide according to any one of claims 1-2 and 4-6, wherein at least one nucleotide of the oligonucleotide is conjugated to one or more targeting ligands, optionally wherein the one or more targeting ligands are saturated or unsaturated fatty acid moieties.

12. An oligonucleotide for reducing STAT3 expression, said oligonucleotide comprising the antisense strand of SEQ ID NO: 1145 and further comprising the sense strand of SEQ ID NO: 1055, wherein said oligonucleotide comprises an antisense strand of 15 to 30 nucleotides in length and a sense strand of 15 to 40 nucleotides in length, and wherein: The antiskewing chain includes [MePhosphonate-4O-mUs][fUs][fAs][fA][fU][mU][fU][mU][mA][fA][mG][mC][mU][fG][mA][mU][mA][mA][mU][mUs][mGs][mG] And the meaningful chain contains [mAs][mA][mU][mU][mA][mU][mC][fA][fG][fC][fU][mU][mA][mA][mA][mA][mU][mU][mA][mA][mG][mC ][mA][mG][mC][mC][mG][ademA-GalNAc][ademA-GalNAc][ademA-GalNAc][mG][mG][mC][mU][mG][mC].

13. A pharmaceutical composition comprising an oligonucleotide or oligonucleotide-ligand conjugate according to any one of the preceding claims and a pharmaceutically acceptable carrier, delivery agent or excipient.

14. A composition for treating a condition or symptom associated with STAT3 expression in patients in need, wherein the composition comprises an oligonucleotide or oligonucleotide-ligand conjugate according to any one of the preceding claims, wherein the condition or symptom associated with STAT3 expression is cancer.

15. The composition of claim 14, wherein the cancer includes carcinoma, sarcoma, melanoma, lymphoma and leukemia, prostate cancer, breast cancer, hepatocellular carcinoma (HCC), colorectal cancer, pancreatic cancer or glioblastoma.

Citation Information

Patent Citations

  • COMPOSITIONS AND METHODS EMPLOYING UNIVERSAL-BINDING NUCLEOTIDES FOR TARGETING MULTIPLE GENE VARIANTS WITH A SINGLE siRNA DUPLEX

    US20070254362A1

  • Universal bases for nucleic acid analyses, methods for using universal bases, and kits comprising universal bases

    US20080274462A1

  • RNA INTERFERENCE MEDIATED INHIBITION OF MYC AND / OR MYB GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

    US20090099115A1

  • Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference

    US20110294869A1

  • Employe s time-recorder

    US467179A